Actavis

Mary-Lou Schoonover
DEA Compliance Analyst

T 862 261 7486
F 862 261 7927
Mary-Lou.Schoonover@actavis.com

Actavis, Inc.
400 Interpace Parkway, Building A
Parsippany, NJ 07054
www.actavis.com

July 12, 2013

Florida Department of Business and Professional Regulation
Division of Drugs, Devices, and Cosmetics Program
Attn: Reginald D. Dixon
1940 North Monroe Street
Tallahassee, FL 32399-0783

Re: Watson Pharma, Inc. to Actavis Pharma, Inc. – Name Change

Dear Mr. Dixon:

The purpose of this communication is to advise the Florida Department of Business and Professional Regulation, Drugs, Devices, and Cosmetics Program that Watson Pharmaceuticals, Inc. (parent company of Watson Pharma, Inc. and Watson Laboratories, Inc.) purchased Actavis Group in October 2012, and Watson Pharmaceuticals, Inc. then changed its name to Actavis, Inc. This acquisition resulted in a January 24, 2013 announcement at the New York Stock Exchange of the change of the Company's stock symbol to NYSE: ACT.

Please note that the parent company and all the subsidiaries have not changed their EIN numbers. As of this date, there have been no changes in any procedures, practices or systems. This change is in name only, existing ownership remains intact.

In conjunction with the parent company name change, the process of changing the Watson Pharma, Inc. entities to Actavis Pharma, Inc. has commenced. Upon completion, all necessary notifications and actions will be taken to ensure our continued licensing compliance with all appropriate regulatory agencies.

In Florida, we have 3 licenses. We will need to change the name on the existing licenses from Watson Pharma, Inc. to Actavis Pharma, Inc. The current license numbers is 26283 at our Corona, CA facility. Our Gurnee, IL facility has 2 licenses, 26276 and 40270.

We have also enclosed the additional documents noting our name change as required.

Should you have any questions or concerns, please contact me directly at 862-261-7486.

Sincerely,

Mary-Lou Schoonover

Mary-Lou Schoonover,
DEA Compliance Analyst

Enclosures

Florida Department of Business & Professional Regulation

Florida Department of Business and Professional Regulation
Drugs, Devices, and Cosmetics Program
1940 North Monroe Street, Tallahassee FL 32399-0783
Phone 850.717.1800

CHANGE OF ADDRESS OR NAME CHANGE

An establishment permit or a product registration is valid only for the name and address to which it is issued.

PERMIT NAME: The name in which the permit is issued must be the name in which the company is doing business, i.e., the name that appears on purchase, sales, and shipping documents. The permit name will be changed, at no cost, upon notification to the department provided the new name complies with Rule 61N-1.015(2)(b), Florida Administrative Code. However, if the name change is a result of a change in ownership, a new application and permit is required.

PERMIT ADDRESS: A new physical location must meet minimal requirements before a permit authorizing business at the new address can be issued. If the establishment is located in Florida, you must complete and sign the Questionnaire and Affidavit on the reverse side of this form.

FEES: There is no charge for a name change or for a change in mailing address of an establishment permit. There is no charge for a change related to a product registration.

$25 if the permit is issued to a Complimentary Drug Distributor located outside of Florida, Veterinary Prescription Drug Wholesaler located outside of Florida, Non-Resident Prescription Drug Manufacturer or Out-of-State Prescription Drug Wholesaler, Third Party Logistics Provider located outside of Florida, or a Health Care Clinic Establishment.

$100 if the permit is issued to a Prescription Drug Manufacturer, Prescription Drug Repackager, Over-the-Counter Drug Manufacturer, Compressed Medical Gas Manufacturer, Device Manufacturer, Cosmetic Manufacturer, Prescription Drug Wholesaler (including Broker Only), Compressed Medical Gas Wholesaler, Retail Pharmacy Wholesaler, Complimentary Drug Distributor located in Florida, Freight Forwarder, Veterinary Legend Drug Retailer, Limited Veterinary Prescription Drug Wholesaler, Veterinary Prescription Drug Wholesaler located in Florida, Medical Oxygen Retailer, Third Party Logistics Provider located in Florida, or any of the Restricted Prescription Drug Distributors.

$25 for each permit, in addition to the $100 fee above, if multiple permits under the same permitted name and address (in state) are relocated concurrently to one new location (in state).

Please print or type legibly.

Permit/Registration Number(s) 26283			
Old Permit Name Watson Pharma, Inc.			
New Permit Name (limit to 41 characters) Actavis Pharma, Inc.			
Old Physical Address N/A --No Change			
New Physical Address (include suite number)			
City	**State**	**Zip Code**	**County**
New Mailing Address (include suite number)			
City	**State**	**Zip**	
New Telephone Number	**Facsimile Number**		
New Opening Hours	**Effective Date of Change** 6/21/13		

Signature of Authorized Representative

Chief Compliance Officer
Title

Florida Department of Business & Professional Regulation

Florida Department of Business and Professional Regulation
Drugs, Devices, and Cosmetics Program
1940 North Monroe Street, Tallahassee FL 32399-0783
Phone 850.717.1800

CHANGE OF ADDRESS OR NAME CHANGE

An establishment permit or a product registration is valid only for the name and address to which it is issued.

PERMIT NAME: The name in which the permit is issued must be the name in which the company is doing business, i.e., the name that appears on purchase, sales, and shipping documents. The permit name will be changed, at no cost, upon notification to the department provided the new name complies with Rule 61N-1.015(2)(b), Florida Administrative Code. However, if the name change is a result of a change in ownership, a new application and permit is required.

PERMIT ADDRESS: A new physical location must meet minimal requirements before a permit authorizing business at the new address can be issued. If the establishment is located in Florida, you must complete and sign the Questionnaire and Affidavit on the reverse side of this form.

FEES: There is no charge for a name change or for a change in mailing address of an establishment permit. There is no charge for a change related to a product registration.

$25 if the permit is issued to a Complimentary Drug Distributor located outside of Florida, Veterinary Prescription Drug Wholesaler located outside of Florida, Non-Resident Prescription Drug Manufacturer or Out-of-State Prescription Drug Wholesaler, Third Party Logistics Provider located outside of Florida, or a Health Care Clinic Establishment.

$100 if the permit is issued to a Prescription Drug Manufacturer, Prescription Drug Repackager, Over-the-Counter Drug Manufacturer, Compressed Medical Gas Manufacturer, Device Manufacturer, Cosmetic Manufacturer, Prescription Drug Wholesaler (including Broker Only), Compressed Medical Gas Wholesaler, Retail Pharmacy Wholesaler, Complimentary Drug Distributor located in Florida, Freight Forwarder, Veterinary Legend Drug Retailer, Limited Veterinary Prescription Drug Wholesaler, Veterinary Prescription Drug Wholesaler located in Florida, Medical Oxygen Retailer, Third Party Logistics Provider located in Florida, or any of the Restricted Prescription Drug Distributors.

$25 for each permit, in addition to the $100 fee above, if multiple permits under the same permitted name and address (in state) are relocated concurrently to one new location (in state).

Please print or type legibly.

Permit/Registration Number(s) 26276 and 40270			
Old Permit Name Watson Pharma, Inc.			
New Permit Name (limit to 41 characters) Actavis Pharma, Inc.			
Old Physical Address N/A --No Change			
New Physical Address (include suite number)			
City	**State**	**Zip Code**	**County**
New Mailing Address (include suite number)			
City	**State**		**Zip**
New Telephone Number	**Facsimile Number**		
New Opening Hours	**Effective Date of Change** 6/21/13		

Signature of Authorized Representative

Chief Compliance Officer
Title

SURETY RIDER

To be attached to and form a part of

Bond No. 105181106

Type of Bond: Other Miscellaneous-Drugs, Devices, and Cosmetics Program

dated effective January 15, 2009
(MONTH-DAY-YEAR)

executed by Watson Pharma, Inc. , as Principal,
(PRINCIPAL)

and by Travelers Casualty and Surety Company of America , as Surety,
(SURETY)

in favor of State of Florida
(OBLIGEE)

in consideration of the mutual agreements herein contained the Principal and the Surety hereby consent to changing

The principal name from Watson Pharma, Inc. to Actavis Pharma, Inc.

Nothing herein contained shall vary, alter or extend any provision or condition of this bond except as herein expressly stated.

This rider is effective June 21, 2013
(MONTH-DAY-YEAR)

Signed and Sealed June 11, 2013
(MONTH-DAY-YEAR)

Actavis Pharma, Inc.
(PRINCIPAL)

By: _____
(PRINCIPAL)

Travelers Casualty and Surety Company of America
(SURETY)

By: TARA MEALER
Tara Mealer, Attorney-In-Fact

S-0443/GEEF 10/99

WARNING: THIS POWER OF ATTORNEY IS INVALID WITHOUT THE RED BORDER

TRAVELERS

POWER OF ATTORNEY

Farmington Casualty Company
Fidelity and Guaranty Insurance Company
Fidelity and Guaranty Insurance Underwriters, Inc.
St. Paul Fire and Marine Insurance Company
St. Paul Guardian Insurance Company
St. Paul Mercury Insurance Company
Travelers Casualty and Surety Company
Travelers Casualty and Surety Company of America
United States Fidelity and Guaranty Company

Attorney-In Fact No. 226691 Certificate No. 005504557

KNOW ALL MEN BY THESE PRESENTS: That Farmington Casualty Company, St. Paul Fire and Marine Insurance Company, St. Paul Guardian Insurance Company, St. Paul Mercury Insurance Company, Travelers Casualty and Surety Company, Travelers Casualty and Surety Company of America, and United States Fidelity and Guaranty Company are corporations duly organized under the laws of the State of Connecticut, that Fidelity and Guaranty Insurance Company is a corporation duly organized under the laws of the State of Iowa, and that Fidelity and Guaranty Insurance Underwriters, Inc., is a corporation duly organized under the laws of the State of Wisconsin (herein collectively called the "Companies"), and that the Companies do hereby make, constitute and appoint

Barbara A. Thompson, Carolyn E. Wheeler, Novetta M. Anderson, Loretta M. Jones, Mary Y. Volmar, Sandra Ward, Vicki Nobinger, Kathryn W. Allen, Kellie McKinney, and Tara Mealer

of the City of Knoxville, State of Tennessee, their true and lawful Attorney(s)-in-Fact, each in their separate capacity if more than one is named above, to sign, execute, seal and acknowledge any and all bonds, recognizances, conditional undertakings and other writings obligatory in the nature thereof on behalf of the Companies in their business of guaranteeing the fidelity of persons, guaranteeing the performance of contracts and executing or guaranteeing bonds and undertakings required or permitted in any actions or proceedings allowed by law.

IN WITNESS WHEREOF, the Companies have caused this instrument to be signed and their corporate seals to be hereto affixed, this 23rd day of May, 2013.

Farmington Casualty Company
Fidelity and Guaranty Insurance Company
Fidelity and Guaranty Insurance Underwriters, Inc.
St. Paul Fire and Marine Insurance Company
St. Paul Guardian Insurance Company
St. Paul Mercury Insurance Company
Travelers Casualty and Surety Company
Travelers Casualty and Surety Company of America
United States Fidelity and Guaranty Company

State of Connecticut
City of Hartford ss.

By: _____
Robert L. Raney, Senior Vice President

On this the 23rd day of May, 2013, before me personally appeared Robert L. Raney, who acknowledged himself to be the Senior Vice President of Farmington Casualty Company, Fidelity and Guaranty Insurance Company, Fidelity and Guaranty Insurance Underwriters, Inc., St. Paul Fire and Marine Insurance Company, St. Paul Guardian Insurance Company, St. Paul Mercury Insurance Company, Travelers Casualty and Surety Company, Travelers Casualty and Surety Company of America, and United States Fidelity and Guaranty Company, and that he, as such, being authorized so to do, executed the foregoing instrument for the purposes therein contained by signing on behalf of the corporations by himself as a duly authorized officer.

In Witness Whereof, I hereunto set my hand and official seal.
My Commission expires the 30th day of June, 2016.

MARIE C. TETREAULT NOTARY PUBLIC CONNECTICUT

Marie C. Tetreault
Marie C. Tetreault, Notary Public

58440-8-12 Printed in U.S.A.

WARNING: THIS POWER OF ATTORNEY IS INVALID WITHOUT THE RED BORDER

This Power of Attorney is granted under and by the authority of the following resolutions adopted by the Boards of Directors of Farmington Casualty Company, Fidelity and Guaranty Insurance Company, Fidelity and Guaranty Insurance Underwriters, Inc., St. Paul Fire and Marine Insurance Company, St. Paul Guardian Insurance Company, St. Paul Mercury Insurance Company, Travelers Casualty and Surety Company, Travelers Casualty and Surety Company of America, and United States Fidelity and Guaranty Company, which resolutions are now in full force and effect, reading as follows:

RESOLVED, that the Chairman, the President, any Vice Chairman, any Executive Vice President, any Senior Vice President, any Vice President, any Second Vice President, the Treasurer, any Assistant Treasurer, the Corporate Secretary or any Assistant Secretary may appoint Attorneys-in-Fact and Agents to act for and on behalf of the Company and may give such appointee such authority as his or her certificate of authority may prescribe to sign with the Company's name and seal with the Company's seal bonds, recognizances, contracts of indemnity, and other writings obligatory in the nature of a bond, recognizance, or conditional undertaking, and any of said officers or the Board of Directors at any time may remove any such appointee and revoke the power given him or her; and it is

FURTHER RESOLVED, that the Chairman, the President, any Vice Chairman, any Executive Vice President, any Senior Vice President or any Vice President may delegate all or any part of the foregoing authority to one or more officers or employees of this Company, provided that each such delegation is in writing and a copy thereof is filed in the office of the Secretary; and it is

FURTHER RESOLVED, that any bond, recognizance, contract of indemnity, or writing obligatory in the nature of a bond, recognizance, or conditional undertaking shall be valid and binding upon the Company when (a) signed by the President, any Vice Chairman, any Executive Vice President, any Senior Vice President or any Vice President, any Second Vice President, the Treasurer, any Assistant Treasurer, the Corporate Secretary or any Assistant Secretary and duly attested and sealed with the Company's seal by a Secretary or Assistant Secretary; or (b) duly executed (under seal, if required) by one or more Attorneys-in-Fact and Agents pursuant to the power prescribed in his or her certificate or their certificates of authority or by one or more Company officers pursuant to a written delegation of authority; and it is

FURTHER RESOLVED, that the signature of each of the following officers: President, any Executive Vice President, any Senior Vice President, any Vice President, any Assistant Vice President, any Secretary, any Assistant Secretary, and the seal of the Company may be affixed by facsimile to any Power of Attorney or to any certificate relating thereto appointing Resident Vice Presidents, Resident Assistant Secretaries or Attorneys-in-Fact for purposes only of executing and attesting bonds and undertakings and other writings obligatory in the nature thereof, and any such Power of Attorney or certificate bearing such facsimile signature or facsimile seal shall be valid and binding upon the Company and any such power so executed and certified by such facsimile signature and facsimile seal shall be valid and binding on the Company in the future with respect to any bond or understanding to which it is attached.

I, Kevin E. Hughes, the undersigned, Assistant Secretary, of Farmington Casualty Company, Fidelity and Guaranty Insurance Company, Fidelity and Guaranty Insurance Underwriters, Inc., St. Paul Fire and Marine Insurance Company, St. Paul Guardian Insurance Company, St. Paul Mercury Insurance Company, Travelers Casualty and Surety Company, Travelers Casualty and Surety Company of America, and United States Fidelity and Guaranty Company do hereby certify that the above and foregoing is a true and correct copy of the Power of Attorney executed by said Companies, which is in full force and effect and has not been revoked.

IN TESTIMONY WHEREOF, I have hereunto set my hand and affixed the seals of said Companies this 11th day of June, 20 13.

Kevin E. Hughes, Assistant Secretary

To verify the authenticity of this Power of Attorney, call 1-800-421-3880 or contact us at www.travelersbond.com. Please refer to the Attorney-In-Fact number, the above-named individuals and the details of the bond to which the power is attached.

SURETY RIDER

To be attached to and form a part of

Bond No. 105181108

Type of Bond: Other Financial Guarantee-FL Dept of Health Drugs, Devices & Cosmetics Program

dated effective January 15, 2009
(MONTH-DAY-YEAR)

executed by Watson Pharma, Inc. , as Principal,
(PRINCIPAL)

and by Travelers Casualty and Surety Company of America , as Surety,
(SURETY)

in favor of State of Florida, Department of Health Drugs, Devices and Cosmetics Program
(OBLIGEE)

in consideration of the mutual agreements herein contained the Principal and the Surety hereby consent to changing

The principal name from Watson Pharma, Inc. to Actavis Pharma, Inc.

Nothing herein contained shall vary, alter or extend any provision or condition of this bond except as herein expressly stated.

This rider is effective June 21, 2013
(MONTH-DAY-YEAR)

Signed and Sealed June 11, 2013
(MONTH-DAY-YEAR)

Actavis Pharma, Inc.
(PRINCIPAL)

By: _____
(PRINCIPAL)

Travelers Casualty and Surety Company of America
(SURETY)

By: TARA MEALER
Tara Mealer, Attorney-In-Fact

S-0443/GEEF 10/99

WARNING: THIS POWER OF ATTORNEY IS INVALID WITHOUT THE RED BORDER

TRAVELERS

POWER OF ATTORNEY

Farmington Casualty Company
Fidelity and Guaranty Insurance Company
Fidelity and Guaranty Insurance Underwriters, Inc.
St. Paul Fire and Marine Insurance Company
St. Paul Guardian Insurance Company

St. Paul Mercury Insurance Company
Travelers Casualty and Surety Company
Travelers Casualty and Surety Company of America
United States Fidelity and Guaranty Company

Attorney-In Fact No. 226691

Certificate No. 005504555

KNOW ALL MEN BY THESE PRESENTS: That Farmington Casualty Company, St. Paul Fire and Marine Insurance Company, St. Paul Guardian Insurance Company, St. Paul Mercury Insurance Company, Travelers Casualty and Surety Company, Travelers Casualty and Surety Company of America, and United States Fidelity and Guaranty Company are corporations duly organized under the laws of the State of Connecticut, that Fidelity and Guaranty Insurance Company is a corporation duly organized under the laws of the State of Iowa, and that Fidelity and Guaranty Insurance Underwriters, Inc., is a corporation duly organized under the laws of the State of Wisconsin (herein collectively called the "Companies"), and that the Companies do hereby make, constitute and appoint

Barbara A. Thompson, Carolyn E. Wheeler, Novetta M. Anderson, Loretta M. Jones, Mary Y. Volmar, Sandra Ward, Vicki Nobinger, Kathryn W. Allen, Kellie McKinney, and Tara Mealer

of the City of Knoxville, State of Tennessee, their true and lawful Attorney(s)-in-Fact, each in their separate capacity if more than one is named above, to sign, execute, seal and acknowledge any and all bonds, recognizances, conditional undertakings and other writings obligatory in the nature thereof on behalf of the Companies in their business of guaranteeing the fidelity of persons, guaranteeing the performance of contracts and executing or guaranteeing bonds and undertakings required or permitted in any actions or proceedings allowed by law.

IN WITNESS WHEREOF, the Companies have caused this instrument to be signed and their corporate seals to be hereto affixed, this 23rd day of May, 2013.

Farmington Casualty Company
Fidelity and Guaranty Insurance Company
Fidelity and Guaranty Insurance Underwriters, Inc.
St. Paul Fire and Marine Insurance Company
St. Paul Guardian Insurance Company

St. Paul Mercury Insurance Company
Travelers Casualty and Surety Company
Travelers Casualty and Surety Company of America
United States Fidelity and Guaranty Company

State of Connecticut
City of Hartford ss.

By: _____
Robert L. Raney, Senior Vice President

On this the 23rd day of May, 2013, before me personally appeared Robert L. Raney, who acknowledged himself to be the Senior Vice President of Farmington Casualty Company, Fidelity and Guaranty Insurance Company, Fidelity and Guaranty Insurance Underwriters, Inc., St. Paul Fire and Marine Insurance Company, St. Paul Guardian Insurance Company, St. Paul Mercury Insurance Company, Travelers Casualty and Surety Company, Travelers Casualty and Surety Company of America, and United States Fidelity and Guaranty Company, and that he, as such, being authorized so to do, executed the foregoing instrument for the purposes therein contained by signing on behalf of the corporations by himself as a duly authorized officer.

In Witness Whereof, I hereunto set my hand and official seal.
My Commission expires the 30th day of June, 2016.

MARIE C. TETREAULT NOTARY PUBLIC CONNECTICUT

Marie C. Tetreault
Marie C. Tetreault, Notary Public

58440-8-12 Printed in U.S.A.

WARNING: THIS POWER OF ATTORNEY IS INVALID WITHOUT THE RED BORDER

WARNING: THIS POWER OF ATTORNEY IS INVALID WITHOUT THE RED BORDER

This Power of Attorney is granted under and by the authority of the following resolutions adopted by the Boards of Directors of Farmington Casualty Company, Fidelity and Guaranty Insurance Company, Fidelity and Guaranty Insurance Underwriters, Inc., St. Paul Fire and Marine Insurance Company, St. Paul Guardian Insurance Company, St. Paul Mercury Insurance Company, Travelers Casualty and Surety Company, Travelers Casualty and Surety Company of America, and United States Fidelity and Guaranty Company, which resolutions are now in full force and effect, reading as follows:

RESOLVED, that the Chairman, the President, any Vice Chairman, any Executive Vice President, any Senior Vice President, any Vice President, any Second Vice President, the Treasurer, any Assistant Treasurer, the Corporate Secretary or any Assistant Secretary may appoint Attorneys-in-Fact and Agents to act for and on behalf of the Company and may give such appointee such authority as his or her certificate of authority may prescribe to sign with the Company's name and seal with the Company's seal bonds, recognizances, contracts of indemnity, and other writings obligatory in the nature of a bond, recognizance, or conditional undertaking, and any of said officers or the Board of Directors at any time may remove any such appointee and revoke the power given him or her; and it is

FURTHER RESOLVED, that the Chairman, the President, any Vice Chairman, any Executive Vice President, any Senior Vice President or any Vice President may delegate all or any part of the foregoing authority to one or more officers or employees of this Company, provided that each such delegation is in writing and a copy thereof is filed in the office of the Secretary; and it is

FURTHER RESOLVED, that any bond, recognizance, contract of indemnity, or writing obligatory in the nature of a bond, recognizance, or conditional undertaking shall be valid and binding upon the Company when (a) signed by the President, any Vice Chairman, any Executive Vice President, any Senior Vice President or any Vice President, any Second Vice President, the Treasurer, any Assistant Treasurer, the Corporate Secretary or any Assistant Secretary and duly attested and sealed with the Company's seal by a Secretary or Assistant Secretary; or (b) duly executed (under seal, if required) by one or more Attorneys-in-Fact and Agents pursuant to the power prescribed in his or her certificate or their certificates of authority or by one or more Company officers pursuant to a written delegation of authority; and it is

FURTHER RESOLVED, that the signature of each of the following officers: President, any Executive Vice President, any Senior Vice President, any Vice President, any Assistant Vice President, any Secretary, any Assistant Secretary, and the seal of the Company may be affixed by facsimile to any Power of Attorney or to any certificate relating thereto appointing Resident Vice Presidents, Resident Assistant Secretaries or Attorneys-in-Fact for purposes only of executing and attesting bonds and undertakings and other writings obligatory in the nature thereof, and any such Power of Attorney or certificate bearing such facsimile signature or facsimile seal shall be valid and binding upon the Company and any such power so executed and certified by such facsimile signature and facsimile seal shall be valid and binding on the Company in the future with respect to any bond or understanding to which it is attached.

I, Kevin E. Hughes, the undersigned, Assistant Secretary, of Farmington Casualty Company, Fidelity and Guaranty Insurance Company, Fidelity and Guaranty Insurance Underwriters, Inc., St. Paul Fire and Marine Insurance Company, St. Paul Guardian Insurance Company, St. Paul Mercury Insurance Company, Travelers Casualty and Surety Company, Travelers Casualty and Surety Company of America, and United States Fidelity and Guaranty Company do hereby certify that the above and foregoing is a true and correct copy of the Power of Attorney executed by said Companies, which is in full force and effect and has not been revoked.

IN TESTIMONY WHEREOF, I have hereunto set my hand and affixed the seals of said Companies this 11th day of June, 20 13.

Kevin E. Hughes, Assistant Secretary

To verify the authenticity of this Power of Attorney, call 1-800-421-3880 or contact us at www.travelersbond.com. Please refer to the Attorney-In-Fact number, the above-named individuals and the details of the bond to which the power is attached.

WARNING: THIS POWER OF ATTORNEY IS INVALID WITHOUT THE RED BORDER

Delaware

The First State

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF "WATSON PHARMA, INC.", CHANGING ITS NAME FROM "WATSON PHARMA, INC." TO "ACTAVIS PHARMA, INC.", FILED IN THIS OFFICE ON THE EIGHTEENTH DAY OF JUNE, A.D. 2013, AT 12:18 O'CLOCK P.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.

Jeffrey W. Bullock, Secretary of State

2352578 8100

130786813

AUTHENTICATION: 0520486

DATE: 06-18-13

You may verify this certificate online at corp.delaware.gov/authver.shtml

State of Delaware
Secretary of State
Division of Corporations
Delivered 12:29 PM 06/18/2013
FILED 12:18 PM 06/18/2013
SRV 130786813 - 2352578 FILE

CERTIFICATE OF AMENDMENT
OF
CERTIFICATE OF INCORPORATION

Watson Pharma, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware,

DOES HEREBY CERTIFY:

FIRST: That the Board of Directors of said corporation, by unanimous written consent of its members, filed with the minutes of the Board adopted a resolution proposing and declaring advisable the following amendment to the Certificate of Incorporation:

RESOLVED, that the Certificate of Incorporation of Watson Pharma, Inc. be amended by changing the First Article thereof so that, as amended, said First Article shall be and read as follows, "FIRST: The name of the Corporation is Actavis Pharma, Inc."

SECOND: That in lieu of a meeting and vote of stockholders, the stockholders have given unanimous written consent of said amendment in accordance with the provisions of Section 228 of the General Corporation Law of the State of Delaware.

THIRD: That the aforesaid Certificate of Amendment was duly adopted in accordance with the applicable provisions of Sections 242 and 228 of the General Corporation Law of the State of Delaware.

FOURTH: That this Certificate of Amendment shall be effective on June 18, 2013.

IN WITNESS WHEREOF, the undersigned has executed this Certificate of Amendment this day of June 18, 2013.

WATSON PHARMA, INC.

By: _____
John LaRocca
Vice Presdent, Legal Affairs – Americas
and Assistant Secretary

Delaware

The First State

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED ARE TRUE AND CORRECT COPIES OF ALL DOCUMENTS ON FILE OF "WATSON PHARMA, INC." AS RECEIVED AND FILED IN THIS OFFICE.

THE FOLLOWING DOCUMENTS HAVE BEEN CERTIFIED:

CERTIFICATE OF INCORPORATION, FILED THE TWENTY-SEVENTH DAY OF SEPTEMBER, A.D. 1993, AT 2:30 O'CLOCK P.M.

CERTIFICATE OF OWNERSHIP, FILED THE FIFTEENTH DAY OF OCTOBER, A.D. 1993, AT 4:30 O'CLOCK P.M.

CERTIFICATE OF AMENDMENT, CHANGING ITS NAME FROM "SCHEIN PHARMACEUTICAL CORP." TO "SCHEIN PHARMACEUTICAL, INC.", FILED THE FOURTEENTH DAY OF DECEMBER, A.D. 1993, AT 1:15 O'CLOCK P.M.

RESTATED CERTIFICATE, FILED THE TWENTY-FIRST DAY OF JUNE, A.D. 1995, AT 3 O'CLOCK P.M.

CERTIFICATE OF OWNERSHIP, FILED THE TWENTY-THIRD DAY OF JUNE, A.D. 1995, AT 3:30 O'CLOCK P.M.

RESTATED CERTIFICATE, FILED THE THIRD DAY OF APRIL, A.D. 1998, AT 9 O'CLOCK A.M.

CERTIFICATE OF MERGER, FILED THE TWENTY-EIGHTH DAY OF AUGUST, A.D. 2000, AT 9:30 O'CLOCK A.M.

2352578 8100H

070741338

SECRETARY'S OFFICE — 1787 DELAWARE 1897

Harriet Smith Windsor

Harriet Smith Windsor, Secretary of State

AUTHENTICATION: 5784788

DATE: 06-22-07

Delaware

The First State

RESTATED CERTIFICATE, FILED THE TWENTY-EIGHTH DAY OF AUGUST, A.D. 2000, AT 9:30 O'CLOCK A.M.

CERTIFICATE OF MERGER, CHANGING ITS NAME FROM "SCHEIN PHARMACEUTICAL, INC." TO "WATSON PHARMA, INC.", FILED THE TWENTY-NINTH DAY OF MARCH, A.D. 2001, AT 9 O'CLOCK A.M.

AND I DO HEREBY FURTHER CERTIFY THAT THE AFORESAID CERTIFICATES ARE THE ONLY CERTIFICATES ON RECORD OF THE AFORESAID CORPORATION, "WATSON PHARMA, INC.".

2352578 8100H

070741338

SECRETARY'S OFFICE 1793 DELAWARE 1953

Harriet Smith Windsor

Harriet Smith Windsor, Secretary of State

AUTHENTICATION: 5784788

DATE: 06-22-07

STATE OF DELAWARE
SECRETARY OF STATE
DIVISION OF CORPORATIONS
FILED 02:30 PM 09/27/1993
753270114 - 2352578

CERTIFICATE OF INCORPORATION

OF

SCHEIN PHARMACEUTICAL CORP.

I, THE UNDERSIGNED, in order to form a corporation for the purposes hereinafter stated, under and pursuant to the provisions of the General Corporation Law of the State of Delaware, do hereby certify as follows:

FIRST: The name of the corporation is SCHEIN PHARMACEUTICAL CORP. (the "Corporation").

SECOND: The registered office of the Corporation in the State of Delaware is to be located at 32 Loockerman Square, Suite L-100, in the city of Dover, County of Kent, State of Delaware. The name of its registered agent at that address is The Prentice-Hall Corporation System, Inc.

THIRD: The nature of the business or purposes to be conducted or promoted by the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware.

FOURTH: The aggregate number of shares which the Corporation shall have authority to issue is 400,000 shares of Common Stock, $.01 par value ("Common Stock").

FIFTH: The number of directors of the Corporation shall be the number from time to time fixed by or in the manner

provided in the By-Laws. Elections of directors need not be by ballot unless the By-Laws of the Corporation shall so provide.

SIXTH: The directors of the Corporation may, by a vote of a majority of directors present at a meeting in which a quorum is present, adopt, amend or repeal any By-Law. The fact that such power has been so conferred on the directors shall not divest the stockholders, nor limit their powers as set forth in Article SEVENTH.

SEVENTH: The stockholders may, by a vote of the holders of a majority of the outstanding shares of Common Stock, adopt, amend or repeal any By-Law.

EIGHTH: The name and mailing address of the Sole Incorporator is Michael I. Kim, c/o Proskauer Rose Goetz & Mendelsohn, 1585 Broadway, New York, New York 10036.

NINTH: Whenever a compromise or arrangement is proposed between the Corporation and its creditors or any class of them and/or between the Corporation and its stockholders, any court of equitable jurisdiction within the State of Delaware may, on the application in a summary way of the Corporation or of any creditor or stockholder thereof or on the application of any receiver or receivers appointed for the Corporation under the provisions of Section 291 of Title 8 of the Delaware Code or on the application of trustees in dissolution or of any receiver or receivers appointed for the Corporation under the provisions of section 279 of Title 8 of the Delaware Code, order a meeting of

the creditors or class of creditors, and/or of the stockholders of the Corporation, as the case may be, to be summoned in such manner as the said court directs. If a majority in number representing three fourths in value of the creditors or class of creditors, and/or of the stockholders of the Corporation, as the case may be, agree to any compromise or arrangement and to any reorganization of the Corporation as a consequence of such compromise or arrangement, the said compromise or arrangement and the said reorganization shall, if sanctioned by the court to which the said application has been made, be binding on all the creditors or class of creditors, and/or on all the stockholders, of the Corporation, as the case may be, and also on the Corporation.

TENTH: No director shall be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty by such director as a director, provided that this Article TENTH shall not eliminate or limit the liability of a director (i) for any breach of such director's duty of loyalty to the Corporation or its stockholders, (ii) for acts or omissions of such director not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the Delaware General Corporation Law, or (iv) for any transaction from which such director derived an improper personal benefit, in respect of which such breach of fiduciary duty occurred; nor shall this Article TENTH eliminate or limit the liability of a director for any act or omission occurring

prior to the date this Article TENTH becomes effective. If the Delaware General Corporation Law is amended after approval by the stockholders of this Article TENTH to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law, as so amended from time to time.

ELEVENTH: (a) Each person who was or is made a party or is threatened to be made a party to or is involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (hereinafter a "proceeding"), by reason of the fact that he or she, or a person of whom he or she is the legal representative, (1) is or was a director or officer of the Corporation or (2) is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans (whether the basis of such proceeding is alleged action in an official capacity as a director, officer, employee or agent or in any other capacity while serving as a director, officer, employee or agent), shall be indemnified and held harmless by the Corporation to the fullest extent authorized by the Delaware General Corporation Law, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide

broader indemnification rights than said law permitted the Corporation to provide prior to such amendment), against all expense, liability and loss (including attorneys' fees, judgments, fines, ERISA excise taxes or penalties and amounts paid or to be paid in settlement) actually and reasonably incurred or suffered by such person in connection therewith and such indemnification shall continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of his or her heirs, executors and administrators; provided, however, that, except as provided in paragraph (b) hereof the Corporation shall indemnify any such person seeking indemnification in connection with a proceeding (or part thereof) initiated by such person only if such proceeding (or part thereof) was authorized by the Board of Directors of the corporation. The right to indemnification conferred in this Article ELEVENTH shall be a contract right and shall include the right to be paid by the Corporation the expenses incurred in defending any such proceeding in advance of its final disposition; provided, however, that, if the Delaware General Corporation Law requires, the payment of such expenses incurred by a director or officer in his or her capacity as such (and not in any other capacity in which service was or is rendered by such person while a director or officer, including, without limitation, service with respect to an employee benefit plan) in advance of the final disposition of a proceeding, shall be made only upon delivery to the Corporation of an undertaking, by or on behalf of such director or officer, to repay all amounts so

advanced if it shall ultimately be determined that such director or officer is not entitled to be indemnified under this Article ELEVENTH or otherwise. The Corporation may, by action of its Board of Directors, provide indemnification to employees and agents of the Corporation with the same scope and effect as the foregoing indemnification of directors and officers.

(b) If a claim under paragraph (a) of this Article ELEVENTH is not paid in full by the Corporation within thirty days after a written claim has been received by the Corporation, the claimant may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim and, if successful in whole or in part, the claimant shall be entitled to be paid also the expense of prosecuting such claim. It shall be a defense to any such action (other than an action brought to enforce a claim for expenses incurred in defending any proceeding in advance of its final disposition where the required undertaking, if any is required, has been tendered to the Corporation) that the claimant has not met the standards of conduct which make it permissible under the Delaware General Corporation Law for the Corporation to indemnify the claimant for the amount claimed, but the burden of proving such defense shall be on the Corporation. Neither the failure of the Corporation (including its Board of Directors, independent legal counsel, or its stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances because he or she has met the

applicable standard of conduct set forth in the Delaware General Corporation Law, nor an actual determination by the Corporation (including its Board of Directors, independent legal counsel, or its stockholders) that the claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that the claimant has not met the applicable standard of conduct.

(c) The right to indemnification and the payment of expenses incurred in defending a proceeding in advance of its final disposition conferred in this Article ELEVENTH shall not be exclusive of any other right which any person may have or hereafter acquire under any statute, provision of the Certificate of Incorporation, by-law, agreement, vote of stockholders or disinterested directors or otherwise.

(d) The Corporation may maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, against any such expense, liability or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the Delaware General Corporation Law.

TWELFTH: The Corporation reserves the right to amend, modify or repeal any provisions contained in this Certificate of Incorporation in the manner now or hereafter prescribed by law,

and all rights and powers conferred herein on stockholders, directors, officers or others are granted subject to this reservation.

IN WITNESS WHEREOF, I have hereunto set my hand this 27th day of September, 1993.

Michael I. Kim

STATE OF DELAWARE
SECRETARY OF STATE
DIVISION OF CORPORATIONS
FILED 04:30 PM 10/15/1993
932915177 - 2352578

CERTIFICATE OF OWNERSHIP AND MERGER

-of-

Schein Pharmaceutical, Inc.

(a New York corporation)

-into-

Schein Pharmaceutical Corp.

(a Delaware corporation)

It is hereby certified that:

1. Schein Pharmaceutical, Inc., a New York corporation (hereinafter called "Schein New York") is a corporation permitted under the laws of the State of New York to be merged with a corporation of another jurisdiction.

2. Schein New York, as the owner of all of the outstanding shares of capital stock of Schein Pharmaceutical Corp., a Delaware corporation ("Schein Delaware"), hereby merges itself into Schein Delaware.

3. The following is a copy of the resolutions adopted on the 27th day of September, 1993, by the Board of Directors of Schein New York to merge Schein New York into Schein Delaware:

> RESOLVED, that, subject to the approval of the shareholders of Schein New York, Schein New York be reincorporated in the State of Delaware by merging itself into Schein Delaware pursuant to the laws of the State of New York and the State of Delaware as hereinafter provided, so that the separate existence of Schein New York shall cease as soon as the merger shall become effective, and thereupon Schein New York and Schein Delaware will become a single corporation, which shall continue to exist under, and be governed by, the laws of the State of Delaware; and
>
> RESOLVED that the terms and conditions of the proposed merger are as follows:
>
> (a) No pro rata issuance of the shares of stock of Schein Delaware which are owned by Schein New York immediately prior to the

effective time of the merger shall be made, and such shares shall be surrendered and extinguished.

(b) Each share of Common Stock, $.01 par value, of Schein New York ("Schein New York Common Stock") which shall be issued and outstanding immediately prior to the effective time of the merger shall, without any action on the part of the holder thereof, be converted at the effective time of the merger into one issued and outstanding share of Common Stock, $.01 par value, of Schein Delaware ("Schein Delaware Common Stock"), and from and after the effective time of the merger, the holders of all of said issued and outstanding shares of Schein New York Common Stock shall automatically be and become holders of shares of Schein Delaware Common Stock upon the basis above specified, whether or not certificates representing said shares are then issued and delivered.

(c) After the effective time of the merger, each holder of record of any outstanding certificate or certificates theretofore representing of Schein New York Common Stock may surrender the same to Schein Delaware at its office in Florham Park, New Jersey and such holder shall be entitled upon such surrender to receive in exchange therefor a certificate or certificates representing the appropriate number of shares of Schein Delaware Common Stock, as calculated in accordance with the terms set forth in the preceding paragraph (b). Until so surrendered, each outstanding certificate which prior to the effective time of the merger represented one or more shares of Schein New York Common Stock shall be deemed for all corporate purposes to evidence ownership of the aforesaid appropriate number of shares of Schein Delaware Common Stock.

(d) From and after the effective time of the merger, the Certificate of Incorporation and the By-Laws of Schein Delaware shall be the Certificate of Incorporation and the By-Laws of Schein Delaware as in effect immediately prior to such effective time.

(e) From and after the effective time of the merger, the members of the Board of

Directors and officers of Schein Delaware shall be the members of the Board of Directors and the corresponding officers of Schein Delaware immediately before the effective time of the merger; and

RESOLVED, that the Certificate of Merger, the Plan of Merger and the Certificate of Ownership and Merger shall be submitted to the shareholder of Schein New York entitled to vote thereon for its approval; and

RESOLVED, that, subject to the approval of the shareholder of Schein New York, the proper officers of Schein New York are hereby authorized, empowered and directed to do any and all acts and things, and to make, execute, deliver, file and/or record any and all instruments, papers and documents which shall be or become necessary, proper or convenient to carry out or put into effect any of the provisions of these resolutions.

4. The proposed merger herein certified has been adopted, approved, certified, executed, and acknowledged, by Schein New York in accordance with the laws under which it is organized.

Signed and attested to on September 27, 1993.

SCHEIN PHARMACEUTICAL, INC., a New York corporation

By: _____
Martin Sperber,
Chairman of the Board

Attest:

By: _____
Paul Feuerman, Secretary

STATE OF DELAWARE
SECRETARY OF STATE
DIVISION OF CORPORATIONS
FILED 01:15 PM 12/14/1993
753348107 - 2352578

CERTIFICATE OF AMENDMENT
OF
CERTIFICATE OF INCORPORATION
OF
SCHEIN PHARMACEUTICAL CORP.

The undersigned corporation, in order to amend its Certificate of Incorporation, hereby certifies as follows:

FIRST: The name of the corporation is

Schein Pharmaceutical Corp.

SECOND: The corporation hereby amends its Certificate of Incorporation as follows:

Paragraph First of the Certificate of Incorporation, relating to the corporate title of the corporation, is hereby amended to read as follows:

FIRST: The name of the corporation is

Schein Pharmaceutical, Inc.

THIRD: The amendment of the certificate of incorporation herein certified has been duly adopted in accordance with the provisions of Sections 228 and 242 of the General Corporation Law of the State of Delaware.

Signed and attested to on December 14, 1993.

David Roa
Senior Vice President

ATTEST:

Paul Feuerman
Secretary

F81\F\0127\65852\001
92815.F81

12/14/93 10:51am
#2571 (142)

STATE OF DELAWARE
SECRETARY OF STATE
DIVISION OF CORPORATIONS
FILED 03:00 PM 06/21/1995
950138460 - 2352578

RESTATED

CERTIFICATE OF INCORPORATION

OF

SCHEIN PHARMACEUTICAL, INC.

(Pursuant to Section 242 of the
General Corporation Law of the State of Delaware)

It is hereby certified that:

1. The name of the corporation is Schein Pharmaceutical, Inc. (the "Corporation"). The name under which the Corporation was originally incorporated was Schein Pharmaceutical Corp., and the date of filing of the original Certificate of Incorporation of the Corporation with the Secretary of State of the State of Delaware was September 27, 1993.

2. The Board of Directors of the Corporation duly adopted a resolution proposing and declaring it advisable that Certificate of Incorporation of the Corporation be amended and restated in its entirety to read as follows:

FIRST

The name of the corporation is Schein Pharmaceutical, Inc. (the "Corporation").

SECOND

The purpose for which the Corporation is formed is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware (the "Delaware General Corporation Law").

THIRD

A.

The total number of shares of capital stock which the Corporation shall have authority to issue is Five Hundred Twenty-Nine Thousand Two Hundred Ninety-Five (529,295) shares of common stock, $.01 par value per share (the "Common Stock"), of which Four Hundred Thousand (400,000) shares shall be Class A Common Stock, $.01 par value per share (the "Class A Common Shares"), and One Hundred Twenty-Nine Thousand Two Hundred Ninety-Five (129,295) shares shall be Class B Common Stock, $.01 par value per share (the "Class B Common Shares"). Shares of capital stock of the Corporation may be issued for such consideration, not less than the par value thereof, as shall be fixed from time to time by the Board of Directors, and shares issued for such consideration shall be fully paid and nonassessable.

B.

Each share of the Class B Common Shares issued and outstanding, or issued and held in the treasury of the Corporation, shall be automatically reclassified as and changed into one new share of the Corporation's Class A Common Shares, without any action on the part of the holder thereof upon the earliest to occur of (1) an initial public offering of shares of Common Stock, (2) the Termination Date, as that term is defined in the Voting Trust Agreement (the "Voting Agreement") dated September 30, 1994 among Schein Holdings, Inc. ("Holdings") and certain shareholders of Holdings, and Martin Sperber, as voting trustee (the "Voting Trustee"), and (3) May 15, 1999. Upon the occurrence of a transfer on the stock transfer records of the Corporation by a holder of any share of Class B Common Shares, each such share of Class B Common Shares so transferred shall be automatically reclassified as and changed into one new share of the Corporation's Class A Common Shares, without any action on the part of the holder thereof. In those cases where a reclassification described in either of the two preceding sentences would cause a shareholder to receive a fractional share, the Corporation shall issue to the shareholder a stock certificate representing such fractional share.

C.

The following is a statement of the powers, preferences and rights and the qualifications, restrictions and limitations of the Common Stock of the Corporation:

(1) Class A Common Shares and Class B Common Shares. Each Class A Common Share shall be identical in every respect to each Class B Common Share, except as provided in subparagraph (C)(4). Any Class B Common Share that is converted into a Class A Common Share in accordance with paragraph B shall thereafter be a Class A Common Share, with all the powers, preferences and rights and the qualifications, restrictions and limitations, including, without limitation, with respect to voting rights, as the Class A Common Share into which it was converted. No amendment to this Certificate of Incorporation shall in any manner amend, alter, change or repeal any provision (other than provisions relating to voting in subparagraph (C)(4)) relating to the Class A Common Shares without at the same time amending, altering, changing or repealing in the same manner the corresponding provision relating to the Class B Common Shares, without the consent of a majority of the outstanding Class B Common Shares or until such time as there are no Class B Common Shares outstanding.

(2) Dividends. The holders of record of Common Stock shall be entitled to receive such dividends ratably as may from time to time be declared by the Board of Directors out of funds legally available therefor.

(3) Liquidation. In the event of any liquidation, dissolution or winding up of the affairs of the Corporation, voluntary or involuntary, the net assets of the Corporation available to shareholders shall be distributed ratably to the holders of Common Stock. Neither the merger or consolidation of the Corporation with or into another corporation nor any sale, lease, conveyance or other disposition of all or substantially all of the property, business or assets of the Corporation shall be deemed to be a liquidation, dissolution or winding up of the affairs of the Corporation within the meaning of this Article THIRD.

(4) Voting Rights. Except as otherwise required by law, the holders of Class A Common Shares shall be entitled to one vote in respect of each share held on all matters voted upon by the shareholders of the Corporation. The holders of Class B Common Shares shall not be entitled to vote on any matter, or to participate in a shareholders meeting, or to receive notice of any meeting of shareholders; provided, however, at any time the sum of (x) the number of Class A Common Shares subject to the Voting Agreement plus (y) the number of Class A Common Shares owned by the Voting Trustee (or his successor) or the Voting Trustee's (or his successor's) affiliates (as defined in Rule 405

under the Securities Act of 1933) ((x) and (y), together, the "Voting Number") constitutes less than a majority of the outstanding voting shares of the Corporation and the Voting Trustee (or his successor) under the Voting Agreement shall have given written notice to the Corporation and to the known beneficial owner of such shares that he wishes to vote the Required Number (as defined below) of Class B Common Shares at a meeting of shareholders or by written consent for which a record date for notice of and voting at the meeting or the consent shall have been established, the Required Number of Class B Common Shares shall automatically be entitled to participate in and vote at that meeting or in that written consent on the same basis as Class A Common Shares (and shall remain Class B Common Shares until reclassified and changed in accordance with this Certificate of Incorporation). As used in this paragraph 4, the term "Required Number" of Class B Common Shares, for purposes of any such meeting or written consent, means a number of shares equal to (a) the sum of (i) one plus (ii) 50% of the number of shares entitled to vote at the meeting or by consent, as the case may be (it being understood that the Required Number of Class B Common Shares shall be counted as though they were voting shares for purposes of this clause (ii)), reduced by (b) the Voting Number on the record date for that meeting or consent (it being understood that the only circumstance in which the Required Number shall exceed zero is where the Corporation shall have issued a number of voting shares that results in the Voting Number at a particular time being less than a majority of the outstanding voting shares at that time).

(5) Other Rights. Except as set forth above, the Common Stock shall not bear any preferential, conversion or preemptive rights. Without limiting the generality of the foregoing, no class of Common Stock may be split, consolidated or reclassified in any manner other than as expressly provided herein, unless the other class of Common Stock is split, consolidated or reclassified, as the case may be, on an identical basis.

D.

Upon the filing in the office of the Secretary of State of the State of Delaware of this Restated Certificate of Incorporation whereby this Article Fourth is amended to read as set forth herein, the 258,570 issued and outstanding shares of common stock, par value $.01 per share, of the Corporation shall be automatically reclassified and changed into 10 validly issued, fully paid and nonassessable shares of Class A Common Shares. No scrip or fractional shares will be issued by reason of this amendment.

FOURTH

The registered office of the Corporation in the State of Delaware is to be located at 32 Loockerman Square, Suite L-100, in the city of Dover, County of Kent, State of Delaware. The name of its registered agent at that address is The Prentice-Hall Corporation System, Inc.

FIFTH

The duration of the Corporation is to be perpetual.

SIXTH

Unless a greater vote requirement in any matter is provided in this Certificate of Incorporation or the By-laws, the affirmative vote of a majority of the directors present and acting at a duly constituted meeting at which a majority of the entire board of directors is present and acting, is sufficient for all action of the Board of Directors.

Any action required or permitted to be taken by the board of directors may be taken without a meeting if all members of the board consent in writing to the adoption of resolutions authorizing the action.

Elections of directors need not be by ballot unless the By-Laws of the Corporation shall so provide.

SEVENTH

A.

No director shall be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty by such director as a director, provided that this Article SEVENTH shall not eliminate or limit the liability of a director (1) for any breach of such director's duty of loyalty to the Corporation or its stockholders, (2) for acts or omissions of such director not in good faith or which involve intentional misconduct or a knowing violation of law, (3) under Section 174 of the Delaware General Corporation Law, or (4) for any transaction from which such director derived an improper personal benefit, in respect of which such breach of fiduciary duty occurred. If the Delaware General Corporation Law is amended after approval by the stockholders of this Article SEVENTH to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited

to the fullest extent permitted by the Delaware General Corporation Law, as so amended from time to time.

B.

(1) Right of Indemnification. Each person who was or is made a party or is threatened to be made a party to or is involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (hereinafter a "proceeding"), by reason of the fact that he or she, or a person of whom he or she is the legal representative, (a) is or was a director or officer of the Corporation or (b) is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans (whether the basis of such proceeding is alleged action in an official capacity as a director, officer, employee or agent or in any other capacity while serving as a director, officer, employee or agent), shall be indemnified and held harmless by the Corporation to the fullest extent authorized by the Delaware General Corporation Law, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than said law permitted the Corporation to provide prior to such amendment), against all expense, liability and loss (including attorneys' fees, judgments, fines, ERISA excise taxes or penalties and amounts paid or to be paid in settlement) actually and reasonably incurred or suffered by such person in connection therewith and such indemnification shall continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of his or her heirs, executors and administrators; provided, however, that, except as provided in paragraph (2) hereof the Corporation shall indemnify any such person seeking indemnification in connection with a proceeding (or part thereof) initiated by such person only if such proceeding (or part thereof) was authorized by the Board of Directors of the corporation. The right to indemnification conferred in this Article SEVENTH shall be a contract right and shall include the right to be paid by the Corporation the expenses incurred in defending any such proceeding in advance of its final disposition; provided, however, that, if the Delaware General Corporation Law requires, the payment of such expenses incurred by a director or officer in his or her capacity as such (and not in any other capacity in which service was or is rendered by such person while a director or officer, including, without limitation, service with respect to an employee benefit plan) in advance of the final disposition of a proceeding, shall be made only upon delivery to the Corporation of an undertaking, by or on behalf of such director or officer, to repay all amounts so advanced if it shall ultimately be determined that such director or officer is not entitled to be indemnified under this

Article SEVENTH or otherwise. The Corporation may, by action of its Board of Directors, provide indemnification to employees and agents of the Corporation with the same scope and effect as the foregoing indemnification of directors and officers.

(2) Right of Claimant to Bring Suit. If a claim under paragraph (1) of this Article SEVENTH is not paid in full by the Corporation within thirty days after a written claim has been received by the Corporation, the claimant may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim and, if successful in whole or in part, the claimant shall be entitled to be paid also the expense of prosecuting such claim. It shall be a defense to any such action (other than an action brought to enforce a claim for expenses incurred in defending any proceeding in advance of its final disposition where the required undertaking, if any is required, has been tendered to the Corporation) that the claimant has not met the standards of conduct which make it permissible under the Delaware General Corporation Law for the Corporation to indemnify the claimant for the amount claimed, but the burden of proving such defense shall be on the Corporation. Neither the failure of the Corporation (including its Board of Directors, independent legal counsel, or its stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances because he or she has met the applicable standard of conduct set forth in the Delaware General Corporation Law, nor an actual determination by the Corporation (including its Board of Directors, independent legal counsel, or its stockholders) that the claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that the claimant has not met the applicable standard of conduct.

(3) Non-Exclusivity of Rights. The right to indemnification and the payment of expenses incurred in defending a proceeding in advance of its final disposition conferred in this Article SEVENTH shall not be exclusive of any other right which any person may have or hereafter acquire under any statute, provision of the Certificate of Incorporation, by-law, agreement, vote of stockholders or disinterested directors or otherwise.

(4) Insurance. The Corporation may maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, against any such expense, liability or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the Delaware General Corporation Law.

EIGHTH

Subject to the provisions of Article NINE below, the directors of the Corporation may, by a vote of a majority of directors present at a meeting in which a quorum is present, adopt, amend or repeal any By-Law.

NINTH

The Corporation shall not, and shall not permit any of its subsidiaries to, and no officer, employee or other agent of the Corporation or any of its subsidiaries shall have the authority, in the name or on behalf of the Corporation or any of its subsidiaries to, directly or indirectly, without the prior written consent of Bayer Corporation ("Bayer," formerly Miles Inc.) (which consent shall be deemed given, if a majority of Bayer's nominees to the board of directors of the Corporation consent in writing (it being understood that consent given in this manner shall not be deemed the exclusive method of giving consent)) amend or restate the Corporation's certificate of incorporation or By-Laws in any respect, (a) as a result of which the ability to (i) elect a majority of the members of the board of directors of the Corporation, (ii) adopt an agreement of merger or consolidation, (iii) approve a sale of all or substantially all the assets of the Corporation or (iv) adopt an amendment to the Corporation's certificate of incorporation or by-laws would require the vote of more than a majority of the outstanding shares of Common Stock entitled to vote thereon, (b) that would adversely affect Bayer differently from other holders of shares of Common Stock or (c) that, by its terms, would prohibit any foreign national from holding shares of Common Stock or serving as a director.

This Article NINTH may be amended only with the prior written consent of Bayer (as described above in this Article NINTH), and the provisions of this Article NINTH shall terminate and be of no further force or effect upon the termination of Bayer's rights under Section 2.5 of the General Shareholders Agreement dated September 30, 1994 among Holdings, Miles Inc. and certain shareholders of Holdings, as provided in such General Shareholders Agreement.

TENTH

Whenever a compromise or arrangement is proposed between the Corporation and its creditors or any class of them and/or between the Corporation and its stockholders or any class of them, any court of equitable jurisdiction within the State of Delaware may, on the application in a summary way of the Corporation or of any creditor or stockholder thereof or on the application of any receiver or receivers appointed for the

Corporation under the provisions of Section 291 of Title 8 of the Delaware Code or on the application of trustees in dissolution or of any receiver or receivers appointed for the Corporation under the provisions of Section 279 of Title 8 of the Delaware Code, order a meeting of the creditors or class of creditors, and/or of the stockholders of the Corporation, as the case may be, to be summoned in such manner as the said court directs. If a majority in number representing three fourths in value of the creditors or class of creditors, and/or of the stockholders or class of stockholders of the Corporation, as the case may be, agree to any compromise or arrangement and to any reorganization of the Corporation as a consequence of such compromise or arrangement, the said compromise or arrangement and the said reorganization shall, if sanctioned by the court to which the said application has been made, be binding on all the creditors or class of creditors, and/or on all the stockholders, of the Corporation, as the case may be, and also on the Corporation.

3. In lieu of a vote, written consent to the foregoing amendment has been given by the sole stockholder of the Corporation, in accordance with Section 228 of the General Corporation Law of the State of Delaware, and such amendment has been duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.

4. This amendment to the Certificate of Incorporation shall be effective on and as of the date of filing this Certificate of Amendment with the office of the Secretary of State of the State of Delaware.

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be executed in its name by its President and attested to by its Secretary this 14th day of June, 1995, and the statements contained herein are affirmed as true under penalties of perjury.

SCHEIN PHARMACEUTICAL, INC.

By: _____
Martin Sparber
President

ATTEST:

By: _____
Paul M. Feuerman
Secretary

STATE OF DELAWARE
SECRETARY OF STATE
DIVISION OF CORPORATIONS
FILED 03:30 PM 06/23/1995
950141270 - 2352578

CERTIFICATE OF OWNERSHIP AND MERGER

-of-

Schein Holdings, Inc.

(a New York corporation)

-into-

Schein Pharmaceutical, Inc.

(a Delaware corporation)

It is hereby certified that:

1. Schein Holdings, Inc., a New York corporation ("Holdings"), is a corporation permitted under the laws of the State of New York to be merged with a corporation of another jurisdiction.

2. Holdings, as the owner of all of the outstanding shares of capital stock of Schein Pharmaceutical, Inc., a Delaware corporation ("SPINC"), hereby merges itself into SPINC.

3. The following is a copy of the resolutions adopted on the 31st day of May, 1995, by the Board of Directors of Holdings to merge Holdings into SPINC:

> RESOLVED, that, subject to the approval of the shareholders of Holdings, Holdings be reincorporated in the State of Delaware by merging itself with and into SPINC pursuant to the laws of the State of New York and the State of Delaware as hereinafter provided, so that the separate existence of Holdings shall cease upon the merger becoming effective, and thereupon Holdings and SPINC will become a single corporation, which shall continue to exist under, and be governed by, the laws of the State of Delaware; and
>
> RESOLVED that the terms and conditions of the proposed merger are as follows:
>
> > (a) No pro rata issuance of shares of stock of SPINC which are owned by Holdings immediately prior to the effective time of the merger shall be made, and such shares shall be surrendered and extinguished.
> >
> > (b) Each share (or fraction of a share) of class A common stock, $.01 par value, of Holdings ("Holdings Class A Common Stock") and

[illegible]
(errm)

class B common stock, $.01 par value, of Holdings ("Holdings Class B Common Stock" and, together with Holdings Class A Common Stock, "Holdings Common Stock") which shall be issued and outstanding immediately prior to the effective time of the merger shall, without any action on the part of the holder thereof, be converted at the effective time of the merger into one issued and outstanding share (or fraction of a share) of class A common stock, $.01 par value, of SPINC ("SPINC Class A Common Stock") and class B common stock, $.01 par value, of SPINC ("SPINC Class B Common Stock" and, together with SPINC Class A Common Stock, "SPINC Common Stock"), respectively, and from and after the effective time of the merger, the holders of all of said issued and outstanding shares of Holdings Common Stock shall automatically be and become holders of shares of SPINC Common Stock upon the basis above specified, whether or not certificates representing said shares are then issued and delivered.

(c) After the effective time of the merger, each holder of record of any outstanding certificate or certificates theretofore representing Holdings Common Stock may surrender the same to SPINC at its office at 100 Campus Drive, Florham Park, New Jersey and such holder shall be entitled upon such surrender to receive in exchange therefor a certificate or certificates representing the appropriate class and number of shares of SPINC Common Stock, as determined in accordance with the terms set forth in the preceding paragraph (b). Until so surrendered, each outstanding certificate which prior to the effective time of the merger represented one or more shares of Holdings Common Stock shall be deemed for all purposes to evidence ownership of the aforesaid class and number of shares of SPINC Common Stock.

(d) From and after the effective time of the merger, the Certificate of Incorporation and the By-Laws of SPINC shall be the Certificate of Incorporation and the By-Laws of SPINC as in effect immediately prior to such effective time.

(e) From and after the effective time of the merger, the members of the board of

directors and officers of SPINC shall be the members of the board of directors and the corresponding officers of SPINC immediately before the effective time of the merger; and

RESOLVED, that the certificate of merger, the plan of merger and the certificate of ownership and merger, forms of which are attached hereto as Exhibits 1, 2 and 3, respectively, shall be submitted to the shareholders of Holdings entitled to vote thereon for their approval; and

RESOLVED, that, subject to the approval of the shareholders of Holdings, the proper officers of Holdings are hereby authorized, empowered and directed to do any and all acts and things, and to make, execute, deliver, file and/or record any and all instruments, papers and documents which shall be or become necessary, proper or convenient to carry out or put into effect any of the provisions of these resolutions.

4. The proposed merger herein certified has been adopted, approved, certified, executed, and acknowledged, by Holdings in accordance with the laws under which it is organized.

Signed and attested to on June 14, 1995.

SCHEIN HOLDINGS, INC.,
a New York corporation

By: _____
Martin Sperber
Chief Executive Officer

Attest:

By: _____
Paul Feiveman
Secretary

Exhibit 1

Certificate of Merger

-of-

Schein Holdings, Inc.
(a New York corporation)

-into-

Schein Pharmaceutical, Inc.
(a Delaware corporation)

(Under Section 907 of the Business Corporation Law)

It is hereby certified, on behalf of each of the constituent corporations herein named, as follows:

FIRST: The Board of Directors of each of the constituent corporations has duly adopted a plan of merger setting forth the terms and conditions of the merger of said corporations.

SECOND: The name of the foreign constituent corporation, which is to be the surviving corporation, and which is hereinafter sometimes referred to as the "surviving corporation," is Schein Pharmaceutical, Inc. The jurisdiction of its incorporation is Delaware; and the date of its incorporation therein is September 27, 1993. The name under which the surviving corporation was originally formed is Schein Pharmaceutical Corp.

THIRD: The name of the domestic constituent corporation, which is being merged into the surviving corporation, and which is hereinafter sometimes referred to as the "terminating corporation," is Schein Holdings, Inc. The date upon which its certificate of incorporation was filed by the Department of State is December 3, 1964. The name under which the terminating corporation was originally formed is Henry Schein, Inc. The terminating corporation is the owner of all of the issued and outstanding stock of the surviving corporation.

FOURTH: With respect to the surviving corporation, the designation and number of authorized shares is 400,000 shares of class A common stock, $.01 par value ("SPINC Class A Common Stock"), each of which are entitled to one vote, and 129,295 shares of class B common stock, $.01 par value ("SPINC Class B Common Stock"). SPINC Class B Common Stock is not entitled to vote on any matter; provided, however, at any time the sum of (x) the number of shares SPINC Class A Common Shares Stock subject to

the voting trust agreement (the "Voting Agreement") dated September 30, 1994, among Holdings, certain shareholders of Holdings, and Martin Sperber, as voting trustee (the "Voting Trustee"), plus (y) the number of shares of SPINC Class A Common Stock owned by the Voting Trustee (or his successor) or the Voting Trustee's (or his successor's) affiliates (as defined in Rule 405 under the Securities Act of 1933) constitutes less than a majority of the outstanding voting shares of the surviving corporation and the Voting Trustee (or his successor) under the Voting Agreement shall have given written notice to the surviving corporation and to the known beneficial owner of such shares that he wishes to vote the Required Number (as defined in the surviving corporation's certificate of incorporation) of shares of SPINC Class B Common Stock at a meeting of stockholders or by written consent for which a record date for notice of and voting at the meeting or the consent shall have been established, the Required Number of shares of SPINC Class B Common Stock shall automatically be entitled to participate in and vote at that meeting or in that written consent on the same basis as SPINC Class A Common Stock.

With respect to the terminating corporation, the designation and number of authorized shares is 400,000 shares of class A common stock, $.01 par value ("Holdings Class A Common Stock"), each of which are entitled to one vote, and 129,295 shares of class B common stock, $.01 par value ("Holdings Class B Common Stock"). Holdings Class B Common Stock has the identical voting rights as SPINC Class B Common Stock.

FIFTH: Each issued and outstanding share (or fraction thereof) of Holdings Class A Common Stock and Holdings Class B Common Stock shall, upon the effective time of the merger, without any action on the part of the holder thereof, be converted into one share (or fraction thereof) of SPINC Class A Common Stock and SPINC Class B Common Stock, respectively. The issued and outstanding shares of the surviving corporation shall not be converted in any manner, but each said share which is issued and outstanding as of the effective time of the merger shall be cancelled and extinguished without any further action on the part of the holder thereof.

SIXTH: The merger herein certified was authorized in respect of the terminating corporation by the written consent of the holders of all outstanding shares of the corporation entitled to vote on the plan of merger, in accordance with Section 903(a) of the New York Business Corporation Law.

SEVENTH: The merger herein certified is permitted by the laws of the jurisdiction of incorporation of the surviving corporation and is in compliance with said laws.

EIGHTH: The surviving corporation agrees that it may be served with process in the State of New York in any action or

special proceeding for the enforcement of any liability or obligation of the terminating corporation, for the enforcement of any liability or obligation of the surviving corporation for which the surviving corporation is previously amenable to suit in the State of New York, and for the enforcement, as provided in the New York Business Corporation Law, of the right of shareholders of the terminating corporation to receive payment for their shares against the surviving corporation.

NINTH: The surviving corporation agrees that, subject to the provisions of Section 623 of the Business Corporation Law of the State of New York, it will promptly pay to the shareholders of the merged constituent corporation the amount, if any, to which they shall be entitled under the provisions of the Business Corporation Law of the State of New York relating to the rights of shareholders to receive payment for their shares.

TENTH: The surviving constituent corporation hereby designates the Secretary of State of the State of New York as its agent upon whom process against it may be served in the manner set forth in paragraph (b) of Section 306 of the New York Business Corporation Law in any action or special proceeding. The post office address within the State of New York to which said Secretary of State shall mail a copy of any process against the surviving corporation served upon him or her is:

Allan H. Cohen, Esq.
c/o Proskauer Rose Goetz & Mendelsohn LLP
1585 Broadway
New York, New York 10036

IN WITNESS WHEREOF, we have subscribed this document on the date set forth below and do hereby affirm, under the penalties of perjury, that the statements contained therein have been examined by us and are true and correct.

Date: May ___, 1995

SCHEIN HOLDINGS, INC.,
a New York corporation

By: _____
Martin Sperber
Chief Executive Officer

ATTEST:

By: _____
Paul M. Feuerman
Secretary

SCHEIN PHARMACEUTICAL, INC.,
a Delaware corporation

By: _____
Martin Sperber
President

ATTEST:

By: _____
Paul M. Feuerman
Secretary

Exhibit 2

PLAN OF MERGER adopted on May ___, 1995 by Schein Holdings, Inc., a New York corporation ("Holdings"), and adopted on May ___, 1995 by Schein Pharmaceutical, Inc., a Delaware corporation and wholly-owned subsidiary of Holdings ("SPINC").

1. The participating corporations, Holdings and SPINC, shall, pursuant to the provisions of the Business Corporation Law of the State of New York, and the provisions of the laws of the State of Delaware, be merged with and into a single corporation, to wit, SPINC, which shall be the surviving corporation upon the effective date of the merger and which is sometimes hereinafter referred to as the "surviving corporation," and which shall continue to exist as said surviving corporation under its present name pursuant to the provisions of the laws of the jurisdiction of its incorporation. The separate existence of Holdings, which is sometimes hereinafter referred to as the "terminating corporation," shall cease upon the effective date of the merger in accordance with the provisions of the Business Corporation Law of the State of New York.

2. With respect to the surviving corporation, the designation and number of outstanding shares is 10 shares, par value $.01, all of which are class A common stock ("SPINC Class A Common Stock"), and all of which are entitled to vote.

With respect to the terminating corporation, the designation and number of outstanding shares is 400,000 shares of class A common stock, par value $.01 ("Holdings Class A Common Stock"), each of which is entitled to one vote, and 139,295 shares of Class B common stock, par value $.01 ("Holdings Class B Common Stock"). Holdings Class B Common Stock is not entitled to vote on any matter; provided, however, at any time the sum of (x) the number of shares Holdings Class A Common Shares Stock subject to the voting trust agreement (the "Voting Agreement") dated September 30, 1994, among the Corporation, certain shareholders of the Corporation, and Martin Sperber, as voting trustee (the "Voting Trustee"), plus (Y) the number of shares of Holdings Class A Common Stock owned by the Voting Trustee (or his successor) or the Voting Trustee's (or his successor's) affiliates (as defined in Rule 405 under the Securities Act of 1933) constitutes less than a majority of the outstanding voting shares of the Corporation and the Voting Trustee (or his successor) under the Voting Agreement shall have given written notice to the Corporation and to the known beneficial owner of such shares that he wishes to vote the Required Number (as defined in Holding's certificate of incorporation) of shares of Holdings Class B Common Stock at a meeting of shareholders or by written consent for which a record date for notice of and voting at the meeting or the consent shall have been established, the Required Number of shares of Holdings Class B Common Stock shall automatically be entitled to participate in and vote at that

meeting or in that written consent on the same basis as Holdings Class A Common Stock.

3. The certificate of incorporation of the surviving corporation upon the effective date of the merger will be the certificate of incorporation of said surviving corporation and will continue in full force and effect until changed, altered or amended as therein provided and in the manner prescribed by the provisions of the laws of the jurisdiction of its incorporation.

4. The by-laws of the surviving corporation upon the effective date of the merger will be the by-laws of said surviving corporation and will continue in full force and effect until changed, altered or amended as therein provided and in the manner prescribed by the provisions of the laws of the jurisdiction of its incorporation.

5. The directors and officers in office of the surviving corporation upon the effective date of the merger shall be the members of the board of directors and the officers of the terminating corporation, all of whom shall hold their directorships and offices until the election and qualification of their respective successors or until their tenure is otherwise terminated in accordance with the by-laws of the surviving corporation.

6. Each issued and outstanding share (or fraction thereof) of Holdings Class A Common Stock and Holdings Class B Common Stock shall, upon the effective date of the merger, without any action on the part of the holder thereof, be converted into one share (or fraction thereof) of SPINC Class A Common Stock and class B common stock of the surviving corporation, par value $.01, respectively. The issued and outstanding shares of the surviving corporation shall not be converted in any manner, but each said share which is issued and outstanding as of the effective date of the merger shall be surrendered and extinguished.

7. The Plan of Merger herein made and adopted shall be submitted to the shareholders of the terminating corporation for their approval or rejection in the manner prescribed by the provisions of the Business Corporation Law of the State of New York, and the merger of the terminating corporation with and into the surviving corporation shall be authorized in the manner prescribed by the laws of the jurisdiction of incorporation of the surviving corporation.

8. In the event that the Plan of Merger shall have been adopted by the shareholders entitled to vote of the terminating corporation in the manner prescribed by the provisions of the Business Corporation Law of the State of New York, and in the event that the merger of the terminating corporation with and into the surviving corporation shall have

been duly authorized in compliance with the laws of the jurisdiction of incorporation of the surviving corporation, the terminating corporation and the surviving corporation hereby stipulate that they will cause to be executed and filed and/or recorded any document or documents prescribed by the laws of the State of New York and of the State of Delaware, and that they will cause to be performed all necessary acts therein and elsewhere to effectuate the merger, subject, however, to any provision or provisions contained hereinafter for abandoning the Plan of Merger before or after the adoption thereof by the shareholders entitled to vote of the terminating corporation or before or after the authorization of the merger on behalf of the surviving corporation.

9. The board of directors and the proper officers of the terminating corporation and of the surviving corporation, respectively, are hereby authorized, empowered, and directed to do any and all acts and things, and to make, execute, deliver, file and/or record any and all instruments, papers and documents which shall be or become necessary, proper or convenient to carry out or put into effect any of the provisions of this Plan of Merger or of the merger herein provided for.

10. Notwithstanding the adoption of the Plan of Merger by the shareholders entitled to vote of the terminating corporation and the authorization of the merger on behalf of the surviving corporation in the manner prescribed by the laws of the jurisdiction of its incorporation, the Plan of Merger may be abandoned at any time prior to the filing of a Certificate of Merger of the corporations by the Department of State of the State of New York in the event that the board of directors of either the terminating or the surviving corporation deems such abandonment to be in the best interests of their respective corporation.

Exhibit 3

CERTIFICATE OF OWNERSHIP AND MERGER

-of-

Schein Holdings, Inc.

(a New York corporation)

-into-

Schein Pharmaceutical, Inc.

(a Delaware corporation)

It is hereby certified that:

1. Schein Holdings, Inc., a New York corporation ("Holdings"), is a corporation permitted under the laws of the State of New York to be merged with a corporation of another jurisdiction.

2. Holdings, as the owner of all of the outstanding shares of capital stock of Schein Pharmaceutical, Inc., a Delaware corporation ("SPINC"), hereby merges itself into SPINC.

3. The following is a copy of the resolutions adopted on the _____ day of May, 1995, by the Board of Directors of Holdings to merge Holdings into SPINC:

RESOLVED, that, subject to the approval of the shareholders of Holdings, Holdings be reincorporated in the State of Delaware by merging itself with and into SPINC pursuant to the laws of the State of New York and the State of Delaware as hereinafter provided, so that the separate existence of Holdings shall cease upon the merger becoming effective, and thereupon Holdings and SPINC will become a single corporation, which shall continue to exist under, and be governed by, the laws of the State of Delaware; and

RESOLVED that the terms and conditions of the proposed merger are as follows:

(a) No pro rata issuance of shares of stock of SPINC which are owned by Holdings immediately prior to the effective time of the merger shall be made, and such shares shall be surrendered and extinguished.

(b) Each share (or fraction of a share) of class A common stock, $.01 par value, of Holdings ("Holdings Class A Common Stock") and class B common stock, $.01 par value, of Holdings ("Holdings Class B Common Stock" and, together with Holdings Class A Common Stock, "Holdings Common Stock") which shall be issued and outstanding immediately prior to the effective time of the merger shall, without any action on the part of the holder thereof, be converted at the effective time of the merger into one issued and outstanding share (or fraction of a share) of class A common stock, $.01 par value, of SPINC ("SPINC Class A Common Stock") and class B common stock, $.01 par value, of SPINC ("SPINC Class B Common Stock" and, together with SPINC Class A Common Stock, "SPINC Common Stock"), respectively, and from and after the effective time of the merger, the holders of all of said issued and outstanding shares of Holdings Common Stock shall automatically be and become holders of shares of SPINC Common Stock upon the basis above specified, whether or not certificates representing said shares are then issued and delivered.

(c) After the effective time of the merger, each holder of record of any outstanding certificate or certificates theretofore representing Holdings Common Stock may surrender the same to SPINC at its office at 100 Campus Drive, Florham Park, New Jersey and such holder shall be entitled upon such surrender to receive in exchange therefor a certificate or certificates representing the appropriate class and number of shares of SPINC Common Stock, as determined in accordance with the terms set forth in the preceding paragraph (b). Until so surrendered, each outstanding certificate which prior to the effective time of the merger represented one or more shares of Holdings Common Stock shall be deemed for all purposes to evidence ownership of the aforesaid class and number of shares of SPINC Common Stock.

(d) From and after the effective time of the merger, the Certificate of Incorporation and the By-Laws of SPINC shall be the Certificate of Incorporation and the By-Laws

of SPINC as in effect immediately prior to such effective time.

(e) From and after the effective time of the merger, the members of the board of directors and officers of SPINC shall be the members of the board of directors and the corresponding officers of Holdings immediately before the effective time of the merger; and

RESOLVED, that the certificate of merger, the plan of merger and the certificate of ownership and merger, forms of which are attached hereto as Exhibits 1, 2 and 3, respectively, shall be submitted to the shareholders of Holdings entitled to vote thereon for their approval; and

RESOLVED, that, subject to the approval of the shareholders of Holdings, the proper officers of Holdings are hereby authorized, empowered and directed to do any and all acts and things, and to make, execute, deliver, file and/or record any and all instruments, papers and documents which shall be or become necessary, proper or convenient to carry out or put into effect any of the provisions of these resolutions.

4. The proposed merger herein certified has been adopted, approved, certified, executed, and acknowledged, by Holdings in accordance with the laws under which it is organized.

Signed and attested to on May ___, 1995.

SCHEIN HOLDINGS, INC.,
a New York corporation

By:_____
Martin Sparber
Chief Executive Officer

Attest:

By:_____
Paul M. Fouerman
Secretary

STATE OF DELAWARE
SECRETARY OF STATE
DIVISION OF CORPORATIONS
FILED 09:00 AM 04/03/1998
981130158 - 2352578

RESTATED

CERTIFICATE OF INCORPORATION

OF

SCHEIN PHARMACEUTICAL, INC.

(Pursuant to Sections 242 and 245 of the
General Corporation Law of the State of Delaware)

It is hereby certified that:

1. The name of the corporation is Schein Pharmaceutical, Inc. (the "Corporation"). The name under which the Corporation was originally incorporated was Schein Pharmaceutical Corp., and the date of filing of the original Certificate of Incorporation of the Corporation with the Secretary of State of the State of Delaware was September 27, 1993.

2. The Board of Directors of the Corporation duly adopted a resolution proposing and declaring it advisable that Certificate of Incorporation of the Corporation be amended and restated in its entirety to read as follows:

FIRST

The name of the corporation is Schein Pharmaceutical, Inc. (the "Corporation").

SECOND

The purpose for which the Corporation is formed is to engage in any lawful act or activity for which corporations may

be organized under the General Corporation Law of the State of Delaware (the "Delaware General Corporation Law").

THIRD

A.

The total number of shares of capital stock which the Corporation shall have authority to issue is One Hundred Million (100,000,000) shares of common stock, $.01 par value per share (the "Common Stock"), of which Seventy-Six Million (76,000,000) shares shall be Class A Common Stock, $.01 par value per share (the "Class A Common Shares"), and Twenty-Four Million (24,000,000) shares shall be Class B Common Stock, $.01 par value per share (the "Class B Common Shares") and Two Million (2,000,000) shares of preferred stock, $.01 par value per share (the "Preferred Stock"). The Board of Directors may authorize, without further stockholder approval, the issuance from time to time of the preferred stock in one or more series with such designations and such powers, preferences and rights, and such qualifications, limitations or restrictions (which may differ with respect to each series) as the Board of Directors may fix by resolution. Shares of capital stock of the Corporation may be issued for such consideration, not less than the par value thereof, as shall be fixed from time to time by the Board of Directors, and shares issued for such consideration shall be fully paid and nonassessable.

B.

Each share of the Class B Common Shares issued and outstanding, or issued and held in the treasury of the Corporation, shall be automatically reclassified as and changed into one new share of the Corporation's Class A Common Shares, without any action on the part of the holder thereof upon the earliest to occur of (1) an initial public offering of shares of Common Stock, (2) the Termination Date, as that term is defined in the Voting Trust Agreement (the "Voting Agreement") dated September 30, 1994 among Schein Holdings, Inc. ("Holdings") and certain shareholders of Holdings, and Martin Sperber, as voting trustee (the "Voting Trustee"), and (3) May 15, 1999. Upon the occurrence of a transfer on the stock transfer records of the Corporation by a holder of any share of Class B Common Shares, each such share of Class B Common Shares so transferred shall be automatically reclassified as and changed into one new share of the Corporation's Class A Common Shares, without any action on the part of the holder thereof. Upon the occurrence of such a reclassification, each outstanding share of the Class A Common Shares shall cease to be called "Class A Common Shares" and shall be called "Common Stock", and shall otherwise be unchanged. In those cases where a reclassification described in the preceding sentences would cause a shareholder to receive a fractional

share, the Corporation shall issue to the shareholder a stock certificate representing such fractional share.

C.

The following is a statement of the powers, preferences and rights and the qualifications, restrictions and limitations of the Common Stock of the Corporation:

(1) Class A Common Shares and Class B Common Shares. Each Class A Common Share shall be identical in every respect to each Class B Common Share, except as provided in subparagraph (C)(4). Any Class B Common Share that is converted into a Class A Common Share in accordance with paragraph B shall thereafter be a Class A Common Share, with all the powers, preferences and rights and the qualifications, restrictions and limitations, including, without limitation, with respect to voting rights, as the Class A Common Share into which it was converted. No amendment to this Certificate of Incorporation shall in any manner amend, alter, change or repeal any provision (other than provisions relating to voting in subparagraph (C)(4)) relating to the Class A Common Shares without at the same time amending, altering, changing or repealing in the same manner the corresponding provision relating to the Class B Common Shares, without the consent of a majority of the outstanding Class B Common Shares or until such time as there are no Class B Common Shares outstanding.

(2) Dividends. The holders of record of Common Stock shall be entitled to receive such dividends ratably as may from time to time be declared by the Board of Directors out of funds legally available therefor.

(3) Liquidation. In the event of any liquidation, dissolution or winding up of the affairs of the Corporation, voluntary or involuntary, the net assets of the Corporation available to shareholders shall be distributed ratably to the holders of Common Stock. Neither the merger or consolidation of the Corporation with or into another corporation nor any sale, lease, conveyance or other disposition of all or substantially all of the property, business or assets of the Corporation shall be deemed to be a liquidation, dissolution or winding up of the affairs of the Corporation within the meaning of this Article THIRD.

(4) Voting Rights. Except as otherwise required by law, the holders of Class A Common Shares shall be entitled to one vote in respect of each share held on all matters voted upon by the shareholders of the Corporation. The holders of Class B Common Shares shall not be entitled to vote on any matter, or to participate in a shareholders meeting, or to receive notice of any meeting of shareholders; provided, however, at any time the sum of (x) the number of Class A Common Shares subject to the

Voting Agreement plus (y) the number of Class A Common Shares owned by the Voting Trustee (or his successor) or the Voting Trustee's (or his successor's) affiliates (as defined in Rule 405 under the Securities Act of 1933) ((x) and (y), together, the "Voting Number") constitutes less than a majority of the outstanding voting shares of the Corporation and the Voting Trustee (or his successor) under the Voting Agreement shall have given written notice to the Corporation and to the known beneficial owner of such shares that he wishes to vote the Required Number (as defined below) of Class B Common Shares at a meeting of shareholders or by written consent for which a record date for notice of and voting at the meeting or the consent shall have been established, the Required Number of Class B Common Shares shall automatically be entitled to participate in and vote at that meeting or in that written consent on the same basis as Class A Common Shares (and shall remain Class B Common Shares until reclassified and changed in accordance with this Certificate of Incorporation). As used in this paragraph 4, the term "Required Number" of Class B Common Shares, for purposes of any such meeting or written consent, means a number of shares equal to (a) the sum of (i) one plus (ii) 50% of the number of shares entitled to vote at the meeting or by consent, as the case may be (it being understood that the Required Number of Class B Common Shares shall be counted as though they were voting shares for purposes of this clause (ii)), reduced by (b) the Voting Number on the record date for that meeting or consent (it being understood that the only circumstance in which the Required Number shall exceed zero is where the Corporation shall have issued a number of voting shares that results in the Voting Number at a particular time being less than a majority of the outstanding voting shares at that time).

(5) Other Rights. Except as set forth above, the Common Stock shall not bear any preferential, conversion or preemptive rights. Without limiting the generality of the foregoing, no class of Common Stock may be split, consolidated or reclassified in any manner other than as expressly provided herein, unless the other class of Common Stock is split, consolidated or reclassified, as the case may be, on an identical basis.

D.

Upon the filing in the office of the Secretary of State of the State of Delaware of this Restated Certificate of Incorporation whereby this Article THIRD is amended to read as set forth herein, each issued and outstanding share of Class A Common Shares, par value $.01 per share, of the Corporation shall be automatically reclassified and changed into 105 validly issued, fully paid and nonassessable shares of Class A Common Shares, and each issued and outstanding share of Class B Common Shares, par value $.01 per share, of the Corporation shall be

automatically reclassified and changed into 105 validly issued, fully paid and nonassessable shares of Class B Common Shares. No scrip or fractional shares will be issued by reason of this amendment.

E.

Action required or permitted to be taken at a meeting of the stockholders of the Corporation may not be taken by consent or consents in writing in lieu of a meeting.

FOURTH

The registered office of the Corporation in the State of Delaware is to be located at 1013 Centre Road, Wilmington, County of New Castle, Delaware, 19805. The name of its registered agent at that address is Corporation Service Company.

FIFTH

The duration of the Corporation is to be perpetual.

SIXTH

(1) The Board of Directors shall be divided into three classes, as nearly equal in number as the then total number of directors (which shall not be fewer than five or more than nine, unless otherwise determined by the Board of Directors) constituting the whole board permits, with the term of office of one class expiring each year. At the next election of directors, directors of the first class (which shall initially be comprised of Martin Sperber and Richard Goldberg) shall be elected to hold office for a term expiring at the next succeeding annual meeting, directors of the second class (which shall initially be comprised of Dariush Ashrafi) shall be elected to hold office for a term expiring at the second succeeding annual meeting and directors of the third class (which shall initially be comprised of David Ebsworth and Paul Feuerman) shall be elected to hold office for a term expiring at the third succeeding annual meeting. Subject to the foregoing, at each annual meeting of stockholders, the successors to the class of directors whose term shall then expire shall be elected to hold office for a term expiring at the third succeeding annual meeting and each director so elected shall hold office until his successor is elected and qualified, or until his earlier resignation or removal. If the number of directors is changed, any increase or decrease in the number of directors shall be apportioned among the three classes to make all classes as nearly equal in number as possible, and the Board of Directors

shall decide which class shall contain an unequal number of directors.

(2) Only persons who are nominated in accordance with the procedures set forth in this paragraph, or in the general stockholders agreement dated September 30, 1994 among Schein Holdings, Inc. (now Schein Pharmaceutical, Inc.), Miles Inc. and certain stockholders of Schein Holdings, Inc. (the "General Stockholders Agreement"), shall be eligible to serve as directors. Nominations of persons for election to the Board of Directors of the Corporation may be made at an annual meeting of stockholders (a) by or at the direction of the Board of Directors or (b) by or on behalf of a stockholder of the Corporation, or a duly authorized proxy for such stockholder, who is a stockholder of record at the time of giving notice provided for in this paragraph and who shall be entitled to vote for the election of directors at the meeting. Any nominations not made by or at the direction of the Board of Directors must be made pursuant to a notice in writing to the Secretary of the Corporation delivered or mailed to, and received at, the principal executive offices of the Corporation not fewer than 60 days or more than 90 days prior to the anniversary date of the immediately preceding annual meeting; provided, however, that in the event the annual meeting with respect to which such notice is to be tendered is not held within 30 days before or after such anniversary date, notice by the stockholder to be timely must be received not earlier than 90 days prior to such annual meeting and not later than 60 days prior to such annual meeting; and further provided, however, that, notwithstanding the foregoing, with respect to the first annual meeting of stockholders after January 2, 1998, such notice by the stockholder must be received at the principal executive offices of the Corporation prior to the close of business on the tenth day following the date on which notice of the meeting was first given or made to stockholders generally. Such stockholder's notice shall set forth (a) as to each person whom the stockholder proposes to nominate for election or reelection as a director, all information relating to such person that is required to be disclosed in solicitations of proxies for election of directors, or is otherwise required, in each case pursuant to Regulation 14A under the Securities Exchange Act of 1934 (including such person's written consent to being named as a nominee and to serving as a director, if elected); and (b) as to the stockholder giving the notice (i) the name and address, as they appear on the Corporation's books, of such stockholder, (ii) the class and number of shares of stock of the Corporation beneficially owned by such stockholder and represented by proxy and (iii) a description of all arrangements or understandings between such stockholder and any other person or persons (including their names) in connection with such nomination and any material interest of such stockholder in such nomination. At the request of the Board of Directors, any person nominated by the Board of Directors for election as a director shall furnish to the Secretary of the Corporation that information required to

be set forth in a stockholder's notice of nomination that pertains to the nominee. If the Board of Directors shall determine, based on the facts, that a nomination was not made in accordance with the above procedures, the Chairman of the meeting shall so declare to the meeting and the defective nomination shall be disregarded.

(3) Unless a greater vote requirement in any matter is provided in this Certificate of Incorporation or the By-laws, the affirmative vote of a majority of the directors present and acting at a duly constituted meeting at which a majority of the entire Board of Directors is present and acting, is sufficient for all action of the Board of Directors.

(4) Any action required or permitted to be taken by the Board of Directors may be taken without a meeting if all members of the Board consent in writing to the adoption of resolutions authorizing the action.

(5) Elections of directors need not be by ballot unless the By-Laws of the Corporation shall so provide.

SEVENTH

A.

No director shall be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty by such director as a director, provided that this Article SEVENTH shall not eliminate or limit the liability of a director (1) for any breach of such director's duty of loyalty to the Corporation or its stockholders, (2) for acts or omissions of such director not in good faith or which involve intentional misconduct or a knowing violation of law, (3) under Section 174 of the Delaware General Corporation Law, or (4) for any transaction from which such director derived an improper personal benefit, in respect of which such breach of fiduciary duty occurred. If the Delaware General Corporation Law is amended after approval by the stockholders of this Article SEVENTH to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law, as so amended from time to time.

B.

(1) Right of Indemnification. Each person who was or is made a party or is threatened to be made a party to or is involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (hereinafter a

"proceeding"), by reason of the fact that he or she, or a person of whom he or she is the legal representative, (a) is or was a director or officer of the Corporation or (b) is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans (whether the basis of such proceeding is alleged action in an official capacity as a director, officer, employee or agent or in any other capacity while serving as a director, officer, employee or agent), shall be indemnified and held harmless by the Corporation to the fullest extent authorized by the Delaware General Corporation Law, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than said law permitted the Corporation to provide prior to such amendment), against all expense, liability and loss (including attorneys' fees, judgments, fines, ERISA excise taxes or penalties and amounts paid or to be paid in settlement) actually and reasonably incurred or suffered by such person in connection therewith and such indemnification shall continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of his or her heirs, executors and administrators; provided, however, that, except as provided in paragraph (2) hereof the Corporation shall indemnify any such person seeking indemnification in connection with a proceeding (or part thereof) initiated by such person only if such proceeding (or part thereof) was authorized by the Board of Directors of the Corporation. The right to indemnification conferred in this Article SEVENTH shall be a contract right and shall include the right to be paid by the Corporation the expenses incurred in defending any such proceeding in advance of its final disposition; provided, however, that, if the Delaware General Corporation Law requires, the payment of such expenses incurred by a director or officer in his or her capacity as such (and not in any other capacity in which service was or is rendered by such person while a director or officer, including, without limitation, service with respect to an employee benefit plan) in advance of the final disposition of a proceeding, shall be made only upon delivery to the Corporation of an undertaking, by or on behalf of such director or officer, to repay all amounts so advanced if it shall ultimately be determined that such director or officer is not entitled to be indemnified under this Article SEVENTH or otherwise. The Corporation may, by action of its Board of Directors, provide indemnification to employees and agents of the Corporation with the same scope and effect as the foregoing indemnification of directors and officers.

(2) Right of Claimant to Bring Suit. If a claim under paragraph (1) of this Article SEVENTH is not paid in full by the Corporation within thirty days after a written claim has been received by the Corporation, the claimant may at any time thereafter bring suit against the Corporation to recover the

unpaid amount of the claim and, if successful in whole or in part, the claimant shall be entitled to be paid also the expense of prosecuting such claim. It shall be a defense to any such action (other than an action brought to enforce a claim for expenses incurred in defending any proceeding in advance of its final disposition where the required undertaking, if any is required, has been tendered to the Corporation) that the claimant has not met the standards of conduct which make it permissible under the Delaware General Corporation Law for the Corporation to indemnify the claimant for the amount claimed, but the burden of proving such defense shall be on the Corporation. Neither the failure of the Corporation (including its Board of Directors, independent legal counsel, or its stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances because he or she has met the applicable standard of conduct set forth in the Delaware General Corporation Law, nor an actual determination by the Corporation (including its Board of Directors, independent legal counsel, or its stockholders) that the claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that the claimant has not met the applicable standard of conduct.

(3) Non-Exclusivity of Rights. The right to indemnification and the payment of expenses incurred in defending a proceeding in advance of its final disposition conferred in this Article SEVENTH shall not be exclusive of any other right which any person may have or hereafter acquire under any statute, provision of the Certificate of Incorporation, by-law, agreement, vote of stockholders or disinterested directors or otherwise.

(4) Insurance. The Corporation may maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, against any such expense, liability or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the Delaware General Corporation Law.

EIGHTH

Subject to the provisions of Article NINTH below, the directors of the Corporation may, by a vote of a majority of directors present at a meeting in which a quorum is present, adopt, amend or repeal any By-Law.

NINTH

The Corporation shall not, and shall not permit any of its subsidiaries to, and no officer, employee or other agent of the Corporation or any of its subsidiaries shall have the authority, in the name or on behalf of the Corporation or any of its subsidiaries to, directly or indirectly, without the prior written consent of Bayer Corporation ("Bayer," formerly Miles Inc.) (which consent shall be deemed given, if a majority of Bayer's nominees to the Board of Directors of the Corporation consent in writing (it being understood that consent given in this manner shall not be deemed the exclusive method of giving consent)) amend or restate the Corporation's certificate of incorporation or By-Laws in any respect, (a) as a result of which the ability to (i) elect a majority of the members of the Board of Directors of the Corporation, (ii) adopt an agreement of merger or consolidation, (iii) approve a sale of all or substantially all the assets of the Corporation or (iv) adopt an amendment to the Corporation's certificate of incorporation or by-laws would require the vote of more than a majority of the outstanding shares of Common Stock entitled to vote thereon, (b) that would adversely affect Bayer differently from other holders of shares of Common Stock or (c) that, by its terms, would prohibit any foreign national from holding shares of Common Stock or serving as a director.

This Article NINTH may be amended only with the prior written consent of Bayer (as described above in this Article NINTH), and the provisions of this Article NINTH shall terminate and be of no further force or effect upon the termination of Bayer's rights under Section 2.5 of General Stockholders Agreement.

TENTH

Whenever a compromise or arrangement is proposed between the Corporation and its creditors or any class of them and/or between the Corporation and its stockholders or any class of them, any court of equitable jurisdiction within the State of Delaware may, on the application in a summary way of the Corporation or of any creditor or stockholder thereof or on the application of any receiver or receivers appointed for the Corporation under the provisions of Section 291 of Title 8 of the Delaware Code or on the application of trustees in dissolution or of any receiver or receivers appointed for the Corporation under the provisions of Section 279 of Title 8 of the Delaware Code, order a meeting of the creditors or class of creditors, and/or of the stockholders of the Corporation, as the case may be, to be summoned in such manner as the said court directs. If a majority in number representing three fourths in value of the creditors or class of creditors, and/or of the stockholders or class of stockholders of the Corporation, as the case may be, agree to any compromise or arrangement and to any reorganization of the Corporation as a consequence of such compromise or arrangement,

the said compromise or arrangement and the said reorganization shall, if sanctioned by the court to which the said application has been made, be binding on all the creditors or class of creditors, and/or on all the stockholders, of the Corporation, as the case may be, and also on the Corporation.

3. The foregoing amendment has been duly adopted by the stockholders of the Corporation in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.

4. This Restated to the Certificate of Incorporation shall be effective on and as of the date of filing this Certificate of Restated with the office of the Secretary of State of the State of Delaware.

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be executed in its name by its President and attested to by its Secretary this 20th day of March, 1998, and the statements contained herein are affirmed as true under penalties of perjury.

SCHEIN PHARMACEUTICAL, INC.

By: _____
Martin Sperber
President

ATTEST:

By: _____
Paul Feuerman, Secretary

STATE OF DELAWARE
SECRETARY OF STATE
DIVISION OF CORPORATIONS
FILED 09:30 AM 08/28/2000
001434235 – 2352578

CERTIFICATE OF MERGER
MERGING
WS ACQUISITION CORP.
WITH AND INTO
SCHEIN PHARMACEUTICAL, INC.

Pursuant to § 251 of the
Delaware General Corporation Law

Schein Pharmaceutical, Inc., a Delaware corporation ("Schein"), does hereby certify as follows:

FIRST: That Schein was incorporated on September 27, 1993, pursuant to §102 of the Delaware General Corporation Law (the "Delaware Law"), and WS Acquisition Corp. ("Merger Sub") was incorporated on May 19, 2000, pursuant to the Delaware Law.

SECOND: That an Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 24, 2000, among Watson Pharmaceuticals, Inc. ("Watson"), a Nevada corporation, Merger Sub and Schein, setting forth the terms and conditions of the merger of Merger Sub with and into Schein (the "Merger"), has been approved, adopted, certified, executed and acknowledged by each of the constituent corporations in accordance with the requirements of § 251 of the Delaware Law.

THIRD: That the surviving corporation (the "Surviving Corporation") shall be Schein, which shall retain the name "Schein Pharmaceutical, Inc."

FOURTH: That pursuant to the Merger Agreement, from and after the effective time of the Merger, the Certificate of Incorporation of Schein shall be the Amended and Restated Certificate of Incorporation of the Surviving Corporation and shall be amended as set forth in Exhibit A attached hereto.

FIFTH: That an executed copy of the Merger Agreement is on file at the principal place of business of the Surviving Corporation at the following address:

Schein Pharmaceutical, Inc.
100 Campus Drive
Florham Park, New Jersey 07932

SIXTH: That a copy of the Merger Agreement will be furnished by the Surviving Corporation, on request and without cost, to any stockholder of any constituent corporation.

SEVENTH: That the Merger shall become effective upon the filing of this Certificate of Merger with the Secretary of State of the State of Delaware.

IN WITNESS WHEREOF, Schein Pharmaceutical, Inc. has caused this Certificate of Merger to be executed in its corporate name as of the 28th day of August, 2000.

SCHEIN PHARMACEUTICAL, INC.

By: _____
Name: Robert C. Funsten
Title: Secretary

EXHIBIT A

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SCHEIN PHARMACEUTICAL, INC.

Pursuant to §242 and §245 of the General Corporation Law of the State of Delaware

1. The original name of this corporation is Schein Pharmaceutical Corp. ("Schein") and the date of filing of the original Certificate of Incorporation of this corporation with the Secretary of State of the State of Delaware was September 27, 1993.

2. The Certificate of Incorporation of the corporation is hereby amended and restated to read as follows:

I.

The name of this corporation is Schein Pharmaceutical, Inc.

II.

The address, including street, number, city, and county, of the registered office of the corporation in the State of Delaware is 1209 Orange Street, City of Wilmington, County of New Castle; and the name of the registered agent of the corporation in the State of Delaware at such address is The Corporation Trust Company.

III.

The purpose of this corporation is to engage in any lawful act or activity for which a corporation may be organized under the Delaware General Corporation Law.

IV.

This corporation is authorized to issue one class of stock to be designated "Common Stock." The total number of shares of Common Stock which the corporation is authorized to issue is one hundred (100) shares, each having a par value of one tenth of one cent ($0.001).

V.

For the management of the business and for the conduct of the affairs of the corporation, and in further definition, limitation and regulation of the powers of

the corporation, of its directors and of its stockholders or any class thereof, as the case may be, it is further provided that:

1. The management of the business and the conduct of the affairs of the corporation shall be vested in its Board of Directors. The number of directors which shall constitute the whole Board of Directors shall be fixed by the Board of Directors in the manner provided in the Bylaws.

2. The Board of Directors may from time to time make, amend, supplement or repeal the Bylaws; provided, however, that the stockholders may change or repeal any Bylaw adopted by the Board of Directors by the affirmative vote of the holders of a majority of the voting power of all of the then outstanding shares of the capital stock of the corporation (considered for this purpose as one class); and, provided further, that no amendment or supplement to the Bylaws adopted by the Board of Directors shall vary or conflict with any amendment or supplement thus adopted by the stockholders.

3. The directors of the corporation need not be elected by written ballot unless the Bylaws so provide.

VI.

A director of the corporation shall, to the full extent not prohibited by the Delaware General Corporation Law, as the same exists or may hereafter be amended, not be liable to the corporation or its stockholders for monetary damages for breach of his fiduciary duty as a director.

VII.

The corporation is to have perpetual existence.

VIII.

The corporation reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, in the manner now or hereafter prescribed by statute, and all rights conferred upon the stockholders herein are granted subject to this right.

IN WITNESS WHEREOF, Schein Pharmaceutical, Inc. has caused this Certificate of Incorporation to be executed in its corporate name as of the 28th day of August, 2000.

SCHEIN PHARMACEUTICAL, INC.

By: _____
Robert C. Funsten
Secretary

V:\Legal\SAP\Schein\cert of merger 8 24 00.DOC

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SCHEIN PHARMACEUTICAL, INC.

Pursuant to §242 and §245 of the General Corporation Law of the State of Delaware

1. The original name of this corporation is Schein Pharmaceutical Corp. ("Schein") and the date of filing of the original Certificate of Incorporation of this corporation with the Secretary of State of the State of Delaware was September 27, 1993.

2. The Certificate of Incorporation of the corporation is hereby amended and restated to read as follows:

I.

The name of this corporation is Schein Pharmaceutical, Inc.

II.

The address, including street, number, city, and county, of the registered office of the corporation in the State of Delaware is 1209 Orange Street, City of Wilmington, County of New Castle; and the name of the registered agent of the corporation in the State of Delaware at such address is The Corporation Trust Company.

III.

The purpose of this corporation is to engage in any lawful act or activity for which a corporation may be organized under the Delaware General Corporation Law.

IV.

This corporation is authorized to issue one class of stock to be designated "Common Stock." The total number of shares of Common Stock which the corporation is authorized to issue is one hundred (100) shares, each having a par value of one tenth of one cent ($0.001).

V.

For the management of the business and for the conduct of the affairs of the corporation, and in further definition, limitation and regulation of the powers of

the corporation, of its directors and of its stockholders or any class thereof, as the case may be, it is further provided that:

1. The management of the business and the conduct of the affairs of the corporation shall be vested in its Board of Directors. The number of directors which shall constitute the whole Board of Directors shall be fixed by the Board of Directors in the manner provided in the Bylaws.

2. The Board of Directors may from time to time make, amend, supplement or repeal the Bylaws; provided, however, that the stockholders may change or repeal any Bylaw adopted by the Board of Directors by the affirmative vote of the holders of a majority of the voting power of all of the then outstanding shares of the capital stock of the corporation (considered for this purpose as one class); and, provided further, that no amendment or supplement to the Bylaws adopted by the Board of Directors shall vary or conflict with any amendment or supplement thus adopted by the stockholders.

3. The directors of the corporation need not be elected by written ballot unless the Bylaws so provide.

VI.

A director of the corporation shall, to the full extent not prohibited by the Delaware General Corporation Law, as the same exists or may hereafter be amended, not be liable to the corporation or its stockholders for monetary damages for breach of his fiduciary duty as a director.

VII.

The corporation is to have perpetual existence.

VIII.

The corporation reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, in the manner now or hereafter prescribed by statute, and all rights conferred upon the stockholders herein are granted subject to this right.

IN WITNESS WHEREOF, Schein Pharmaceutical, Inc. has caused this Certificate of Incorporation to be executed in its corporate name as of the 28th day of August, 2000.

SCHEIN PHARMACEUTICAL, INC.

By: _____
Robert C. Furnsten
Secretary

CERTIFICATE OF MERGER
OF
WATSON PHARMA, INC.
AND
SCHEIN PHARMACEUTICAL PA, INC.
WITH AND INTO
SCHEIN PHARMACEUTICAL, INC.

Pursuant to the provisions of Section 251 of the Delaware General Corporation Law, Schein Pharmaceutical, Inc. certifies that:

1. The name and state of incorporation of each of the constituent corporations are as follows: (a) Schein Pharmaceutical, Inc., a Delaware corporation, (b) Watson Pharma, Inc., a Delaware corporation, and (c) Schein Pharmaceutical PA, Inc., a Delaware corporation.

2 A plan and agreement of merger has been approved, adopted, certified, executed, and acknowledged by each of the constituent corporations in accordance with Section 251 of the General Corporation Law of the State of Delaware.

3. The surviving corporation is Schein Pharmaceutical, Inc.

4. The amended and restated certificate of incorporation of Schein Pharmaceutical, Inc. shall be the certificate of incorporation of the surviving corporation, which is hereby amended.

5. Article I of the amended and restated certificate of incorporation of the surviving corporation shall be amended to change the name of the surviving corporation to Watson Pharma, Inc.

6 Article IV of the amended and restated certificate of incorporation of the surviving corporation shall be amended to change the authorized capital of the surviving corporation to one thousand (1,000) shares of common stock, each having a par value of one-tenth of one cent ($0.001).

7. The executed agreement and plan of merger is on file at the principal place of business of the surviving corporation. The address of the principal place of business of the surviving corporation is 100 Campus Drive, Florham Park, New Jersey 07932.

8. The surviving corporation will furnish a copy of the agreement and plan of merger, on request and without cost, to any stockholder of any constituent corporation.

STATE OF DELAWARE
SECRETARY OF STATE
DIVISION OF CORPORATIONS
FILED 09:00 AM 03/29/2001
010156087 – 2352578

IN WITNESS WHEREOF, Schein Pharmaceutical, Inc. has caused this Certificate of Merger to be duly executed on the 29th day of March, 2001.

SCHEIN PHARMACEUTICAL, INC.

By: _____

Robert C. Funsten,
Senior Vice President, General Counsel
and Secretary

OFFICE OF THE SECRETARY OF STATE

JESSE WHITE • Secretary of State

JUNE 19, 2013

6171-875-3

C T CORPORATION SYSTEM
600 S 2ND ST
SPRINGFIELD, IL 62704

RE ACTAVIS PHARMA, INC.

DEAR SIR OR MADAM:

ENCLOSED YOU WILL FIND THE AMENDED AUTHORITY FOR THE ABOVE CORPORATION.

FEES IN THIS CONNECTION HAVE BEEN RECEIVED AND CREDITED.

SINCERELY,

JESSE WHITE
SECRETARY OF STATE
DEPARTMENT OF BUSINESS SERVICES
CORPORATION DIVISION
TELEPHONE (217) 782-6961

FORM **BCA 13.40** (rev. Dec. 2003)
APPLICATION FOR AMENDED AUTHORITY TO TRANSACT BUSINESS IN ILLINOIS
Business Corporation Act

Jesse White, Secretary of State
Department of Business Services
Springfield, IL 62756
Telephone (217) 782-6961
http://www.cyberdriveillinois.com

Remit payment in the form of a check or money order payable to the Secretary of State.

FILED

JUN 19 2013

JESSE WHITE
SECRETARY OF STATE

File # 6171-875-3 Filing Fee: $25.00 Approved:

Submit in duplicate — Type or Print clearly in black ink — Do not write above this line

1. (a) CORPORATE NAME: Watson Pharma, Inc.

   (b) **If changed,** NEW CORPORATE NAME: Actavis Pharma, Inc.

   (c) (Complete only if the new corporate name is not available in this state.)
   ASSUMED CORPORATE NAME: _____
   (By electing this assumed name, the corporation hereby agrees NOT to use its corporate name in the transaction of business in Illinois. Form BCA 4.15 is attached.)

2. (a) State or Country of Incorporation: Delaware (b) If changed, Period of Duration: _____

3. If changed, Purpose or Purposes proposed to be pursued in transacting business in this State:
   (If not sufficient space to cover this point, use reverse side or add one or more sheets of this size.)

4. **This application is accompanied by a copy of the articles of Amendment to the Articles of Incorporation, if any, as evidence of any change of name, duration or purpose reported herein, such copy being duly authenticated by the proper officer of the state or country wherein the corporation is incorporated, which certification is not more than ninety (90) days old. The filing fee for the certified copy of the Articles of Amendment is $50 unless the amendment acts as a restatement of the Articles of Incorporation, in which case the filing fee is $150. In the event the statutory change was effected in a merger, a certified copy of the merger is required, plus applicable fee. The fees outlined in this paragraph are in addition to the $25 filing fee in the upper right hand corner of this form.**

5. The undersigned corporation has caused this application to be signed by a duly authorized officer who affirms, under penalties of perjury, that the facts stated herein are true. (All signatures must be in **BLACK INK**.)

Dated June 18 (Month/Day), 2013 (Year) Actavis Pharma, Inc. (Exact Name of Corporation)

(Any Authorized Officer's Signature)

John LaRocca VP, Legal Affairs, Americas and Asst. Secretary
(Type or Print Name and Title)

C-196.11

IL023 - 12/09/03 C T Filing Manager Online

6171-8753

FILED Delaware

PAGE 1

$ 50.00

BCA 1330

JUN 19 2013

The First State

JESSE WHITE
SECRETARY OF STATE

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF "WATSON PHARMA, INC.", CHANGING ITS NAME FROM "WATSON PHARMA, INC." TO "ACTAVIS PHARMA, INC.", FILED IN THIS OFFICE ON THE EIGHTEENTH DAY OF JUNE, A.D. 2013, AT 12:18 O'CLOCK P.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.

Jeffrey W. Bullock, Secretary of State

2352578 8100

130786813

AUTHENTICATION: 0520488

DATE: 06-18-13

You may verify this certificate online at corp.delaware.gov/authver.shtml

State of Delaware
Secretary of State
Division of Corporations
Delivered 12:29 PM 06/18/2013
FILED 12:18 PM 06/18/2013
SRV 130786813 - 2352578 FILE

CERTIFICATE OF AMENDMENT
OF
CERTIFICATE OF INCORPORATION

Watson Pharma, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware,

DOES HEREBY CERTIFY:

FIRST: That the Board of Directors of said corporation, by unanimous written consent of its members, filed with the minutes of the Board adopted a resolution proposing and declaring advisable the following amendment to the Certificate of Incorporation:

RESOLVED, that the Certificate of Incorporation of Watson Pharma, Inc. be amended by changing the First Article thereof so that, as amended, said First Article shall be and read as follows, "FIRST: The name of the Corporation is Actavis Pharma, Inc."

SECOND: That in lieu of a meeting and vote of stockholders, the stockholders have given unanimous written consent of said amendment in accordance with the provisions of Section 228 of the General Corporation Law of the State of Delaware.

THIRD: That the aforesaid Certificate of Amendment was duly adopted in accordance with the applicable provisions of Sections 242 and 228 of the General Corporation Law of the State of Delaware.

FOURTH: That this Certificate of Amendment shall be effective on June 18, 2013.

IN WITNESS WHEREOF, the undersigned has executed this Certificate of Amendment this day of June 18, 2013.

WATSON PHARMA, INC.

By: _____
John LaRocca
Vice Presdent, Legal Affairs – Americas
and Assistant Secretary

State of California
Secretary of State

NAME CHANGE
CERTIFICATE OF QUALIFICATION

C2461479

I, DEBRA BOWEN, Secretary of State of the State of California, hereby certify that on the **18th day of June, 2013**, there was filed in this office an Amended Statement and Designation by Foreign Corporation whereby the corporate name of **WATSON PHARMA, INC.**, a corporation organized and existing under the laws of **Delaware**, was changed to **ACTAVIS PHARMA, INC**. This corporation complied with the requirements of California law in effect on that date for the purpose of qualifying to transact intrastate business in the State of California and as of said date has been and is qualified and authorized to transact intrastate business in the State of California, subject however, to any licensing requirements otherwise imposed by the laws of this State.

IN WITNESS WHEREOF, I execute this certificate and affix the Great Seal of the State of California this day of June 19, 2013.

Debra Bowen

DEBRA BOWEN
Secretary of State

le

NP-25 (REV 1/2007)

A0742207

FILED
Secretary of State
State of California
JUN 18 2013

Amended Statement By Foreign Corporation

2461479

Actavis Pharma, Inc.
[Name of Corporation]

a corporation organized and existing under the laws of Delaware
[State or Place of Incorporation]

and which is presently qualified for the transaction of intrastate business in the State of California, makes the following statement:

That the name of the corporation has been changed to that hereinabove set forth and that the name relinquished at the time of such change was

Watson Pharma, Inc.

[Signature of Corporate Officer]

John LaRocca, VP, Legal Affairs America and Asst Secretary
[Typed Name and Title of Officer Signing]

ASDC-Form (Rev. 01/2013)

California Secretary of State
www.sos.ca.gov/business/be
(916) 657-5448

CA050 - 02/27/2013 Wolters Kluwer Online

Delaware

The First State

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THAT THE SAID "WATSON PHARMA, INC.", FILED A CERTIFICATE OF AMENDMENT, CHANGING ITS NAME TO "ACTAVIS PHARMA, INC.", THE EIGHTEENTH DAY OF JUNE, A.D. 2013, AT 12:18 O'CLOCK P.M.



Jeffrey W. Bullock, Secretary of State

2352578 8320

130786813

AUTHENTICATION: 0520492

DATE: 06-18-13

You may verify this certificate online at corp.delaware.gov/authver.shtml

June 19, 2013

FLORIDA DEPARTMENT OF STATE
Division of Corporations

ACTAVIS PHARMA, INC.
311 BONNIE CIRCLE
CORONA, CA 92880

Re: Document Number F01000003775

The Amendment to the Application of a Foreign Corporation for WATSON PHARMA, INC. which changed its name to ACTAVIS PHARMA, INC., a Delaware corporation authorized to transact business in Florida, was filed on June 19, 2013.

This document was electronically received and filed under FAX audit number H13000139316.

Should you have any questions regarding this matter, please telephone (850) 245-6050, the Amendment Filing Section.

Sylvia Gilbert
Regulatory Specialist II
Division of Corporation

Letter Number: 413A00015474

P.O BOX 6327 – Tallahassee, Florida 32314

COVER LETTER

TO: Amendment Section
Division of Corporations

SUBJECT: Watson Pharma, Inc.
Name of Corporation

DOCUMENT NUMBER: F01000003775

The enclosed Amendment and fee are submitted for filing.

Please return all correspondence concerning this matter to the following:

CT to pick up
Name of Contact Person

Firm/Company

Address

City/State and Zip Code

E-mail address: (to be used for future annual report notification)

For further information concerning this matter, please call:

Name of Contact Person at ( ) Area Code & Daytime Telephone Number

Enclosed is a check for the following amount:

- ☐ $35.00 Filing Fee
- ☐ $43.75 Filing Fee & Certificate of Status
- ☐ $43.75 Filing Fee & Certified Copy (Additional copy is enclosed)
- ☐ $52.50 Filing Fee, Certificate of Status & Certified Copy (Additional copy is enclosed)

Mailing Address:
Amendment Section
Division of Corporations
P.O. Box 6327
Tallahassee, FL 32314

Street Address:
Amendment Section
Division of Corporations
Clifton Building
2661 Executive Center Circle
Tallahassee, FL 32301

FL021 - 05/07/2009 C T Filing Manager Online

PROFIT CORPORATION
APPLICATION BY FOREIGN PROFIT CORPORATION TO FILE AMENDMENT TO APPLICATION FOR AUTHORIZATION TO TRANSACT BUSINESS IN FLORIDA

(Pursuant to s. 607.1504, F.S.)

SECTION I
(1-3 MUST BE COMPLETED)

F01000003775
(Document number of corporation (if known))

1. Watson Pharma, Inc.
(Name of corporation as it appears on the records of the Department of State)

2. Delaware
(Incorporated under laws of)

3. 07/17/2001
(Date authorized to do business in Florida)

SECTION II
(4-7 COMPLETE ONLY THE APPLICABLE CHANGES)

4. If the amendment changes the name of the corporation, when was the change effected under the laws of its jurisdiction of incorporation? June 18, 2013

5. Actavis Pharma, Inc.
(Name of corporation after the amendment, adding suffix "corporation," "company," or "incorporated," or appropriate abbreviation, if not contained in new name of the corporation)

(If new name is unavailable in Florida, enter alternate corporate name adopted for the purpose of transacting business in Florida)

6. If the amendment changes the period of duration, indicate new period of duration.

(New duration)

7. If the amendment changes the jurisdiction of incorporation, indicate new jurisdiction.

(New jurisdiction)

8. Attached is a certificate or document of similar import, evidencing the amendment, authenticated not more than 90 days prior to delivery of the application to the Department of State, by the Secretary of State or other official having custody of corporate records in the jurisdiction under the laws of which it is incorporated.

(Signature of a director, president or other officer - if in the hands of a receiver or other court appointed fiduciary, by that fiduciary)

John LaRocca
(Typed or printed name of person signing)

VP, Legal Affairs and Asst. Secretary
(Title of person signing)

FL021 - 05/07/2009 C T Filing Manager Online

Delaware

The First State

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THAT THE SAID "WATSON PHARMA, INC.", FILED A CERTIFICATE OF AMENDMENT, CHANGING ITS NAME TO "ACTAVIS PHARMA, INC.", THE EIGHTEENTH DAY OF JUNE, A.D. 2013, AT 12:18 O'CLOCK P.M.

2352578 8320

130786813

You may verify this certificate online at corp.delaware.gov/authver.shtml

Jeffrey W. Bullock, Secretary of State

AUTHENTICATION: 0520492

DATE: 06-18-13

ACTAVIS PHARMA, INC. (f/k/a Watson Pharma, Inc.)

(a Delaware Corporation)

DIRECTOR:

Paul M. Bisaro

SENIOR OFFICERS:

Paul M. Bisaro Morris Corporate Center III 400 Interpace Parkway Parsippany, NJ 07054	President & Chief Executive Officer PII
G. Frederick Wilkinson Morris Corporate Center III 400 Interpace Parkway Parsippany, NJ 07054	President Global Brands & Biosimiliars PII
Robert A. Stewart Morris Corporate Center III 400 Interpace Parkway Parsippany, NJ 07054	President, Global Operations PII
R. Todd Joyce Morris Corporate Center III 400 Interpace Parkway Parsippany, NJ 07054	Chief Financial Officer – Global and Principal Accounting Officer PII
David A. Buchen Morris Corporate Center III 400 Interpace Parkway Parsippany, NJ 07054	Chief Legal Officer – Global and Secretary PII
Ranjana B. Pathak Morris Corporate Center III 400 Interpace Parkway Parsippany, NJ 07054	Senior Vice President Quality PII
Andrew Boyer Morris Corporate Center III 400 Interpace Parkway Parsippany, NJ 07054	Senior Vice President, Sales & Marketing, US Generics Div. PII
Charles M. Mayr Morris Corporate Center III 400 Interpace Parkway Parsippany, NJ 07054	Chief Communications Officer - Global PII
Deborah M. Penza Morris Corporate Center III 400 Interpace Parkway Parsippany, NJ 07054	PII

Actavis, Inc. Entity List
Domestic & International
Rev. 6/17/13

Company Name	Status
Actavis EAD Representative Office Albania	Dissolved
Actavis International Limited Representative Office Albania	Active
Watson Laboratories, Inc.	Active
Actavis Australia Pty Limited	Active
Arrow Laboratories Limited Australia Branch	Active
Ascent Australia Pty Ltd	Active
Ascent Pharma Pty Ltd	Active
Ascent Pharmaceuticals Pty Ltd	Active
Ascent Pharmahealth Pty Ltd	Active
Eremad Pty Limited	Active
SC Pharma Pty Ltd	Active
Spirit Pharmaceuticals Pty Ltd	Active
Watson Pharma Pty Ltd	Active
Willow Pharmaceuticals Pty Ltd	Active
Actavis GmbH	Active
Actavis EAD Representative Office Azerbaijan	Active
Actavis International Limited Representative Office Azerbaijan	Active
Actavis EAD Representative Office Belarus	Dissolved
Actavis International Limited Representative Office Belarus	Active
Estetra SPRL	Active
Femalon SPRL	Active
Odyssea Pharma SPRL	Active
Uteron Pharma Operations SPRL	Active
Uteron Pharma SPRL	Active
Uteron Pharma Technologies SPRL	Active
Schein Pharmaceutical Limited	Sleeping
Actavis International Limited Representative Office Bosnia and Herzegovina	Active
Zdravlje AD Representative office Bosnia	Dissolved
Actavis Do Brasil Servicos EM Marketing LTDA.	Active
Actavis Farmaceutica Ltda	Active
Seeker Investments Limited	Active
Soosysoo Limited	Active
Watson Pharmaceuticals (Asia) Limited	Active

Watson Pharmaceuticals International, Limited	Active
Watson Pharmaceuticals, China Limited	Active
WP Holding Limited	Active
Actavis EAD	Active
Actavis Operations EOOD	Active
Balkanpharma Dupnitsa AD	Active
Balkanpharma Razgrad AD	Sold
Balkanpharma Security EOOD	Active
Balkanpharma Troyan AD	Active
Higia EAD	Sold
Higia Trans EAD	Sold
OPENING PHARMA BULGARIA EOOD	Active
3242038 Nova Scotia Company	Active
Abri Pharmaceuticals Company	Active
Actavis Canada Company	Active
Actavis Pharma Company	Active
Actavis Pharma OTC Company	Active
Actavis Specialty Pharmaceuticals Co.	Active
Actavis (Foshan) Pharmaceutical Co., Limited	Active
Zhejiang Chiral Medicine Chemicals Co., Limited	Sold
Watson Laboratories, Inc.	Active
Watson Laborаties, Inc.	Active
Actavis (Cyprus) Limited	Active
Balkanpharma Healthcare International (Cyprus) Limited	Active
Paomar Plc	Active
Actavis CZ a.s.	Active
Pharma Avalanche s.r.o.	Dissolved
Actavis A/S	Active
Actavis Nordic A/S	Active
Arrow ApS	Active
Arrow Group ApS	Active
Arrow Pharma ApS	Active
Colotech A/S	Active
Medis-Danmark A/S (in liquidation)	Active

Nordisk Ibu-Pharma ApS	Liquidated
Ophtha A/S	Dissolved
Orbita ApS	Dissolved
Breath Limited	Active
UAB Actavis Baltics Branch Office Estonia	Active
Actavis OY	Active
Alpharma OY	Dissolved
Watson Laboratories, Inc.	Active
Actavis France SAS	Active
ARROW GENERIQUES SAS	Active
Fondation d' Entreprise Actavis France	Active
Medis Pharma France	Active
Opening Pharma France	Active
Actavis EAD Representative Office Georgia	Active
Actavis Deutschland GmbH & Co. KG	Active
Actavis Holding Germany GmbH	Active
Actavis Management GmbH	Active
Alpharma International GmbH	Merged
Alpharma Pharmaceuticals GmbH	Dissolved
Juta Pharma GmbH	Sold
Key Pharma GmbH	Sold
Medis Pharma GmbH	Active
ALET Pharmaceuticals Industrial and Commercial Societe Anonyme	Active
Actavis (China) Holding Limited	Active
Ascent Pharmahealth Hong Kong Limited	Active
China Medicinal & Chemical Industrial Development Group Limited	Sold
Actavis Hungary Kft.	Active
Actavis ehf.	Active
Actavis eignarhaldsfelag ehf	Active
Actavis Equity ehf.	Merged
Actavis Group ehf	Active
Actavis Group PTC ehf	Active
Actavis HY ehf.	Merged
Actavis Pharma Holding 4 ehf	Active

Actavis Pharma Holding 5 ehf	Active
Actavis SD ehf.	Merged
Fjallkonugil ehf.	Liquidated
Herkonugil ehf.	Liquidated
Lyfjaproun ehf.	Merged
Medis ehf.	Active
NM Pharma ehf.	Merged
Actavis Pharma Development Centre Private Limited	Active
Actavis Pharma Manufacturing Pvt.Ltd	Active
Actavis Pharma Private Limited	Active
Lotus Laboratories Pvt. Limited	Active
Watson Pharma Private Limited	Active
PT Actavis Indonesia	Active
Actavis Ireland Limited	Active
Breathe Pharmaceuticals Limited	Dissolved
Selamine Limited	Liquidated
Watson Pharma S.ar.l. (Irish Branch)	Active
Actavis Isle of Man Limited	Active
Arrow Blue Ltd	Active
Actavis Italy S.p.A.	Active
Actavis ASKA K.K.	Active
Actavis K.K.	Active
Arrow Pharmaceuticals KK	Active
Actavis EAD Representative Office Kazakhstan	Active
Actavis International Limited Representative Office Kazakhstan	Active
Actavis International LTD – Branch Kosovo	Active
UAB Actavis Baltics Latvijas filiale	Active
UAB Actavis Baltics	Active
Actavis Finco S.ar.l.	Liquidated
Actavis S.a r.l.	Active
AP5 S.ar.l.	Liquidated
Argon Acquisition Debt S.a r.l.	Sold
Argon Acquisition S.a r.l.	Sold
Argon Equity S.a r.l.	Sold

Argon Hold S.a r.l.	Sold
Argon Management S.ar.l.	Sold
Argon New S.a r.l.	Sold
Argon PIK S.a r.l.	Sold
Watson Pharma 2 S.a.r.l	Active
Watson Pharma Actavis S.a r.l.	Active
Watson Pharma Holding S.a.r.l.	Active
Watson Pharma International Holding S.a.r.l.	Active
Watson Pharma S.a r.l.	Active
Watson Pharmaceuticals, Inc. SCS	Active
Actavis International Limited Representative Office Macedonia	Active
Zdravlje AD Representative office Macedonia	Dissolved
Ascent Pharmahealth Malaysia Sdn Bhd	Active
Actavis Export International Limited	Active
Actavis International Limited	Active
Actavis Limited	Active
Actavis Malta Ltd	Active
Arrow International Limited	Active
Arrow Laboratories Limited	Active
Arrow Pharm (Malta) Limited	Active
Arrow Pharmaceuticals Holdings Limited	Active
Arrow Supplies Limited	Active
Little John Limited	Active
Marrow Holdings Limited	Active
Robin Hood Holdings Limited	Active
Actavis SA de C.V.	Active
ArrowCobalt de Mexico S.A. de C.V.	Active
Watson Laboratories S. de R.L. de C.V.	Active
Watson Pharmaceuticals Services S. de R.L. de C.V.	Active
Actavis EAD Representative Office Moldova (in liquidation)	Active
Actavis International Limited Representative Office Moldova	Active
Actavis EAD Representative Office Mongolia	Dissolved
Actavis International Limited Representative Office Mongolia	Active
Watson Laboratories, Inc.	Active

Actavis New Zealand Limited	Liquidated
Arrow Pharmaceuticals NZ Ltd	Active
Spirit Pharmaceuticals NZ Limited	Active
Nicobrand Limited	Active
Actavis AS	Liquidated
Actavis Lier (Inpac AS)	Sold
Actavis Norway AS	Active
Arrow Pharma AS	Active
Watson Laboraties, Inc Ohio	Active
Actavis Polska Sp. z o.o.	Active
Arrow Poland SA	Active
Biovena Pharma Sp. z o.o.	Active
Sindan Polska S.A.	Liquidated
Actavis A/S Branch Office Portugal	Active
Arrowblue Produtos Farmaceuticos SA	Active
Anda Puerto Rico, Inc.	Active
Actavis Srl	Active
Sindan Foundation	Sleeping
Sindan Pharma Srl	Active
Actavis EAD Representative Office Russian Federation	Dissolved
Actavis International Limited Representative Office Russian Federation	Sleeping
Balkanpharma LLC	Liquidated
LLC Actavis	Active
Zdravlje AD Representative office Russia (liquidated)	Liquidated
ZIO Zdorovie CJSC	Active
Open Pharma LLC	Active
Watson Laboratories, Inc.	Active
Actavis d.o.o. Belgrade	Active
Actavis Trading Limited Representative Office Serbia	Dissolved
Zdravlje AD	Active
Zdravlje Trade d.o.o.	Active
Actavis (China) Holding Limited Representative Office Singapore	Dissolved
Actavis Asia Pacific Private Limited	Active
Actavis International Limited Representative Office Singapore	Dissolved

Ascent Pharmahealth Asia Pte Ltd	Active
Drug Houses of Australia Pte Ltd	Active
Actavis s.r.o.	Active
ARROW PHARMA, marketing in distribucija zdravil, d.o.o.	Active
Arrow Pharma Tender (Pty) Ltd	Active
Makewhey Products Pty Ltd	Active
Pharmascript Pharmaceuticals Limited	Active
Referral-net (pty) Ltd	Sleeping
Scriptharm Marketing (pty) Ltd	Sleeping
Scriptharm Risk management (Pty) Ltd	Active
Spear Pharmaceuticals (Pty) Ltd	Active
Watson Pharma (Pty) Ltd	Active
Watson Pharma Holdings South Africa (pty) Ltd	Active
Watson Pharma No1 (pty) Ltd	Active
Zelphy 1308 (pty) ltd	Sleeping
Actavis Dutch Holding B.V. Representative Office Spain	Active
Actavis Spain S.A.	Active
Actavis AB	Active
Actavis Holding AB	Active
Arrow Lakemedel AB	Active
Arrow Scandinavia AB	Active
Recept Pharma RP AB	Active
Actavis Bioton GmbH	Sold
Actavis S.a.r.l., Luxembourg, Zweigniederlassung Steinhausen branch	Active
Actavis Switzerland AG	Active
Oncopharma AG	Active
Sindan AG	Merged
Actavis B.V.	Active
Actavis Dutch Holding B.V.	Active
Actavis Holding Asia B.V.	Active
Actavis Holding B.V.	Active
Actavis Holding CEE B.V.	Active
Actavis Holding NWE B.V.	Active
Arrow Pharma Holdings BV	Active

Gaja Investments B.V.	Sold
GM Invest BV	Active
PharmaPack International B.V.	Active
Actavis Ilaclari Anonim Sirketi	Active
Actavis Istanbul Ilac Sanayi Ve Ticaret Limited Sirketi	Active
Arrow Saglik Urun Leri Pazarlama Ticaret Limited Sirketi (in liquidation)	Active
Actavis EAD Representative Office Ukraine	Active
Actavis Ukraine LLC	Active
Actavis (MEEA) FZE	Active
Actavis A/S Branch Office United Arab Emirates	Dissolved
Actavis Holdings UK II Limited	Active
Actavis Holdings UK Limited	Active
Actavis UK Limited	Active
Alpharma (U.K.) Limited	Dissolved
Alpharma Laboratories Limited	Dissolved
Arrow Generics Limited	Active
Arrow No.7 Limited	Active
Arthur H Cox & Co Limited	Dissolved
Bowmed Limited	Active
Cairnstores Limited	Dissolved
Cox Investments Limited	Dissolved
Eden Biodesign Ltd	Active
Eden Biopharm Limited	Active
Eden Biopharma Group Ltd	Active
PB North America Limited	Active
Sindan Ltd.	Dissolved
Zenara Pharma Limited	Sold
Actavis Elizabeth LLC	Active
Actavis Inc.	Merged
Actavis Kadian LLC	Active
Actavis LLC	Active
Actavis Mid Atlantic LLC	Active
Actavis South Atlantic LLC	Active
Actavis Totowa LLC	Active

Actavis US Holding LLC	Active
Alpharma US Pharmaceutical LLC	Merged
Alpharma USPD Inc.	Merged
Amide Pharmaceuticals, Inc.	Merged
Ancirc Pharmaceuticals	Active
Anda Marketing, Inc.	Active
Anda Pharmaceuticals, Inc.	Active
Anda Veterinary Supply, Inc.	Active
Anda, Inc.	Active
Andrx Corporation	Active
Andrx Laboratories (NJ), Inc.	Active
Andrx Labs LLC	Active
Andrx Pharmaceuticals Equipment no. 1, LLC	Active
Andrx Pharmaceuticals Sales and Marketing, Inc.	Active
Andrx Pharmaceuticals, (NC) Equipment LLC	Active
Andrx Pharmaceuticals, (NC) LLC	Active
Andrx Pharmaceuticals, Inc.	Active
Andrx South Carolina I, Inc.	Active
Circa Pharmaceuticals West, Inc.	Active
Circa Sub	Active
Cobalt Laboratories, LLC	Active
Colony Pharmaceuticals Inc	Merged
Columbia Labratories, Inc.	Active
Coventry Acuisition, LLC	Active
Cybear, LLC	Active
Del Mar Indemnity Co Inc. (Captive Insurance Company)	Active
Eden Biodestign Inc.	Active
G.F. Reilly Company	Merged
Makoff R&D Laborаties, Inc.	Active
Marsam Pharma, LLC	Active
MM Pharma LLC	Liquidated
MSI, Inc.	Active
Natrapac, Inc.	Active
Point Holdings Inc.	Liquidated

R&D Ferriecit Capital Resources, Inc.	Active
R&D New Media Services, Inc.	Active
R&D Pharmaceutical, Inc.	Active
R&D Research & Development Corp.	Active
Royce Laboraties, Inc.	Active
Royce Research & Development Limited Partnership	Active
Royce Research Group, Inc.	Active
Rugby Laboratories, Inc.	Active
RxAPS, Inc.	Active
Schein Bayer Pharmaceutical Services, Inc.	Active
Schein Pharmaceutical International, Inc.	Active
SR Six, Inc.	Active
The Rugby Group, Inc.	Active
Valmed Pharmaceuticals, Inc.	Active
Watson Cobalt Holdings, LLC	Active
Watson Diagnostics, Inc.	Active
Watson Laboratories, LLC	Active
Watson Management Corporation	Active
Watson Manufacturing Services, Inc.	Active
Watson Pharma, Inc.	Active
Watson Pharmaceuticals (NJ) Inc.	Active
Watson Therapeutics, Inc.	Active
Verben S.A.	Active
Cobalt Laboratories, LLC	Sold
Watson Pharmaceuticals, Inc.	Active
Actavis EAD Representative Office Uzbekistan	Merged
Actavis International Limited Representative Office Uzbekistan	Liquidated
Actavis (China) Holding Limited Representative Office Vietnam	Active
Actavis International Limited Representative Office Vietnam	Dissolved
Actavis, Inc.	Active
Specifar Commercial Industrial Pharmaceutical, Chemical and Construction Exploitations Societe Anonyme (ABEE)	Active
Watson Phama S.a.r.l (Irish Branch)	Active

Actavis Pharma, Inc. – Sites

Corona B5:
Actavis Pharma, Inc.
2455 Wardlow Road
Corona, CA 92880
DEA: RW0288921
FEIN# 11-2726505

Located in Riverside County
Telephone# 951-493-5300
Fax# 951-493-5833
Site Representatives: Donal Loughrey, Samy Kuppusamy or Miguel Gomez

Gurnee 605:
Actavis Pharma, Inc.
605 Tri-State Parkway
Gurnee, IL 60031
DEA: RW0237900
FEIN# 11-2726505

Located in Lake County
Telephone# 847-377-5500
Fax# 847-377-5501
Site Representative: Edward Grover

Gurnee 705B:
Actavis Pharma, Inc.
705 Tri-State Parkway, Unit B
Gurnee, IL 60031
DEA: N/A (OTC and RX only, no CDS)
FEIN# 11-2726505

Located in Lake County
Telephone# 847-377-5500
Fax# 847-377-5501
Site Representative: Richard Lichtenberger

Parsippany Corporate:
Lynn DaCunha, Sr. DEA Compliance Analyst
Actavis, Inc.
Morris Corporate Center III
400 Interpace Pkwy, Bldg A
Parsippany, NJ 07054-1120
Phone: 862-691-7179
Fax: 862-691-7927
Email: lynn.dacunha@actavis.com

Mary-Lou Schoonover, DEA Compliance Analyst
Actavis, Inc.
Morris Corporate Center III
400 Interpace Pkwy, Bldg A
Parsippany, NJ 07054-1120
Phone: 862-691-7486
Fax: 862-691-7927
Email: mary-lou.schoonover@actavis.com

Actavis

CHALLENGE · CONNECT · COMMIT
Our Winning Way

DEA and State Registrations for Gurnee

605 Tri-State Parkway

Gurnee, IL 60031

RegistrationType	Agency Name	RegistrationNumber	ExpirationDate
DEA	Drug Enforcement Administration	RW0237900	05/31/2014
DEA	Drug Enforcement Administration	RW0271142	05/31/2014
DEA	Drug Enforcement Administration	RW0387262	05/31/2014
State	Alabama State Board of Pharmacy	192171	12/31/2014
State	Alabama State Board of Pharmacy	192171	12/31/2014
State	Arizona State Board of Pharmacy	W001029	10/31/2013
State	Arkansas State Board of Pharmacy	WD01959	12/31/2014
State	California State Board of Pharmacy	18510-Motta	02/01/2014
State	California State Board of Pharmacy	18533-Grover	02/01/2014
State	California State Board of Pharmacy	18536-Johannsen	02/01/2013
State	California State Board of Pharmacy	OSD3550	12/01/2013
State	Colorado State Board of Pharmacy	7167	10/31/2014
State	Connecticut Department of Consumer Protection	CSW.0000607	06/30/2013
State	DC Dept. of Health	DM9500263	01/31/2014
State	DC Dept. of Health	CF9500298	02/28/2014
State	Delaware Health and Social Services	DS0319	06/30/2013
State	Delaware State Board of Pharmacy	A4-0000683	09/30/2014
State	FL Dept. of Business & Professional Regulation	40:00270	06/30/2014
State	FL Dept. of Business & Professional Regulation	26:00276	11/30/2014
State	Georgia State Board of Pharmacy	PHWH000825	06/30/2013
State	Hawaii Dept. of Public Safety Narcotics Enforcement Div.	E08913	05/31/2014

Actavis

CCC
CHALLENGE · CONNECT · COMMIT
Our Winning Way

DEA and State Registrations for Gurnee

605 Tri-State Parkway

Gurnee, IL 60031

Registration Type	Agency Name	Registration Number	Expiration Date
State	Idaho State Board of Pharmacy	W2278	06/30/2013
State	Idaho State Board of Pharmacy	D475	06/30/2013
State	Illinois Department of Professional Regulation	004-001033	12/31/2014
State	Illinois Department of Professional Regulation	304-006370	12/31/2014
State	Indiana Health Professions Bureau	48222170A	09/30/2014
State	Iowa Board of Pharmacy Examiners	5292	12/31/2013
State	Kansas State Board of Pharmacy	5-01978	06/30/2013
State	Kansas State Board of Pharmacy	6-00414	06/30/2013
State	Kansas State Board of Pharmacy	15-00056	06/30/2013
State	Kentucky Board of Pharmacy	W00796	09/30/2013
State	KY Cab. Hlth Svcs. Drug Cont.&Prof. Prac. Branch	16607	06/30/2013
State	Louisiana Board of Pharmacy	CDS.022364-DIS	01/01/2013
State	Louisiana Board of Wholesale Drug Distributors	5081	12/31/2013
State	Maine Dept. of Prof. & Financial Reg.	WH70001138	12/31/2013
State	Maryland Board of Pharmacy	D00501	12/31/2012
State	Maryland State Dept of Health Div. of Drug Cont.	247602	02/28/2014
State	Michigan Board of Pharmacy	5306001641	06/30/2013
State	Michigan Board of Pharmacy	5306001641	06/30/2013
State	Minnesota Board of Pharmacy	359824	05/31/2014
State	Mississippi State Board of Pharmacy	CS02536	12/31/2013
State	Mississippi State Board of Pharmacy	02536/06.2	12/31/2013
State	Missouri Board of Pharmacy	901424	10/31/2013
State	Montana Board of Pharmacy	540	11/30/2013

Actavis

CHALLENGE · CONNECT · COMMIT
Our Winning Way

DEA and State Registrations for Gurnee

605 Tri-State Parkway

Gurnee, IL 60031

RegistrationType	Agency Name	Registration Number	Expiration Date
State	NABP-VAWD	12590-39589	05/05/2014
State	Nebraska Dept. of Health & Human Services	595	07/01/2013
State	Nevada State Board of Pharmacy	WH00523	10/31/2014
State	New Hampshire Board of Pharmacy	3941	06/30/2013
State	New Jersey Dept. of Health	5003854	01/31/2013
State	New Mexico Board of Pharmacy	WD00006546	12/31/2013
State	New Mexico Board of Pharmacy	CS00016531	04/30/2014
State	New York State Dept. of Health Control Subs.	02A0501	02/07/2014
State	New York State Education Department	025849	08/31/2015
State	North Carolina Dept of Health & Human Svcs.	NC-PW00001214	07/31/2013
State	North Carolina Dept. of Ag. & Consumer Svcs.	144	12/31/2013
State	North Dakota State Board of Pharmacy	360	06/30/2013
State	Ohio State Board of Pharmacy	WMAN -011166000	06/30/2013
State	Ohio State Board of Pharmacy	WCSM-0217	06/30/2013
State	OK Bureau of Narcotics & Dangerous Drugs (OBNDD)	42032	10/31/2013
State	OK Bureau of Narcotics & Dangerous Drugs (OBNDD)	42031	10/31/2013
State	Oklahoma State Board of Pharmacy	88-W-1476	08/31/2013
State	Oregon Board of Pharmacy	W1-0001671-CS	09/30/2013
State	Pennsylvania Department of Health	3000006838	02/28/2014
State	Rhode Island Board of Pharmacy	DIS01528	09/30/2013
State	Rhode Island Board of Pharmacy	DIS01528	09/30/2013
State	South Carolina Board of Pharmacy	70-008426	06/30/2013
State	South Dakota Board of Pharmacy	600-0484	12/31/2013

Actavis

CHALLENGE · CONNECT · COMMIT
Our Winning Way

DEA and State Registrations for Gurnee

605 Tri-State Parkway

Gurnee, IL 60031

RegistrationType	Agency Name	Registration Number	Expiration Date
State	South Dakota Department of Health	RW0237900SD	05/31/2014
State	Tenn. Bd of Phcy Dept. of Commerce & Ins.	886	08/31/2013
State	Tenn. Bd of Phcy Dept. of Commerce & Ins.	886	08/31/2013
State	Texas Department of Health	0040146	07/26/2014
State	Vermont Board of Pharmacy	039-0000556	07/31/2013
State	Virginia Board of Pharmacy	0219000262	02/28/2014
State	Washington State Dept. of Health Bd of Phcy	PHWHFX60010321	09/30/2013
State	West Virginia Board of Pharmacy	WD0557666	06/30/2013
State	Wisconsin Department of Regulation & Licensing	1837-045	05/31/2014
State	Wyoming State Board of Pharmacy	WD-1443WY	06/30/2013
State	Wyoming State Board of Pharmacy	0731WPIL09	06/30/2013

Actavis

CHALLENGE · CONNECT · COMMIT
Our Winning Way

DEA and State Registrations for Gurnee #705B

705 Tri-State Parkway, Unit B

Gurnee, IL 60031

Registration Type	Agency Name	Registration Number	Expiration Date
State	Alabama State Board of Pharmacy	194558	12/31/2014
State	Arizona State Board of Pharmacy	W002418	10/31/2013
State	Arkansas State Board of Pharmacy	WD04307	12/31/2014
State	California State Board of Pharmacy	Application Pending	
State	Colorado State Board of Pharmacy	WHO.0007962	10/31/2014
State	Connecticut Department of Consumer Protection	CSW.0002988	06/30/2014
State	DC Dept. of Health	Application Pending	
State	Delaware State Board of Pharmacy	A4-0001998	09/30/2014
State	FL Dept. of Business & Professional Regulation	Application Pending	
State	Georgia State Board of Pharmacy	Application Pending	
State	Idaho State Board of Pharmacy	W21584	06/30/2013
State	Illinois Department of Professional Regulation	004-003641	12/31/2014
State	Illinois Department of Professional Regulation	304-006370	12/31/2014
State	Indiana Health Professions Bureau	Application Pending	
State	Iowa Board of Pharmacy Examiners	7599	12/31/2013
State	Kansas State Board of Pharmacy	5-30981	06/30/2014
State	Kentucky Board of Pharmacy	W03195	09/30/2013
State	Louisiana Board of Wholesale Drug Distributors	7659	12/31/2013
State	Maine Dept. of Prof. & Financial Reg.	WH70002153	12/31/2013
State	Maryland Board of Pharmacy	Application Pending	
State	Michigan Board of Pharmacy	5306004157	06/30/2014
State	Minnesota Board of Pharmacy	362900	05/31/2014
State	Mississippi State Board of Pharmacy	12287/6.2	12/31/2013
State	Missouri Board of Pharmacy	2013014941	10/31/2013
State	Montana Board of Pharmacy	Application Pending	
State	Nebraska Dept. of Health & Human Services	Application Pending	
State	Nevada State Board of Pharmacy	Application Pending	
State	New Hampshire Board of Pharmacy	MWD-00022	06/30/2014
State	New Jersey Dept. of Health	Application Pending	
State	New Mexico Board of Pharmacy	Application Pending	
State	New York State Education Department	032088	05/31/2016

Actavis

CCC
CHALLENGE · CONNECT · COMMIT
Our Winning Way

DEA and State Registrations for Gurnee #705B

705 Tri-State Parkway, Unit B

Gurnee, IL 60031

Registration Type	Agency Name	Registration Number	Expiration Date
State	North Carolina Dept. of Ag. & Consumer Svcs.	1225	12/31/2013
State	North Dakota State Board of Pharmacy	Application Pending	
State	Ohio State Board of Pharmacy	Application Pending	
State	Oklahoma State Board of Pharmacy	88-W-3598	05/31/2014
State	Oregon Board of Pharmacy	Application Pending	
State	Pennsylvania Department of Health	3000009056	05/03/2014
State	Rhode Island Board of Pharmacy	DIS02496	09/30/2013
State	South Carolina Board of Pharmacy	Application Pending	
State	South Dakota Board of Pharmacy	600-2163	12/31/2013
State	Tenn. Bd of Phcy Dept. of Commerce & Ins.	0000003972	05/31/2015
State	Texas Department of Health	Application Pending	
State	Vermont Board of Pharmacy	39.0094969	07/31/2015
State	Virginia Board of Pharmacy	0219001356	02/28/2014
State	Washington State Dept. of Health Bd of Phcy	PHWH.FX.60378185	09/30/2013
State	West Virginia Board of Pharmacy	WD0559211	06/30/2014
State	Wisconsin Department of Regulation & Licensing	2536-45	05/31/2014
State	Wyoming State Board of Pharmacy	WD-1768 WY	06/30/2014

Actavis

CCC
CHALLENGE · CONNECT · COMMIT
Our Winning Way

Registrations by Site

DEA and State Registrations for Corona B5

2455 Wardlow Road
Corona, CA 92880

Registration Type	Agency Name	Registration Number	Expiration Date
DEA	Drug Enforcement Administration	RW0288921	05/31/2014
DEA	Drug Enforcement Administration	RW0246050	05/31/2014
DEA	Drug Enforcement Administration	RW0322937	05/31/2014
DEA	Drug Enforcement Administration	RW0288933	05/31/2014
State	Alabama State Board of Pharmacy	192959	12/31/2014
State	Alabama State Board of Pharmacy	192959	12/31/2014
State	Arizona State Board of Pharmacy	1030	10/31/2014
State	Arkansas State Board of Pharmacy	WD02592	12/31/2014
State	CA Dept. of Health Services Food and Drug Branch	40809	08/11/2013
State	California State Board of Pharmacy	17086-Moore	07/01/2013
State	California State Board of Pharmacy	17061-Gaji	07/01/2013
State	California State Board of Pharmacy	WLS4258	05/01/2014
State	Connecticut Department of Consumer Protection	CSW.0001612	06/30/2013
State	DC Dept. of Health	DM0400778	03/31/2013
State	DC Dept. of Health	CF0400581	03/31/2014
State	Delaware Health and Social Services	DS0503	06/30/2013
State	Delaware State Board of Pharmacy	A4-0000627	09/30/2014
State	FL Dept. of Business & Professional Regulation	26:00283	06/30/2014
State	Georgia State Board of Pharmacy	PHWH002045	06/30/2013
State	Hawaii Dept. of Public Safety Narcotics Enforcement Div.	E08912	05/31/2014

Actavis

CHALLENGE · CONNECT · COMMIT
Our Winning Way

Registrations by Site

DEA and State Registrations for Corona B5

2455 Wardlow Road
Corona, CA 92880

Registration Type	Agency Name	Registration Number	Expiration Date
State	Idaho State Board of Pharmacy	W2198	06/30/2012
State	Idaho State Board of Pharmacy	D443	06/30/2012
State	Illinois Department of Professional Regulation	004-001917	12/31/2014
State	Illinois Department of Professional Regulation	304-06741	12/31/2014
State	Iowa Board of Pharmacy Examiners	6196	12/31/2013
State	Kansas State Board of Pharmacy	5-02428	06/30/2013
State	Kentucky Board of Pharmacy	W00635	09/30/2013
State	KY Cab. Hlth Svcs. Drug Cont.&Prof. Prac. Branch	16203	06/30/2013
State	Louisiana Board of Pharmacy	CDS032159-DIS	02/01/2013
State	Louisiana Board of Wholesale Drug Distributors	3910	12/31/2013
State	Maine Dept. of Prof. & Financial Reg.	WH70001069	12/31/2013
State	Michigan Board of Pharmacy	5306001630	06/30/2014
State	Michigan Board of Pharmacy	5306001630	06/30/2014
State	Minnesota Board of Pharmacy	361205	05/31/2014
State	Mississippi State Board of Pharmacy	CS06386	12/31/2013
State	Mississippi State Board of Pharmacy	06386/06.2	12/31/2013
State	Missouri Board of Pharmacy	901188	10/31/2013
State	Montana Board of Pharmacy	506	11/30/2013
State	Nevada State Board of Pharmacy	WH01285	10/31/2014
State	New Hampshire Board of Pharmacy	4350	06/30/2013
State	New Jersey Dept. of Health	5003854	01/31/2014

Actavis

CCC
CHALLENGE · CONNECT · COMMIT
Our Winning Way

Registrations by Site

DEA and State Registrations for Corona B5

2455 Wardlow Road
Corona, CA 92880

Registration Type	Agency Name	Registration Number	Expiration Date
State	New Mexico Board of Pharmacy	WD00010438	12/31/2013
State	New Mexico Board of Pharmacy	CS00209952	05/31/2014
State	New York State Dept. of Health Control Subs.	01A0147	09/19/2013
State	New York State Education Department	026378	08/31/2015
State	North Carolina Dept of Health & Human Svcs.	NC-AW00001706	07/31/2013
State	North Carolina Dept. of Ag. & Consumer Svcs.	399	12/31/2013
State	North Dakota State Board of Pharmacy	732	06/30/2013
State	Ohio State Board of Pharmacy	WMAN -010703350	06/30/2013
State	Ohio State Board of Pharmacy	WCSW-1470	06/30/2013
State	Oklahoma State Board of Pharmacy	88-M-1260	02/28/2014
State	Oregon Board of Pharmacy	M-0001437-CS	09/30/2013
State	Pennsylvania Department of Health	3000007713	08/31/2013
State	Rhode Island Board of Pharmacy	DIS01479	09/30/2013
State	Rhode Island Board of Pharmacy	DIS01479	09/30/2013
State	South Carolina Board of Pharmacy	70-005737	06/30/2013
State	South Dakota Board of Pharmacy	600-0909	12/31/2013
State	South Dakota Department of Health	RW0288921SD	05/31/2014
State	Tenn. Bd of Phcy Dept. of Commerce & Ins.	1251	08/31/2014
State	Tenn. Bd of Phcy Dept. of Commerce & Ins.	1251	08/31/2014
State	Texas Department of Health	0074066	06/30/2014

Actavis

CCC
CHALLENGE · CONNECT · COMMIT
Our Winning Way

Registrations by Site

DEA and State Registrations for Corona B5

2455 Wardlow Road
Corona, CA 92880

Registration Type	Agency Name	Registration Number	Expiration Date
State	Vermont Board of Pharmacy	039-0000965	07/31/2013
State	Virginia Board of Pharmacy	0219000845	02/28/2014
State	Washington State Dept. of Health Bd of Phcy	PHWHFX60010335	09/30/2013
State	West Virginia Board of Pharmacy	WD0557561	06/30/2013
State	Wyoming State Board of Pharmacy	0731WPI09	06/30/2014
State	Wyoming State Board of Pharmacy	WD-1442WY	06/30/2014

WHOLESALE DRUG DISTRIBUTOR INSPECTION

BUSINESS NAME			INSPECTION NUMBER
WATSON PHARMA			
ADDRESS			LICENSE NUMBER
1 TRISTATE PARKWAY			4001033
CITY	COUNTY	TELEPHONE NUMBER (Include Area Code)	DATE
GURNEE	LAKE	(847) 377-5500	7/15/05
ICSA LICENSE	EXPIRATION DATE	FAX NUMBER (include Area Code)	INSPECTOR ID
30406370	12/31/06	(847) 377-5501	171
DEA LICENSE	EXPIRATION DATE	TYPE OF LICENSE	
RW0237900	5/31/06	ILLINOIS IN-STATE DRUG DISTRIBUTOR	
PERSON(S) RESPONSIBLE FOR DRUGS		EMERGENCY TELEPHONE NUMBER	
TRACY HERNANDEZ		(973) 355-8479	
Edward Grover ✓		(847) 830.1702	

VIOLATIONS		YES	NO
8301.25(a)	All wholesale distributors must have valid license.		X
1510.50(i)	Must comply with all Federal, State & Local laws.		X
8301.25(e)(1)	Acceptable storage & handling conditions and standards.		X
1510.50(a)	(1) Facility is of suitable size (2) Storage area meets requirements (3) Quarantine area is separate, distinct from general area (4) Maintained in clean & orderly condition (5) Free from infestation by insects, rodents, birds or vermin		X
1510.50(c)	Drugs are stored under proper temperature and humidity conditions. (1) Room temperature is controlled (2) Temperature& humidity equipment to document storage conditions.		X
8301.25(e)(2)	Minimum liability and other insurance.		X
8301.25(e)(3)	Must have acceptable security system.		X
1510.50(b)(1)	Secure from unauthorized entry. (a) Limited& well-controlled access from outside the premises. (b) Outside perimeter is well-lighted. (c) Prescription drug area limited to authorized personnel.		X
(2)	Alarm system to detect after hour entry.		
(3)	Protection against theft & diversion.		
8301.25(e)(4)	Records shall be maintained for 2 years.		X
1510.50(f)	(1) Records& inventories for receipt, distribution, disposal. (a) Source of drugs & location from where shipped.		X

VIOLATIONS		YES	NO
	(b) Identify & quantity of drugs received, distributed, disposed of. (c) Dates of receipt, distribution, disposal. (2) Inventories & records area available for inspection and copying. (3) Records are stored at site off-site location (on-site)		X
8301.25(e)(5)	Personnel must be qualified.		X
1510.50(h)	List of persons responsible & duties is maintained.		X
8301.25(e)(7)	Written Policies& procedures are maintained.		X
1510.50(g)(1)	(1) Procedure to rotate stock. (2) Procedure for recalls & withdrawals of drugs. (a) FDA or other law enforcement action. (b) Manufacturer recall. (c) Replacement action. (3) Procedures for crisis (fire, flood, etc.) (4) Procedures to remove, segregate & document disposition of outdates.		X
(e)	(1) Drugs are quarantined & physically separated (outdates, damaged, etc.) (2) Drugs are quarantined that have been used or are open.		
8301.25(e)(8)	Inspection procedures for all incoming and outgoing drug shipments.		X
1510.50(d)	(1) Visual examination upon receipt for damage. (2) Outgoing shipments are inspected to prevent outdates or deteriorated. (3) Records are maintained.		X

INVESTIGATOR'S SIGNATURE	LICENSEE'S SIGNATURE	SUPERVISOR'S SIGNATURE AND DATE
171 7/15/05	X Edward Grover 7/15/05	

IL486-1777 3/06(ENF)

New

WHOLESALE DRUG DISTRIBUTOR INSPECTION

BUSINESS NAME			INSPECTION NUMBER
Watson Pharma Inc			
ADDRESS			LICENSE NUMBER
705 Tri-State Pkwy Unit B			004-003641
CITY	COUNTY	TELEPHONE NUMBER (Include Area Code)	DATE
Gurnee, Illinois	Lake	(847) 377-5562	4/2/13
ICSA LICENSE	EXPIRATION DATE	FAX NUMBER (Include Area Code)	INSPECTOR ID
na		(847) 377-5501.	490
DEA LICENSE	EXPIRATION DATE	TYPE OF LICENSE	
na		WDDL	

PERSON(S) RESPONSIBLE FOR DRUGS	EMERGENCY TELEPHONE NUMBER
Richard Lichtenberger JR	(224) 213-5617 cell phone
Ed Grower - Executive Director, Distribution	(847) 830-1702 cell phone

	VIOLATIONS	YES	NO
8301.25(a)	All wholesale distributors must have valid license.		✓
1510.50(i)	Must comply with all Federal, State & Local laws.		✓
8301.25(e)(1)	Acceptable storage & handling conditions and standards.		✓
1510.50(a)	(1) Facility is of suitable size (2) Storage area meets requirements (3) Quarantine area is separate, distinct from general area (4) Maintained in clean & orderly condition (5) Free from infestation by insects, rodents, birds or vermin		X
1510.50(c)	Drugs are stored under proper temperature and humidity conditions. (1) Room temperature is controlled (2) Temperature& humidity equipment to document storage conditions.		X
8301.25(e)(2)	Minimum liability and other insurance.		X
8301.25(e)(3)	Must have acceptable security system.		X
1510.50(b)(1)	Secure from unauthorized entry. (a) Limited& well-controlled access from outside the premises. (b) Outside perimeter is well-lighted. (c) Prescription drug area limited to authorized personnel.		X
(2)	Alarm system to detect after hour entry.		
(3)	Protection against theft & diversion.		
8301.25(e)(4)	Records shall be maintained for 2 years. Discussed		
1510.50(f)	(1) Records& inventories for receipt, distribution, disposal. (a) Source of drugs & location from where shipped. Attached		✓

	VIOLATIONS	YES	NO
	(b) Identify & quantity of drugs received, distributed, disposed of. (c) Dates of receipt, distribution, disposal. (2) Inventories & records area available for inspection and copying. (3) Records are stored at site off-site location On-Site		
8301.25(e)(5)	Personnel must be qualified.		X
1510.50(h)	List of persons responsible & duties is maintained. attached		X
8301.25(e)(7)	Written Policies& procedures are maintained.		X
1510.50(g)(1)	(1) Procedure to rotate stock. Explained (2) Procedure for recalls & withdrawals of drugs. (a) FDA or other law enforcement action. (b) Manufacturer recall. (c) Replacement action. (3) Procedures for crisis (fire, flood, etc.) (4) Procedures to remove, segregate & document disposition of outdates.		X
(e)	(1) Drugs are quarantined & physically separated (outdates, damaged, etc.) (2) Drugs are quarantined that have been used or are open.		
8301.25(e)(8)	Inspection procedures for all incoming and outgoing drug shipments.		✓
1510.50(d)	(1) Visual examination upon receipt for damage. (2) Outgoing shipments are inspected to prevent outdates or deteriorated. SOP 13-075 -036 -040 + SOP 14-002 (3) Records are maintained. Section 13-022 3rd pty		✓

INVESTIGATOR'S SIGNATURE	LICENSEE'S SIGNATURE	SUPERVISOR'S SIGNATURE AND DATE
Andrea Cruz for 490		

IL486-1777 3/96(ENF)

California State Board of Pharmacy
400 R Street, Suite 4070, Sacramento, CA 95814
Phone (916) 445-5014
Fax (916) 327-6308

STATE AND CONSUMER SERVICES AGENCY
DEPARTMENT OF CONSUMER AFFAIRS
GRAY DAVIS, GOVERNOR

INSPECTION REPORT

rmacy ___ Hospital Pharmacy ___ Clinic ___ Exempt Hospital ___ Wholesaler X Hypodermic

:: 10/2/2003 Inspector: Robert Grimm

: WATSON PHARMA INC Phone: (909) 270-1400

ress: 2455 WARDLOW RD City: CORONA Zip: 92880

ership: CORPORATION

nit #: WLS4258 Permit Exp: 5/1/2004 DEA#: RW0288921 DEA Exp: 5/31/2004

of Self Assessment Form: ___ Other Permit #: N/A Date of DEA Inventory: ___

rs M-F: 8-5 Hours Saturday ___ Hours Sunday: ___

Administrator CLAUS WEISEMANN

H Consultant ___

T RPH Name:	License #:	Staff Name:	License #:
		MICHAEL M MOORE	EXC17086
		BETTY V AMARAL	EXC10630
		LAURA ARNETT	EXC11426
		PAMELA M BUELNA	EXC17082
		FERNANDO CAMARENA	EXC17058
		EARL R CHRISTENSEN	EXC17059
		BHUPENDRA N GAJJ	EXC17061
		GARY J HARTZELL	EXC14214
		BRIAN M JONES	EXC17065
		ESAUL MCLEOD	EXC17068
		JERRY O'BRYAN	EXC11957
		HECTOR F MENDOZA PENA	EXC17070
		JOHN J PEREZ	EXC17109
		DEREK WATTS	EXC11851

Reference	
4058	Display of Permit required must display permit in area readily seen by the public. WAS CORRECTED during inspection.

California State Board of Pharmacy
400 R Street, Suite 4070, Sacramento, CA 95814
Phone (916) 445-5014
Fax (916) 327-6308

STATE AND CONSUMER SERVICES AGENCY
DEPARTMENT OF CONSUMER AFFAIRS
GRAY DAVIS, GOVERNOR

INSPECTION REPORT

spector Remarks:
LS has Manufacturing DEA permit.
ldition al Watson site has WLS permit. Inspected approximately 1 year ago. By Valerie Knight 11/20/02. For WLS 2652.
irrections required are implemented by WLS4258.
st of Corp. Officers provided. CEO Allen Chao. COO Joseph Papa, CFO Charles Slacik, VP Supply Ian McInnes. VP QA Donald
ill., etc.
:cords are not located in one place. – are readily available.
lis site permitted less than one year. No DEA inventory taken at this time. Monthly inventories are taken.
linimum Standards for Wholesalers is compliant CCR 1780. Proper security. Properly alarmed. Properly restricted to designated
rsonnel. Policy & procedured available & compliant.
he permit was relocated to the main lobby during inspection.
raining: Record of Training for Jerry O'Bryan reviewed. Significant training has been recorded.
ustomer Licensing: Files reviewed. Licenses are current.

licensee Remarks:

have reviewed, discussed, understand and received a copy of this form.

Exemptee (sign) Jerry O'Bryan
Exemptee (print) Jerry O'Bryan

Inspector (sign) Robert Gelman
Inspector (print) Robert Gelman

Owner(sign) _____
Owner(print) _____

Additional information (for example - corrective plan of action, Quality Assurance outcomes, factors in mitigation, etc.) you want to submit for consideration may be sent on the attached form to my attention at the above address no later than 14 calendar days from the date above. Please include a copy of this form with any information that you submit.

Within 14 calendar days from the above date, please submit to me at the above address the following:

CERTIFICATE OF LIABILITY INSURANCE

DATE (MM/DD/YYYY): 06/18/2013

THIS CERTIFICATE IS ISSUED AS A MATTER OF INFORMATION ONLY AND CONFERS NO RIGHTS UPON THE CERTIFICATE HOLDER. THIS CERTIFICATE DOES NOT AFFIRMATIVELY OR NEGATIVELY AMEND, EXTEND OR ALTER THE COVERAGE AFFORDED BY THE POLICIES BELOW. THIS CERTIFICATE OF INSURANCE DOES NOT CONSTITUTE A CONTRACT BETWEEN THE ISSUING INSURER(S), AUTHORIZED REPRESENTATIVE OR PRODUCER, AND THE CERTIFICATE HOLDER.

IMPORTANT: If the certificate holder is an ADDITIONAL INSURED, the policy(ies) must be endorsed. If SUBROGATION IS WAIVED, subject to the terms and conditions of the policy, certain policies may require an endorsement. A statement on this certificate does not confer rights to the certificate holder in lieu of such endorsement(s).

PRODUCER
Marsh Risk & Insurance Services
4445 Eastgate Mall, Suite 300
San Diego, CA 92121-1979
Ph 858-552-4200 Fax (4299)
Attn: 858-552-4200
400672-WATS-GAWUP-13-14

CONTACT NAME:
PHONE (A/C, No, Ext):
FAX (A/C, No):
E-MAIL ADDRESS:

INSURER(S) AFFORDING COVERAGE	NAIC #
INSURER A : N/A	N/A
INSURER B : N/A	N/A
INSURER C : N/A	N/A
INSURER D : Ironshore Specialty Insurance Company	25445
INSURER E : N/A	N/A
INSURER F :	

INSURED
Actavis, Inc.
Morris Corporate Center III
400 Interpace Parkway
Parsippany, NJ 07054

COVERAGES **CERTIFICATE NUMBER:** LOS-001560596-01 **REVISION NUMBER:** 6

THIS IS TO CERTIFY THAT THE POLICIES OF INSURANCE LISTED BELOW HAVE BEEN ISSUED TO THE INSURED NAMED ABOVE FOR THE POLICY PERIOD INDICATED. NOTWITHSTANDING ANY REQUIREMENT, TERM OR CONDITION OF ANY CONTRACT OR OTHER DOCUMENT WITH RESPECT TO WHICH THIS CERTIFICATE MAY BE ISSUED OR MAY PERTAIN, THE INSURANCE AFFORDED BY THE POLICIES DESCRIBED HEREIN IS SUBJECT TO ALL THE TERMS, EXCLUSIONS AND CONDITIONS OF SUCH POLICIES. LIMITS SHOWN MAY HAVE BEEN REDUCED BY PAID CLAIMS.

INSR LTR	TYPE OF INSURANCE	ADDL INSR	SUBR WVD	POLICY NUMBER	POLICY EFF (MM/DD/YYYY)	POLICY EXP (MM/DD/YYYY)	LIMITS	
D	GENERAL LIABILITY			001668500	05/15/2013	05/15/2014	EACH OCCURRENCE	$ 1,000,000
	X COMMERCIAL GENERAL LIABILITY						DAMAGE TO RENTED PREMISES (Ea occurrence)	$ 1,000,000
	CLAIMS-MADE X OCCUR						MED EXP (Any one person)	$ Excluded
	X SIR: $250,000						PERSONAL & ADV INJURY	$ 1,000,000
	GEN'L AGGREGATE LIMIT APPLIES PER:						GENERAL AGGREGATE	$ 2,000,000
	X POLICY PRO-JECT LOC						PRODUCTS - COMP/OP AGG	$ Excluded
								$
	AUTOMOBILE LIABILITY						COMBINED SINGLE LIMIT (Ea accident)	$
	ANY AUTO						BODILY INJURY (Per person)	$
	ALL OWNED AUTOS / SCHEDULED AUTOS						BODILY INJURY (Per accident)	$
	HIRED AUTOS / NON-OWNED AUTOS						PROPERTY DAMAGE (Per accident)	$
								$
	UMBRELLA LIAB OCCUR						EACH OCCURRENCE	$
	EXCESS LIAB CLAIMS-MADE						AGGREGATE	$
	DED RETENTION $							$
	WORKERS COMPENSATION AND EMPLOYERS' LIABILITY Y / N						WC STATU-TORY LIMITS / OTH-ER	
	ANY PROPRIETOR/PARTNER/EXECUTIVE OFFICER/MEMBER EXCLUDED? N / A (Mandatory in NH)						E.L. EACH ACCIDENT	$
	If yes, describe under DESCRIPTION OF OPERATIONS below						E.L. DISEASE - EA EMPLOYEE	$
							E.L. DISEASE - POLICY LIMIT	$

DESCRIPTION OF OPERATIONS / LOCATIONS / VEHICLES (Attach ACORD 101, Additional Remarks Schedule, if more space is required)
Re: 605 Tri-State Parkway, Gurnee, IL 60031-5277

General Evidence of Insurance

CERTIFICATE HOLDER
Actavis, Inc.
Morris Corporate Center III
400 Interpace Parkway
Parsippany, NJ 07054

CANCELLATION
SHOULD ANY OF THE ABOVE DESCRIBED POLICIES BE CANCELLED BEFORE THE EXPIRATION DATE THEREOF, NOTICE WILL BE DELIVERED IN ACCORDANCE WITH THE POLICY PROVISIONS.

AUTHORIZED REPRESENTATIVE
of Marsh USA Inc.
E. Deguia

ACORD 25 (2010/05)

AGENCY CUSTOMER ID: 400672

LOC #: San Diego

ADDITIONAL REMARKS SCHEDULE

AGENCY Marsh Risk & Insurance Services	NAMED INSURED Actavis, Inc. Morris Corporate Center III 400 Interpace Parkway Parsippany, NJ 07054
POLICY NUMBER	
CARRIER / NAIC CODE	EFFECTIVE DATE:

ADDITIONAL REMARKS

THIS ADDITIONAL REMARKS FORM IS A SCHEDULE TO ACORD FORM,

FORM NUMBER: 25 FORM TITLE: Certificate of Liability Insurance

Named Insured includes:

Actavis Pharma, Inc.
Watson Pharma, Inc.,
Watson Laboratories, Inc.,
Royce Laboratories, Inc.,
Oclassen Pharmaceuticals, Inc.,
The Rugby Group Inc.,
Makoff R&D Laboratories, Inc.,
Watson Pharmaceuticals, Inc.,
Schein Pharmaceutical, Inc.,
Danbury Pharmacal, Inc.,
Steris Laboratories,
Schein,
Thera Tech, Inc..
and WP Development AB.

CERTIFICATE OF LIABILITY INSURANCE

DATE (MM/DD/YYYY): 06/18/2013

THIS CERTIFICATE IS ISSUED AS A MATTER OF INFORMATION ONLY AND CONFERS NO RIGHTS UPON THE CERTIFICATE HOLDER. THIS CERTIFICATE DOES NOT AFFIRMATIVELY OR NEGATIVELY AMEND, EXTEND OR ALTER THE COVERAGE AFFORDED BY THE POLICIES BELOW. THIS CERTIFICATE OF INSURANCE DOES NOT CONSTITUTE A CONTRACT BETWEEN THE ISSUING INSURER(S), AUTHORIZED REPRESENTATIVE OR PRODUCER, AND THE CERTIFICATE HOLDER.

IMPORTANT: If the certificate holder is an ADDITIONAL INSURED, the policy(ies) must be endorsed. If SUBROGATION IS WAIVED, subject to the terms and conditions of the policy, certain policies may require an endorsement. A statement on this certificate does not confer rights to the certificate holder in lieu of such endorsement(s).

PRODUCER
Marsh Risk & Insurance Services
4445 Eastgate Mall, Suite 300
San Diego, CA 92121-1979
Ph 858-552-4200 Fax (4299)
Attn: 858-552-4200
400672-WATS-GAWUP-13-14

CONTACT NAME:
PHONE (A/C, No, Ext):
FAX (A/C, No):
E-MAIL ADDRESS:

INSURER(S) AFFORDING COVERAGE		NAIC #
INSURER A :	N/A	N/A
INSURER B :	N/A	N/A
INSURER C :	N/A	N/A
INSURER D :	Ironshore Specialty Insurance Company	25445
INSURER E :	N/A	N/A
INSURER F :		

INSURED
Actavis, Inc.
Morris Corporate Center III
400 Interpace Parkway
Parsippany, NJ 07054

COVERAGES **CERTIFICATE NUMBER:** LOS-001560641-01 **REVISION NUMBER:** 1

THIS IS TO CERTIFY THAT THE POLICIES OF INSURANCE LISTED BELOW HAVE BEEN ISSUED TO THE INSURED NAMED ABOVE FOR THE POLICY PERIOD INDICATED. NOTWITHSTANDING ANY REQUIREMENT, TERM OR CONDITION OF ANY CONTRACT OR OTHER DOCUMENT WITH RESPECT TO WHICH THIS CERTIFICATE MAY BE ISSUED OR MAY PERTAIN, THE INSURANCE AFFORDED BY THE POLICIES DESCRIBED HEREIN IS SUBJECT TO ALL THE TERMS, EXCLUSIONS AND CONDITIONS OF SUCH POLICIES. LIMITS SHOWN MAY HAVE BEEN REDUCED BY PAID CLAIMS.

INSR LTR	TYPE OF INSURANCE	ADDL INSR	SUBR WVD	POLICY NUMBER	POLICY EFF (MM/DD/YYYY)	POLICY EXP (MM/DD/YYYY)	LIMITS		
D	GENERAL LIABILITY			001668500	05/15/2013	05/15/2014	EACH OCCURRENCE	$	1,000,000
	X COMMERCIAL GENERAL LIABILITY						DAMAGE TO RENTED PREMISES (Ea occurrence)	$	1,000,000
	CLAIMS-MADE X OCCUR						MED EXP (Any one person)	$	Excluded
	X SIR: $250,000						PERSONAL & ADV INJURY	$	1,000,000
	GEN'L AGGREGATE LIMIT APPLIES PER:						GENERAL AGGREGATE	$	2,000,000
	X POLICY PRO-JECT LOC						PRODUCTS - COMP/OP AGG	$	Excluded
								$	
	AUTOMOBILE LIABILITY						COMBINED SINGLE LIMIT (Ea accident)	$	
	ANY AUTO						BODILY INJURY (Per person)	$	
	ALL OWNED AUTOS / SCHEDULED AUTOS						BODILY INJURY (Per accident)	$	
	HIRED AUTOS / NON-OWNED AUTOS						PROPERTY DAMAGE (Per accident)	$	
								$	
	UMBRELLA LIAB OCCUR						EACH OCCURRENCE	$	
	EXCESS LIAB CLAIMS-MADE						AGGREGATE	$	
	DED RETENTION $							$	
	WORKERS COMPENSATION AND EMPLOYERS' LIABILITY Y / N						WC STATU-TORY LIMITS / OTH-ER		
	ANY PROPRIETOR/PARTNER/EXECUTIVE OFFICER/MEMBER EXCLUDED? N / A (Mandatory in NH)						E.L. EACH ACCIDENT	$	
	If yes, describe under DESCRIPTION OF OPERATIONS below						E.L. DISEASE - EA EMPLOYEE	$	
							E.L. DISEASE - POLICY LIMIT	$	

DESCRIPTION OF OPERATIONS / LOCATIONS / VEHICLES (Attach ACORD 101, Additional Remarks Schedule, if more space is required)
Re: 705 Tri-State Parkway, Unit B, Gurnee IL 60031

General Evidence of Insurance

CERTIFICATE HOLDER
Actavis, Inc.
Morris Corporate Center III
400 Interpace Parkway
Parsippany, NJ 07054

CANCELLATION
SHOULD ANY OF THE ABOVE DESCRIBED POLICIES BE CANCELLED BEFORE THE EXPIRATION DATE THEREOF, NOTICE WILL BE DELIVERED IN ACCORDANCE WITH THE POLICY PROVISIONS.

AUTHORIZED REPRESENTATIVE
of Marsh USA Inc.
E. Deguia

AGENCY CUSTOMER ID: 400672
LOC #: San Diego

ADDITIONAL REMARKS SCHEDULE

AGENCY Marsh Risk & Insurance Services	NAMED INSURED Actavis, Inc. Morris Corporate Center III 400 Interpace Parkway Parsippany, NJ 07054
POLICY NUMBER	
CARRIER / NAIC CODE	EFFECTIVE DATE:

ADDITIONAL REMARKS

THIS ADDITIONAL REMARKS FORM IS A SCHEDULE TO ACORD FORM,
FORM NUMBER: 25 FORM TITLE: Certificate of Liability Insurance

Named Insured includes:

Actavis Pharma, Inc.
Watson Pharma, Inc.,
Watson Laboratories, Inc.,
Royce Laboratories, Inc.,
Oclassen Pharmaceuticals, Inc.,
The Rugby Group Inc.,
Makoff R&D Laboratories, Inc.,
Watson Pharmaceuticals, Inc.,
Schein Pharmaceutical, Inc.,
Danbury Pharmacal, Inc.,
Steris Laboratories,
Schein,
Thera Tech, Inc.,
and WP Development AB.

CERTIFICATE OF LIABILITY INSURANCE

DATE (MM/DD/YYYY): 06/18/2013

THIS CERTIFICATE IS ISSUED AS A MATTER OF INFORMATION ONLY AND CONFERS NO RIGHTS UPON THE CERTIFICATE HOLDER. THIS CERTIFICATE DOES NOT AFFIRMATIVELY OR NEGATIVELY AMEND, EXTEND OR ALTER THE COVERAGE AFFORDED BY THE POLICIES BELOW. THIS CERTIFICATE OF INSURANCE DOES NOT CONSTITUTE A CONTRACT BETWEEN THE ISSUING INSURER(S), AUTHORIZED REPRESENTATIVE OR PRODUCER, AND THE CERTIFICATE HOLDER.

IMPORTANT: If the certificate holder is an ADDITIONAL INSURED, the policy(ies) must be endorsed. If SUBROGATION IS WAIVED, subject to the terms and conditions of the policy, certain policies may require an endorsement. A statement on this certificate does not confer rights to the certificate holder in lieu of such endorsement(s).

PRODUCER Marsh Risk & Insurance Services 4445 Eastgate Mall, Suite 300 San Diego, CA 92121-1979 Ph 858-552-4200 Fax (4299) Attn: 858-552-4200 400672-WATS-GAWUP-13-14	**CONTACT NAME:** **PHONE (A/C, No, Ext):** **FAX (A/C, No):** **E-MAIL ADDRESS:**
INSURED Actavis, Inc. Morris Corporate Center III 400 Interpace Parkway Parsippany, NJ 07054	**INSURER(S) AFFORDING COVERAGE** — **NAIC #** INSURER A : N/A — N/A INSURER B : N/A — N/A INSURER C : N/A — N/A INSURER D : Ironshore Specialty Insurance Company — 25445 INSURER E : N/A — N/A INSURER F :

COVERAGES **CERTIFICATE NUMBER:** LOS-001560642-01 **REVISION NUMBER:** 1

THIS IS TO CERTIFY THAT THE POLICIES OF INSURANCE LISTED BELOW HAVE BEEN ISSUED TO THE INSURED NAMED ABOVE FOR THE POLICY PERIOD INDICATED. NOTWITHSTANDING ANY REQUIREMENT, TERM OR CONDITION OF ANY CONTRACT OR OTHER DOCUMENT WITH RESPECT TO WHICH THIS CERTIFICATE MAY BE ISSUED OR MAY PERTAIN, THE INSURANCE AFFORDED BY THE POLICIES DESCRIBED HEREIN IS SUBJECT TO ALL THE TERMS, EXCLUSIONS AND CONDITIONS OF SUCH POLICIES. LIMITS SHOWN MAY HAVE BEEN REDUCED BY PAID CLAIMS.

INSR LTR	TYPE OF INSURANCE	ADDL INSR	SUBR WVD	POLICY NUMBER	POLICY EFF (MM/DD/YYYY)	POLICY EXP (MM/DD/YYYY)	LIMITS	
D	**GENERAL LIABILITY**			001668500	05/15/2013	05/15/2014	EACH OCCURRENCE	$ 1,000,000
	X COMMERCIAL GENERAL LIABILITY						DAMAGE TO RENTED PREMISES (Ea occurrence)	$ 1,000,000
	CLAIMS-MADE X OCCUR						MED EXP (Any one person)	$ Excluded
	X SIR: $250,000						PERSONAL & ADV INJURY	$ 1,000,000
							GENERAL AGGREGATE	$ 2,000,000
	GEN'L AGGREGATE LIMIT APPLIES PER:						PRODUCTS - COMP/OP AGG	$ Excluded
	X POLICY PRO-JECT LOC							$
	AUTOMOBILE LIABILITY						COMBINED SINGLE LIMIT (Ea accident)	$
	ANY AUTO						BODILY INJURY (Per person)	$
	ALL OWNED AUTOS / SCHEDULED AUTOS						BODILY INJURY (Per accident)	$
	HIRED AUTOS / NON-OWNED AUTOS						PROPERTY DAMAGE (Per accident)	$
								$
	UMBRELLA LIAB OCCUR						EACH OCCURRENCE	$
	EXCESS LIAB CLAIMS-MADE						AGGREGATE	$
	DED RETENTION $							$
	WORKERS COMPENSATION AND EMPLOYERS' LIABILITY Y / N						WC STATU-TORY LIMITS / OTH-ER	
	ANY PROPRIETOR/PARTNER/EXECUTIVE OFFICER/MEMBER EXCLUDED? N / A **(Mandatory in NH)**						E.L. EACH ACCIDENT	$
	If yes, describe under DESCRIPTION OF OPERATIONS below						E.L. DISEASE - EA EMPLOYEE	$
							E.L. DISEASE - POLICY LIMIT	$

DESCRIPTION OF OPERATIONS / LOCATIONS / VEHICLES (Attach ACORD 101, Additional Remarks Schedule, if more space is required)

Re: 2455 Wardlow Road, Corona CA 92880

General Evidence of Insurance

CERTIFICATE HOLDER

Actavis, Inc.
Morris Corporate Center III
400 Interpace Parkway
Parsippany, NJ 07054

CANCELLATION

SHOULD ANY OF THE ABOVE DESCRIBED POLICIES BE CANCELLED BEFORE THE EXPIRATION DATE THEREOF, NOTICE WILL BE DELIVERED IN ACCORDANCE WITH THE POLICY PROVISIONS.

AUTHORIZED REPRESENTATIVE
of Marsh USA Inc.

E. Deguia

AGENCY CUSTOMER ID: 400672
LOC #: San Diego

ADDITIONAL REMARKS SCHEDULE

AGENCY	NAMED INSURED
Marsh Risk & Insurance Services	Actavis, Inc. Morris Corporate Center III 400 Interpace Parkway Parsippany, NJ 07054
POLICY NUMBER	
CARRIER / NAIC CODE	EFFECTIVE DATE:

ADDITIONAL REMARKS

THIS ADDITIONAL REMARKS FORM IS A SCHEDULE TO ACORD FORM,
FORM NUMBER: 25 FORM TITLE: Certificate of Liability Insurance

Named Insured includes:

Actavis Pharma, Inc.
Watson Pharma, Inc.,
Watson Laboratories, Inc.,
Royce Laboratories, Inc.,
Oclassen Pharmaceuticals, Inc.,
The Rugby Group Inc.,
Makoff R&D Laboratories, Inc.,
Watson Pharmaceuticals, Inc.,
Schein Pharmaceutical, Inc.,
Danbury Pharmacal, Inc.,
Steris Laboratories,
Schein,
Thera Tech, Inc.,
and WP Development AB.

URL: https://www.idfpr.com/LicenseLookUp/LicenseLookup.asp (Illinois On-Line Licensure Verification)

Search by License Number (004001033) ...selected multiple licenses

(**Gurnee 605** – Changed on on-line verification system, both licenses Regular & CDS)

6/27/2013 Information found on:
Activis Pharma Inc, GURNEE, IL

Profession	License No	License Status	Original Issue Date	Current Exprtn	Ever Disciplined
Controlled Substance Drug Dist, Licensed	N/A	ACTIVE	06/08/1998	12/31/2014	N
Drug Distributor, Licensed	004000398	CLOSED	10/20/1993	12/31/2002	N
Drug Distributor, Licensed	004001033	ACTIVE	06/08/1998	12/31/2014	N

Search by License Number (004003641) ...selected multiple licenses

(**Gurnee 705B** – Changed on on-line verification system, Regular license only – no controlled drugs at this location)

6/27/2013 Information found on:
Activis Pharma Inc, Gurnee, IL

Profession	License No	License Status	Original Issue Date	Current Exprtn	Ever Disciplined
Controlled Substance Drug Dist, Licensed	N/A	CLOSED	11/16/1992	12/31/2010	N
Drug Distributor, Licensed	004000089	CLOSED	11/02/1992	12/31/2010	N
Drug Distributor, Licensed	004003641	ACTIVE	04/02/2013	12/31/2014	N

Search by License Number (004001917) ...selected multiple licenses

(**Corona B5** – no changes yet on-line verification system as of 6/27/13 at 6:17 p.m. EST)

6/27/2013 Information found on:
WATSON PHARMA INC, CORONA, CA

Profession	License No	License Status	Original Issue Date	Current Exprtn	Ever Disciplined
Controlled Substance Drug Dist, Licensed	N/A	ACTIVE	11/10/2004	12/31/2014	N
Drug Distributor, Licensed	004001917	ACTIVE	11/10/2004	12/31/2014	N

State of Illinois

Department of Financial and Professional Regulation
Division of Professional Regulation

LICENSE NO.
004.001033

The person, firm or corporation whose name appears on this certificate has complied with the provisions of the Illinois Statutes and/or rules and regulations and is hereby authorized to engage in the activity as indicated below.

EXPIRES:
12/31/2014

LICENSED
WHOLESALE DRUG DISTRIBUTOR
WHOLESALE DRUG

ACTIVIS PHARMA INC
EDWARD GROVER
605 TRI-STATE PARKWAY
GURNEE, IL 60031

MANUEL FLORES
ACTING SECRETARY

JAY STEWART
DIRECTOR

The official status of this license can be verified at www.idfpr.com

7800610

Cut on Dotted Line

For further reference, the Department is now providing a personal customer identification "Contact Number" which you may use in lieu of your social security number or FEIN number when contacting the Department. Your number is: 303419

State of Illinois
LICENSE NO. Department of Financial and Professional Regulation
Division of Professional Regulation

**** VOID ****

**** VOID ****

**** VOID ****

EXPIRES

MANUEL FLORES
ACTING SECRETARY

JAY STEWART
DIRECTOR

The official status of this license can be verified at www.idfpr.com

7800610

Cut on Dotted Line

20130626-1/00003

State of Illinois

Department of Financial and Professional Regulation
Division of Professional Regulation

LICENSE NO.
004.003641

The person, firm or corporation whose name appears on this certificate has complied with the provisions of the Illinois Statutes and/or rules and regulations and is hereby authorized to engage in the activity as indicated below.

EXPIRES:
12/31/2014

LICENSED
WHOLESALE DRUG DISTRIBUTOR
WHOLESALE DRUG

ACTIVIS PHARMA INC
RICHARD LICHTENBERGER JR
705 TRI STATE PKWY UNIT B
GURNEE, IL 60031

MANUEL FLORES
ACTING SECRETARY

JAY STEWART
DIRECTOR

The official status of this license can be verified at www.idfpr.com

7800599

Cut on Dotted Line

For further reference, the Department is now providing a personal customer identification "Contact Number" which you may use in lieu of your social security number or FEIN number when contacting the Department. Your number is: 302535

State of Illinois
LICENSE NO. Department of Financial and Professional Regulation
Division of Professional Regulation

**** VOID ****

**** VOID ****

**** VOID ****

EXPIRES:

MANUEL FLORES
ACTING SECRETARY

JAY STEWART
DIRECTOR

The official status of this license can be verified at www.idfpr.com

7800599

Cut on Dotted Line

20130626-1/00005



State of Illinois

Department of Financial and Professional Regulation
Division of Professional Regulation

LICENSE NO.
004.001917

The person, firm or corporation named on this certificate has complied with the provisions of the Illinois Statutes and rules and regulations and is hereby authorized to engage in the activity as indicated below.

EXPIRES
12/31/2014

LICENSED
WHOLESALE DRUG DISTRIBUTOR
WHOLESALE DRUG

ACTAVIS PHARMA INC
MIGUEL GOMEZ
2455 WARDLOW RD
CORONA, CA 92880

MANUEL FLORES
ACTING SECRETARY

JAY STEWART
DIRECTOR

The official status of this license can be verified at www.idfpr.com

7801953

Cut on Dotted Line

For further reference, the Department is now providing a personal customer identification "Contact Number" which you may use in lieu of your social security number or FEIN number when contacting the Department. Your number is: 304284



State of Illinois
Department of Financial and Professional Regulation
Division of Professional Regulation

LICENSE NO.

**** VOID ****

**** VOID ****

**** VOID ****

EXPIRES

MANUEL FLORES
ACTING SECRETARY

JAY STEWART
DIRECTOR

The official status of this license can be verified at www.idfpr.com

7801953

Cut on Dotted Line

20130628-1/00002

State of Illinois

Department of Financial and Professional Regulation
Division of Professional Regulation

LICENSE NO.
304.006370
004.001033

The person, firm or corporation whose name appears on this certificate has complied with the provisions of the Illinois Statutes and/or rules and regulations and is hereby authorized to engage in the activity as indicated below.

EXPIRES:
12/31/2014

LICENSED
DRUG DISTRIBUTOR
CONTROLLED SUBSTANCE
F II III IIN IIIN IV V

ACTIVIS PHARMA INC
605 TRI-STATE
GURNEE, IL 60031

MANUEL FLORES
ACTING SECRETARY

JAY STEWART
DIRECTOR

The official status of this license can be verified at www.idfpr.com

7893213

Cut on Dotted Line

For further reference, the Department is now providing a personal customer identification "Contact Number" which you may use in lieu of your social security number or FEIN number when contacting the Department. Your number is: 303419

State of Illinois
LICENSE NO Department of Financial and Professional Regulation
Division of Professional Regulation

**** VOID ****

**** VOID ****

**** VOID ****

EXPIRES:

MANUEL FLORES
ACTING SECRETARY

JAY STEWART
DIRECTOR

The official status of this license can be verified at www.idfpr.com

7893213

Cut on Dotted Line

20130702-1/00624

State of Illinois

Department of Financial and Professional Regulation

Division of Professional Regulation

LICENSE NO.
304.006741
004.001917

The person, firm or corporation whose name appears on this certificate has complied with the provisions of the Illinois Statutes and/or rules and regulations and is hereby authorized to engage in the activity as indicated below.

EXPIRES:
12/31/2014

LICENSED
DRUG DISTRIBUTOR
CONTROLLED SUBSTANCE
F II III IIIN IV

ACTAVIS PHARMA INC
2455 WARDLOW RD
CORONA, CA 92880

MANUEL FLORES
ACTING SECRETARY

JAY STEWART
DIRECTOR

The official status of this license can be verified at www.idfpr.com

7893215

Cut on Dotted Line

For further reference, the Department is now providing a personal customer identification "Contact Number" which you may use in lieu of your social security number or FEIN number when contacting the Department. Your number is: 304284

State of Illinois
LICENSE NO. Department of Financial and Professional Regulation
Division of Professional Regulation

**** VOID ****

**** VOID ****

**** VOID ****

EXPIRES:

MANUEL FLORES
ACTING SECRETARY

JAY STEWART
DIRECTOR

The official status of this license can be verified at www.idfpr.com

7893215

Cut on Dotted Line

20130702-1/00625

DEA REGISTRATION NUMBER	THIS REGISTRATION EXPIRES	FEE PAID
RW0237900	05-31-2014	$1523

SCHEDULES	BUSINESS ACTIVITY	DATE ISSUED
2,2N,3 3N,4,5	DISTRIBUTOR	04-16-2013

WATSON PHARMA
605 TRI-STATE PARKWAY
GURNEE, IL 60031

CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE
UNITED STATES DEPARTMENT OF JUSTICE
DRUG ENFORCEMENT ADMINISTRATION
WASHINGTON, D.C, 20537

Sections 304 and 1008 (21 U.S.C. 824 and 958) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacturer, distribute, dispense, import or export a controlled substance.

THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, OR BUSINESS ACTIVITY, AND IS NOT VALID AFTER THE EXPIRATION DATE.

CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE
UNITED STATES DEPARTMENT OF JUSTICE
DRUG ENFORCEMENT ADMINISTRATION
WASHINGTON, D.C, 20537

DEA REGISTRATION NUMBER	THIS REGISTRATION EXPIRES	FEE PAID
RW0237900	05-31-2014	$1523

SCHEDULES	BUSINESS ACTIVITY	DATE ISSUED
2,2N,3 3N,4,5	DISTRIBUTOR	04-16-2013

WATSON PHARMA
605 TRI-STATE PARKWAY
GURNEE, IL 60031

Sections 304 and 1008 (21 U.S.C. 824 and 958) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance.

THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, BUSINESS ACTIVITY, OR VALID AFTER THE EXPIRATION DATE.

Form DEA-223 (05/04)

DEA REGISTRATION NUMBER	THIS REGISTRATION EXPIRES	FEE PAID
RW0288921	05-31-2014	$1523

SCHEDULES	BUSINESS ACTIVITY	DATE ISSUED
2,2N,3 3N,4	DISTRIBUTOR	04-25-2013

WATSON PHARMA INC
2455 WARDLOW ROAD
CORONA, CA 92880 2882

CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE
UNITED STATES DEPARTMENT OF JUSTICE
DRUG ENFORCEMENT ADMINISTRATION
WASHINGTON, D.C. 20537

Sections 304 and 1008 (21 U.S.C. 824 and 958) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacturer, distribute, dispense, import or export a controlled substance.

THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, OR BUSINESS ACTIVITY, AND IS NOT VALID AFTER THE EXPIRATION DATE.

CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE
UNITED STATES DEPARTMENT OF JUSTICE
DRUG ENFORCEMENT ADMINISTRATION
WASHINGTON, D.C, 20537

DEA REGISTRATION NUMBER	THIS REGISTRATION EXPIRES	FEE PAID
RW0288921	05-31-2014	$1523

SCHEDULES	BUSINESS ACTIVITY	DATE ISSUED
2,2N,3 3N,4	DISTRIBUTOR	04-25-2013

WATSON PHARMA INC
2455 WARDLOW ROAD
CORONA, CA 92880 2882

Sections 304 and 1008 (21 U.S.C. 824 and 958) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance.

THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, BUSINESS ACTIVITY, OR VALID AFTER THE EXPIRATION DATE.

Form DEA-223 (05/04)

RX Products - Corona & Gurnee 605

NDC	Description
16252-0525-01	ACARBOSE 100MG TAB 100
16252-0523-01	ACARBOSE 25MG TAB 100
16252-0524-01	ACARBOSE 50MG TAB 100
00472-0882-82	ACETASOL HC 1%/2% OTIC SOL 10ML
52544-0930-01	ACTIGALL 300MG CAP 100
00472-0082-16	ACYCLOVIR 200MG/5ML ORAL SUSP 16OZ
00591-3193-01	AFEDITAB CR 30MG TAB 100
00591-3193-05	AFEDITAB CR 30MG TAB 500
00591-3194-01	AFEDITAB CR 60MG TAB 100
00591-3194-05	AFEDITAB CR 60MG TAB 500
00591-3797-83	ALBUTEROL SULFATE INH 0.083% 25X3ML 75
00591-3797-30	ALBUTEROL SULFATE INH 0.083% 30X3ML 90
00591-3797-60	ALBUTEROL SULFATE INH 0.083% 60X3ML 180
00591-3467-53	ALBUTEROL SULF 0.63MG/3ML INH SOL 25X3ML
00591-3468-53	ALBUTEROL SULF 1.25MG/3ML INH SOL 25X3ML
16252-0599-02	ALENDRONATE SODIUM 35MG TAB 12UD
16252-0599-44	ALENDRONATE SODIUM 35MG TAB 4UD
16252-0601-02	ALENDRONATE SODIUM 70MG TAB 12UD
16252-0601-44	ALENDRONATE SODIUM 70MG TAB 4UD
00591-5543-01	ALLOPURINOL 100MG TAB 100
00591-5543-10	ALLOPURINOL 100MG TAB 1000
00591-5544-01	ALLOPURINOL 300MG TAB 100
00591-5544-05	ALLOPURINOL 300MG TAB 500
52544-0884-08	ALORA TS 0.025MG/DAY 8
52544-0471-08	ALORA TS 0.05MG/DAY 8
52544-0472-08	ALORA TS 0.075MG/DAY 8
52544-0473-08	ALORA TS 0.1MG/DAY 8
00228-2027-10	ALPRAZOLAM 0.25MG TAB 100
00228-2027-96	ALPRAZOLAM 0.25MG TAB 1000
00228-2027-50	ALPRAZOLAM 0.25MG TAB 500
00228-2029-10	ALPRAZOLAM 0.5MG TAB 100
00228-2029-96	ALPRAZOLAM 0.5MG TAB 1000
00228-2029-50	ALPRAZOLAM 0.5MG TAB 500
00228-2031-10	ALPRAZOLAM 1MG TAB 100
00228-2031-96	ALPRAZOLAM 1MG TAB 1000
00228-2031-50	ALPRAZOLAM 1MG TAB 500
00228-2039-10	ALPRAZOLAM 2MG TAB 100
00228-2039-50	ALPRAZOLAM 2MG TAB 500
00228-3083-06	ALPRAZOLAM ER 0.5MG TAB 60
00228-3084-06	ALPRAZOLAM ER 1MG TAB 60
00228-3087-06	ALPRAZOLAM ER 2MG TAB 60
00228-3086-06	ALPRAZOLAM ER 3MG TAB 60

00228-4019-11	ALPRAZOLAM 0.25MG ODT 100
00228-4022-11	ALPRAZOLAM 0.5MG ODT 100
00228-4024-11	ALPRAZOLAM 1MG ODT 100
00228-4025-11	ALPRAZOLAM 2MG ODT 100
52544-0268-29	AMETHIA 0.15/0.03MG +0.01MG TAB 2X91
52544-0228-29	AMETHIA LO 0.1/0.02MG+0.01MG TAB 2X91
52544-0295-28	AMETHYST 90/20MCG TAB 28
00591-3760-01	AMLODIPINE BESY/BENAZEPRIL 10/20MG CP100
00591-3760-05	AMLODIPINE BESY/BENAZEPRIL 10/20MG CP500
00591-3762-01	AMLODIPINE BESY/BENAZEPRIL 10/40MG CP100
00591-3757-01	AMLODIPINE BESY/BENAZEPRIL 2.5/10MG C100
00591-3758-01	AMLODIPINE BESY/BENAZEPRIL 5/10MG CAP100
00591-3758-05	AMLODIPINE BESY/BENAZEPRIL 5/10MG CAP500
00591-3759-01	AMLODIPINE BESY/BENAZEPRIL 5/20MG CAP100
00591-3759-05	AMLODIPINE BESY/BENAZEPRIL 5/20MG CAP500
00591-3761-01	AMLODIPINE BESY/BENAZEPRIL 5/40MG CAP100
00591-2157-80	AMMONIUM LACTATE 12% CREAM 280G
00591-2157-38	AMMONIUM LACTATE 12% CREAM 385G
00591-2158-22	AMMONIUM LACTATE 12% LOTION 225G
00591-2158-46	AMMONIUM LACTATE 12% LOTION 400G
00591-5715-01	AMOXAPINE 100MG TAB 100
00591-5716-30	AMOXAPINE 150MG TAB 30
00591-5713-01	AMOXAPINE 25MG TAB 100
00591-5714-01	AMOXAPINE 50MG TAB 100
52544-0076-60	ANDRODERM 2MG/DY P 60
52544-0077-30	ANDRODERM 4MG/DY P 30
00591-5783-01	ATENOLOL/CHLOR 100/25MG TAB 100
00591-5782-01	ATENOLOL/CHLOR 50/25MG TAB 100
52544-0940-28	AZURETTE 0.15/0.02+0.01MG TAB 6X28 168
00591-3369-01	BUTAL/APAP/CAFF 50/325/40MG TAB 100
00591-3369-05	BUTAL/APAP/CAFF 50/325/40MG TAB 500
00591-3220-01	BUTAL/APAP/CAF/COD 50/325/40/30MG CAP100
00472-0370-15	BETAMETH VALERAT 0.1% CR 15G ACT
00472-0370-45	BETAMETH VALERAT 0.1% CR 45G ACT
00472-0371-15	BETAMETH VALERAT 0.1% OINT 15G ACT
00472-0371-45	BETAMETH VALERAT 0.1% OINT 45G ACT
00472-0380-15	BETAMETH DIPROPT 0.05% CR 15G ACT
00472-0380-45	BETAMETH DIPROPT 0.05% CR 45G ACT
00472-0381-15	BETAMETH DIPROPT 0.05% OINT 15G ACT
00472-0381-45	BETAMETH DIPROPT 0.05% OINT 45G ACT
00472-0382-15	BETAMETH DIPROPT 0.05% OT AUG 15G ACT
00472-0382-45	BETAMETH DIPROPT 0.05% OT AUG 45G ACT
52544-0254-28	BREVICON WALLETTE 0.5/0.035MG T 3X28
00591-3767-30	BUDESONIDE 0.25MG/2ML SUSP INH 30 UD
00591-3768-30	BUDESONIDE 0.5MG/2ML SUSP INH 30 UD
00228-3154-03	BUPREN/NALOX 2/0.5MG TAB 30
00228-3155-03	BUPREN/NALOX 8/2MG TAB 30

67767-0171-60	BUPROPION SR W 100MG TAB 60
67767-0133-25	BUPROPION SR W 150MG TAB 250
67767-0133-05	BUPROPION SR W 150MG TAB 500
67767-0133-60	BUPROPION SR W 150MG TAB 60
67767-0135-60	BUPROPION SR W 200MG TAB 60
00591-3540-05	BUPROPION HCL ER (SR DEP) 100MG TAB 500
00591-3540-60	BUPROPION HCL ER (SR DEP) 100MG TAB 60
00591-3541-25	BUPROPION HCL ER (SR DEP) 150MG TAB 250
00591-3541-05	BUPROPION HCL ER (SR DEP) 150MG TAB 500
00591-3541-60	BUPROPION HCL ER (SR DEP) 150MG TAB 60
00591-3542-60	BUPROPION HCL ER (SR DEP) 200MG TAB 60
00591-3331-30	BUPROPION HCL XL 150MG TAB 30
00591-3331-05	BUPROPION HCL XL 150MG TAB 500
00591-3331-19	BUPROPION HCL XL 150MG TAB 90
00591-3332-30	BUPROPION HCL XL 300MG TAB 30
00591-3332-05	BUPROPION HCL XL 300MG TAB 500
67767-0141-30	BUPROPION XL 150MG TAB 30
67767-0141-90	BUPROPION XL 150MG TAB 90
67767-0142-05	BUPROPION XL 300MG TAB 500
67767-0142-90	BUPROPION XL 300MG TAB 90
00591-3543-60	BUPROPION HCL SR (SC) REF 150MG TAB 60
00591-3543-76	BUPROPION HCL SR(SC)150MG TAB 60 STARTER
00591-0658-01	BUSPIRONE HCL 10MG TAB 100
00591-0658-10	BUSPIRONE HCL 10MG TAB 1000
00591-0658-05	BUSPIRONE HCL 10MG TAB 500
00591-0718-18	BUSPIRONE HCL 15MG TAB 180
00591-0718-05	BUSPIRONE HCL 15MG TAB 500
00591-0718-60	BUSPIRONE HCL 15MG TAB 60
00591-0657-01	BUSPIRONE HCL 5MG TAB 100
00591-0657-10	BUSPIRONE HCL 5MG TAB 1000
00591-0657-05	BUSPIRONE HCL 5MG TAB 500
00591-3546-01	BUTAL/ASA/CAF/COD 50/325/40/30MG CAP 100
00591-3546-05	BUTAL/ASA/CAF/COD 50/325/40/30MG CAP 500
00591-3219-01	BUTAL/ASA/CAFF 50/325/40MG CAP 100
16252-0536-08	CABERGOLINE 0.5MG TAB 8
00228-2538-10	CARBI/LEVO 10/100MG TAB 100
00228-2538-50	CARBI/LEVO 10/100MG TAB 500
00228-2539-10	CARBI/LEVO 25/100MG TAB 100
00228-2539-96	CARBI/LEVO 25/100MG TAB 1000
00228-2539-50	CARBI/LEVO 25/100MG TAB 500
00228-2540-10	CARBI/LEVO 25/250MG TAB 100
00228-2540-96	CARBI/LEVO 25/250MG TAB 1000
00228-2540-50	CARBI/LEVO 25/250MG TAB 500
00591-5513-01	CARISOPRODOL 350MG TAB 100
00591-5513-10	CARISOPRODOL 350MG TAB 1000
00591-5513-05	CARISOPRODOL 350MG TAB 500
62037-0597-05	CARTIA XT 120MG CAP 500

62037-0597-90	CARTIA XT 120MG CAP 90
62037-0598-05	CARTIA XT 180MG CAP 500
62037-0598-90	CARTIA XT 180MG CAP 90
62037-0599-05	CARTIA XT 240MG CAP 500
62037-0599-90	CARTIA XT 240MG CAP 90
62037-0600-05	CARTIA XT 300MG CAP 500
62037-0600-90	CARTIA XT 300MG CAP 90
52544-0959-31	CAZIANT 0.1+0.125+0.15/.025MG TAB 3X28
00591-2520-01	CHLORZOXAZONE 500MG TAB 100
00591-2520-05	CHLORZOXAZONE 500MG TAB 500
00591-2159-90	CICLOPIROX 1% SHAMPOO 120ML
16252-0514-01	CIPROFLOXACIN 250MG TAB 100
16252-0515-01	CIPROFLOXACIN 500MG TAB 100
16252-0516-05	CIPROFLOXACIN 750MG TAB 50
62037-0777-60	CLARITHROMYCIN ER 500MG TAB 60
00591-3120-01	CLINDAMYCIN 300MG CAP 100
00591-5708-01	CLINDAMYCIN HCL 150MG CAP 100
00472-0404-92	CLOBETASOL 0.05% LOTION 2 OZ ACT
00472-0404-94	CLOBETASOL 0.05% LOTION 4 OZ ACT
00472-0403-94	CLOBETASOL 0.05% SHAMPOO 4 OZ ACT
00591-0781-30	CLOMIPHENE CITRATE 50MG TAB 30
00228-3003-11	CLONAZEPAM 0.5MG TAB 100
00228-3003-50	CLONAZEPAM 0.5MG TAB 500
00228-3004-11	CLONAZEPAM 1.0MG TAB 100
00228-3004-50	CLONAZEPAM 1.0MG TAB 500
00228-3005-11	CLONAZEPAM 2.0MG TAB 100
00228-3005-50	CLONAZEPAM 2.0MG TAB 500
00228-2127-10	CLONIDINE 0.1MG TAB 100
00228-2127-50	CLONIDINE 0.1MG TAB 500
00228-2128-10	CLONIDINE 0.2MG TAB 100
00228-2128-50	CLONIDINE 0.2MG TAB 500
00228-2129-10	CLONIDINE 0.3MG TAB 100
00472-0379-15	CLOTRIMAZOLE/BMD 1%/0.05% CR 15G ACT
00472-0379-45	CLOTRIMAZOLE/BMD 1%/0.05% CR 45G ACT
52544-0045-13	CONDYLOX GEL 0.5% 3.5GM 3.5
52544-0046-13	CONDYLOX SOLN 0.5% 3.5ML 3.5
52544-0044-24	CORDRAN TAPE 4MCG/CM2 ROLL 1-24X3
52544-0044-80	CORDRAN TAPE 4MCG/CM2 ROLL 1-80X3
52544-0283-24	CRINONE 4% GEL APPLTR 6X1.45G 8.7G
52544-0284-12	CRINONE 8% GEL APPLTR 15X1.45G 21.75G
00591-5658-01	CYCLOBENZAPRINE HCL 10MG TAB 100
00591-5658-10	CYCLOBENZAPRINE HCL 10MG TAB 1000
00591-5658-05	CYCLOBENZAPRINE HCL 10MG TAB 500
00591-3256-01	CYCLOBENZAPRINE HCL 5MG TAB 100
00591-2223-15	CYCLOSPORINE 100MG CAP 30 BLISTER
00591-2224-55	CYCLOSPORINE 100MG/ML ORAL SOL 50ML
00591-2222-15	CYCLOSPORINE 25MG CAP 30 BLISTER

00472-1400-16	CYPROHEPTADINE 2MG/5ML SYP 16 OZ
45963-0345-02	DESIPRAMINE 100MG TAB 100
45963-0341-02	DESIPRAMINE 10MG TAB 100
45963-0346-50	DESIPRAMINE 150MG TAB 50
45963-0342-02	DESIPRAMINE 25MG TAB 100
45963-0343-02	DESIPRAMINE 50MG TAB 100
45963-0344-02	DESIPRAMINE 75MG TAB 100
00591-2464-01	DESMOPRESSIN ACETATE 0.1MG TAB 100
00591-2465-01	DESMOPRESSIN ACETATE 0.2MG TAB 100
00472-0803-02	DESONIDE 0.05% LOTION 2 OZ
00472-0803-04	DESONIDE 0.05% LOTION 4 OZ
00591-5620-01	DIAZEPAM 10MG TAB 100
00591-5620-10	DIAZEPAM 10MG TAB 1000
00591-5620-05	DIAZEPAM 10MG TAB 500
00591-5621-01	DIAZEPAM 2MG TAB 100
00591-5621-10	DIAZEPAM 2MG TAB 1000
00591-5621-05	DIAZEPAM 2MG TAB 500
00591-5619-01	DIAZEPAM 5MG TAB 100
00591-5619-10	DIAZEPAM 5MG TAB 1000
00591-5619-05	DIAZEPAM 5MG TAB 500
00591-0397-60	DICLOFENAC SOD/MISOPROSTOL50/0.2MG TAB60
00591-0398-60	DICLOFENAC SOD/MISOPROSTOL75/0.2MG TAB60
00228-2550-11	DICLOFENAC DR 50MG TAB 100
00228-2550-96	DICLOFENAC DR 50MG TAB 1000
00228-2550-06	DICLOFENAC DR 50MG TAB 60
00228-2551-11	DICLOFENAC DR 75MG TAB 100
00228-2551-96	DICLOFENAC DR 75MG TAB 1000
00228-2551-06	DICLOFENAC DR 75MG TAB 60
00591-0338-10	DICLOFENAC SODIUM DR 50MG TAB 1000
00591-0676-01	DICLOFENAC SODIUM ER 100MG TAB 100
00228-2717-11	DICLOFENAC ER 100MG TAB 100
00591-0794-01	DICYCLOMINE HCL 10MG CAP 100
00591-0794-10	DICYCLOMINE HCL 10MG CAP 1000
00591-0795-01	DICYCLOMINE HCL 20MG TAB 100
00591-0795-10	DICYCLOMINE HCL 20MG TAB 1000
00591-0783-01	DIETHYLPROPION HCL 25MG TAB 100
00591-0782-01	DIETHYLPROPION HCL ER (CR) 75MG TAB 100
52544-0484-01	DILACOR XR 240MG CAP 100
00591-5560-01	DISOPYRAMIDE 100MG CAP 100
00591-5561-01	DISOPYRAMIDE 150MG CAP 100
00591-5440-50	DOXYCYCLINE HYCLATE 100MG CAP 50
00591-5440-05	DOXYCYCLINE HYCLATE 100MG CAP 500
00591-5553-50	DOXYCYCLINE HYCLATE 100MG TAB 50
00591-5553-05	DOXYCYCLINE HYCLATE 100MG TAB 500
00591-5535-50	DOXYCYCLINE HYCLATE 50MG CAP 50
00591-0411-50	DOXYCYCLINE MONO 100MG CAP 50
00591-0410-01	DOXYCYCLINE MONO 50MG CAP 100

00591-3593-60	DRONABINOL 10MG CAP 60
00591-3591-60	DRONABINOL 2.5MG CAP 60
00591-3592-60	DRONABINOL 5MG CAP 60
52544-0238-54	ELLA 30MG TAB 1
62037-0863-20	ENOXAPARIN SOD 100MG/1ML INJ 10 x 1ml
62037-0866-20	ENOXAPARIN SOD 150MG/1ML INJ 10 x 1ml
62037-0839-20	ENOXAPARIN SOD 30MG/0.3ML INJ 10 x 0.3ml
62037-0849-20	ENOXAPARIN SOD 40MG/0.4ML INJ 10 x 0.4ml
62037-0861-20	ENOXAPARIN SOD 60MG/0.6ML INJ 10 x 0.6ml
62037-0862-20	ENOXAPARIN SOD 80MG/0.8ML INJ 10 x 0.8ml
62037-0864-20	ENOXAPARIN SOD120MG/0.8ML INJ 10 x 0.8ml
00591-0744-01	ESTAZOLAM 1MG TAB 100
00591-0745-01	ESTAZOLAM 2MG TAB 100
00591-0528-01	ESTRADIOL 0.5MG TAB 100
00591-0487-01	ESTRADIOL 1MG TAB 100
00591-0487-05	ESTRADIOL 1MG TAB 500
00591-0488-01	ESTRADIOL 2MG TAB 100
00591-0488-05	ESTRADIOL 2MG TAB 500
00591-0414-01	ESTROPIPATE 0.75MG TAB 100
00591-0415-01	ESTROPIPATE 1.5MG TAB 100
00591-0416-01	ESTROPIPATE 3MG TAB 100
00591-3271-30	FAMCICLOVIR 125MG TAB 30
00591-3272-30	FAMCICLOVIR 250MG TAB 30
00591-3273-30	FAMCICLOVIR 500MG TAB 30
55253-0074-30	FENTANYL CITRATE EQ ORAL TRANS 1200MCG30
55253-0075-30	FENTANYL CITRATE EQ ORAL TRANS 1600MCG30
55253-0070-30	FENTANYL CITRATE EQ ORAL TRANS 200MCG 30
55253-0071-30	FENTANYL CITRATE EQ ORAL TRANS 400MCG 30
55253-0072-30	FENTANYL CITRATE EQ ORAL TRANS 600MCG 30
55253-0073-30	FENTANYL CITRATE EQ ORAL TRANS 800MCG 30
00591-3214-72	FENTANYL PATCH 100MCG 5
00591-3198-72	FENTANYL PATCH 25MCG 5
00591-3212-72	FENTANYL PATCH 50MCG 5
00591-3213-72	FENTANYL PATCH 75MCG 5
45963-0500-02	FINASTERIDE 5MG TAB 100
45963-0500-30	FINASTERIDE 5MG TAB 30
45963-0500-08	FINASTERIDE 5MG TAB 90
52544-0957-01	FIORICET 50/325/40MG TAB 100
52544-0957-05	FIORICET 50/325/40MG TAB 500
52544-0958-01	FIORICET/CODEINE 50/325/40/30MG CAP 100
52544-0955-01	FIORINAL 50/325/40MG CAP 100
52544-0956-01	FIORINAL/COD 50/325/40/30MG CAP 100
00591-2466-18	FLUTAMIDE 125MG CAP 180
00228-2665-11	GABAPENTIN 100MG CAP 100
14550-0511-02	GABAPENTIN 100MG CAP 100
00228-2665-50	GABAPENTIN 100MG CAP 500
14550-0511-04	GABAPENTIN 100MG CAP 500

00228-2666-11	GABAPENTIN 300MG CAP 100
14550-0512-02	GABAPENTIN 300MG CAP 100
00228-2666-50	GABAPENTIN 300MG CAP 500
14550-0512-04	GABAPENTIN 300MG CAP 500
00228-2667-11	GABAPENTIN 400MG CAP 100
14550-0513-02	GABAPENTIN 400MG CAP 100
00228-2667-50	GABAPENTIN 400MG CAP 500
14550-0513-04	GABAPENTIN 400MG CAP 500
00228-2636-11	GABAPENTIN 600MG TAB 100
00228-2636-50	GABAPENTIN 600MG TAB 500
00228-2637-11	GABAPENTIN 800MG TAB 100
00228-2637-50	GABAPENTIN 800MG TAB 500
00591-3497-30	GALANTAMINE HYDROBROMIDE ER 16MG CAP 30
00591-3498-30	GALANTAMINE HYDROBROMIDE ER 24MG CAP 30
00591-3496-30	GALANTAMINE HYDROBROMIDE ER 8MG CAP 30
52544-0084-30	GELNIQUE 10% TGEL 30 SACHET
52544-0041-54	GELNIQUE 3.0% GEL 92G 30MD
52544-0204-31	GENERESS FE .8MG/25MCG TAB 3x28
00591-0461-01	GLIPIZIDE 10MG TAB 100
00591-0461-10	GLIPIZIDE 10MG TAB 1000
00591-0461-05	GLIPIZIDE 10MG TAB 500
00591-0460-01	GLIPIZIDE 5MG TAB 100
00591-0460-10	GLIPIZIDE 5MG TAB 1000
00591-0460-05	GLIPIZIDE 5MG TAB 500
00591-0845-01	GLIPIZIDE ER 10MG TAB 100
00591-0845-10	GLIPIZIDE ER 10MG TAB 1000
00591-0845-15	GLIPIZIDE ER 10MG TAB BLISTER 30
00591-0900-30	GLIPIZIDE ER 2.5MG TAB 30
00591-0844-01	GLIPIZIDE ER 5MG TAB 100
00591-0844-10	GLIPIZIDE ER 5MG TAB 1000
00591-0844-15	GLIPIZIDE ER 5MG TAB BLISTER 30
00591-3973-01	GLIPIZIDE METFORMIN HCL 5/500MG TAB 100
00591-3971-01	GLIPIZIDE METFORMIN HCL2.5/250MG TAB 100
00591-3972-01	GLIPIZIDE METFORMIN HCL2.5/500MG TAB 100
00228-2751-11	GLYBURIDE/METFORMIN 1.25/250MG TAB 100
00228-2751-50	GLYBURIDE/METFORMIN 1.25/250MG TAB 500
00228-2752-11	GLYBURIDE/METFORMIN 2.5/500MG TAB 100
00228-2752-50	GLYBURIDE/METFORMIN 2.5/500MG TAB 500
00228-2753-11	GLYBURIDE/METFORMIN 5/500MG TAB 100
00228-2753-50	GLYBURIDE/METFORMIN 5/500MG TAB 500
00472-0013-04	GRISEOFULVIN 125MG/5ML ORAL SUS 4 OZ
00591-0444-01	GUANFACINE HCL 1MG TAB 100
00591-0453-01	GUANFACINE HCL 2MG TAB 100
00591-0347-01	HYDROCHLOROTHIAZIDE 12.5MG CAP 100
00591-0347-05	HYDROCHLOROTHIAZIDE 12.5MG CAP 500
45963-0412-61	HYDRO/ACETIC ACID 1%/2% SOL 10ML
00228-2820-11	HYDROCHLOROTHIAZIDE 12.5MG TAB 100

00591-0853-01	HYDROCODONE/APAP 10/325MG TAB 100
00591-2612-05	HYDROCODONE/APAP 10/325MG TAB 500
00591-2609-01	HYDROCODONE/APAP 10/500MG TAB 100
00591-2609-05	HYDROCODONE/APAP 10/500MG TAB 500
00591-2610-01	HYDROCODONE/APAP 10/650MG TAB 100
00591-0503-05	HYDROCODONE/APAP 10/650MG TAB 500
00591-0517-01	HYDROCODONE/APAP 10/660MG TAB 100
00591-3228-01	HYDROCODONE/APAP 10/750MG TAB 100
00591-0388-01	HYDROCODONE/APAP 2.5/500MG TAB 100
00591-3202-01	HYDROCODONE/APAP 5/325MG TAB 100
00591-0349-01	HYDROCODONE/APAP 5/500MG TAB 100
00591-0349-05	HYDROCODONE/APAP 5/500MG TAB 500
00591-2605-01	HYDROCODONE/APAP 7.5/325MG TAB 100
00591-0385-01	HYDROCODONE/APAP 7.5/500MG TAB 100
00591-0385-05	HYDROCODONE/APAP 7.5/500MG TAB 500
00591-0502-01	HYDROCODONE/APAP 7.5/650MG TAB 100
00591-0502-05	HYDROCODONE/APAP 7.5/650MG TAB 500
00591-0387-01	HYDROCODONE/APAP 7.5/750MG TAB 100
00591-0387-05	HYDROCODONE/APAP 7.5/750MG TAB 500
62037-0524-01	HYDROCODONE/IBUPROFEN 7.5/200MG TAB 100
62037-0524-05	HYDROCODONE/IBUPROFEN 7.5/200MG TAB 500
00472-0321-26	HYDROCORTISONE 1% RX CR 1 OZ ACT
00472-1326-26	HYDROCORTISONE 1% RX OINT 1 OZ ACT
00472-0337-20	HYDROCORTISONE 2.5% CR 20G ACT
00472-0337-30	HYDROCORTISONE 2.5% CR 30G ACT
00472-1030-16	HYDROMET 5/1.5MG/5ML SYR 16OZ ACT
00591-2888-30	HYDROXOCOBALAMIN INJ 1000MCG/ML 1x30ML 1
00591-0698-01	HYDRXYCHLQN SULFATE 200MG TAB 100
00591-0698-05	HYDRXYCHLQN SULFATE 200MG TAB 500
00591-0800-01	HYDROXYZINE PAMOATE 25MG CAP 100
00591-0800-05	HYDROXYZINE PAMOATE 25MG CAP 500
00591-0801-01	HYDROXYZINE PAMOATE 50MG CAP 100
00591-0801-05	HYDROXYZINE PAMOATE 50MG CAP 500
00591-3770-31	IBANDRONATE SODIUM 150MG TAB 3
00472-1270-16	IBUPROFEN 100MG/5ML RX ORAL SUSP 16 OZ
00472-1270-94	IBUPROFEN 100MG/5ML RX ORAL SUSP 4 OZ
00228-2597-11	INDAPAMIDE 1.25MG TAB 100
00228-2597-96	INDAPAMIDE 1.25MG TAB 1000
00228-2571-11	INDAPAMIDE 2.5MG TAB 100
00228-2571-96	INDAPAMIDE 2.5MG TAB 1000
52544-0931-02	INFED (IRON DEXTRAN INJ) 50MG 10X2ML
16252-0547-33	IPRATROPIUM/ALBUTEROL INH.5MG/3MG 30X3ML
16252-0547-66	IPRATROPIUM/ALBUTEROL INH.5MG/3MG 60X3ML
00591-3798-83	IPRATROPIUM BROMIDE 0.02% 25X2.5ML 62.5
00591-3798-30	IPRATROPIUM BROMIDE 0.02% 30X2.5ML 75
00591-3798-60	IPRATROPIUM BROMIDE 0.02% 60X2.5ML 150
00591-3433-30	IPRATROPIUM B ALB 0.5/3MG INH SLN 30X3ML

00591-3433-60	IPRATROPIUM B ALB 0.5/3MG INH SLN 60X3ML
00591-2783-30	IRBESARTAN 150MG TAB 30
00591-2783-19	IRBESARTAN 150MG TAB 90
00591-2784-30	IRBESARTAN 300MG TAB 30
00591-2784-19	IRBESARTAN 300MG TAB 90
00591-2782-30	IRBESARTAN 75MG TAB 30
00591-2782-19	IRBESARTAN 75MG TAB 90
00591-2785-30	IRBESARTAN/HCTZ 150/12.5MG TAB 30
00591-2785-19	IRBESARTAN/HCTZ 150/12.5MG TAB 90
00591-2786-30	IRBESARTAN/HCTZ 300/12.5MG TAB 30
00591-2786-19	IRBESARTAN/HCTZ 300/12.5MG TAB 90
00228-2631-11	ISOSORBIDE MONONITRATE 10MG TAB 100
00228-2620-11	ISOSORBIDE MONONITRATE 20MG TAB 100
16252-0539-01	ISRADIPINE 2.5MG CAP 100
16252-0540-01	ISRADIPINE 5MG CAP 100
52544-0892-28	JOLIVETTE 0.35MG TAB 6X28
46987-0324-11	KADIAN ER 100MG CAP 100
46987-0410-11	KADIAN ER 10MG CAP 100
46987-0329-11	KADIAN ER 130MG CAP 100
46987-0330-11	KADIAN ER 150MG CAP 100
46987-0377-11	KADIAN ER 200MG CAP 100
46987-0322-11	KADIAN ER 20MG CAP 100
46987-0325-11	KADIAN ER 30MG CAP 100
46987-0327-11	KADIAN ER 40MG CAP 100
46987-0323-11	KADIAN ER 50MG CAP 100
46987-0326-11	KADIAN ER 60MG CAP 100
46987-0328-11	KADIAN ER 70MG CAP 100
46987-0412-11	KADIAN ER 80MG CAP 100
00591-0605-01	LABETALOL HCL 100MG TAB 100
00591-0605-05	LABETALOL HCL 100MG TAB 500
00591-0606-01	LABETALOL HCL 200MG TAB 100
00591-0606-05	LABETALOL HCL 200MG TAB 500
00591-0607-01	LABETALOL HCL 300MG TAB 100
45963-0439-65	CONSTULOSE/LACTULOSE SOL 10G/15ML 32 OZ
45963-0439-63	CONSTULOSE/LACTULOSE SOL 10G/15ML 8 OZ
45963-0438-64	ENULOSE/LACTULOSE SOL 16 OZ
16252-0598-01	LAMOTRIGINE 25MG CHEWABLE TAB 100
16252-0597-01	LAMOTRIGINE 5MG CHEWABLE TAB 100
45963-0460-03	LANSOPRAZOLE DR 15MG CAP 30
45963-0461-10	LANSOPRAZOLE DR 30MG CAP 100
45963-0461-96	LANSOPRAZOLE DR 30MG CAP 1000
45963-0461-03	LANSOPRAZOLE DR 30MG CAP 30
52544-0219-28	LEENA .5;1;.5/.035MG TAB 6X28
00591-2918-23	LEVALBUTEROL HCL 0.31MG INH SOL PCH 24x3
00591-2919-23	LEVALBUTEROL HCL 0.63MG INH SOL PCH 24x3
00591-2920-23	LEVALBUTEROL HCL 1.25MG INH SOL PCH 24x3
00591-3635-60	LEVETIRACETAM ER 500MG TAB 60

00591-3699-60	LEVETIRACETAM ER 750MG TAB 60
00472-0235-16	LEVETIRACETAM 100MG/ML ORAL SOL 16OZ
52544-0279-28	LEVORA 0.15/0.03MG TAB 6X28 168
00591-0407-01	LISINOPRIL 10MG TAB 100
00591-0407-10	LISINOPRIL 10MG TAB 1000
00591-0405-01	LISINOPRIL 2.5MG TAB 100
00591-0405-05	LISINOPRIL 2.5MG TAB 500
00591-0408-01	LISINOPRIL 20MG TAB 100
00591-0408-10	LISINOPRIL 20MG TAB 1000
00591-0885-01	LISINOPRIL 30MG TAB 100
00591-0409-01	LISINOPRIL 40MG TAB 100
00591-0409-05	LISINOPRIL 40MG TAB 500
00591-0406-01	LISINOPRIL 5MG TAB 100
00591-0406-10	LISINOPRIL 5MG TAB 1000
00591-0860-01	LISINOPRIL HCTZ 10/12.5MG TAB 100
00591-0860-05	LISINOPRIL HCTZ 10/12.5MG TAB 500
00591-0861-01	LISINOPRIL HCTZ 20/12.5MG TAB 100
00591-0861-05	LISINOPRIL HCTZ 20/12.5MG TAB 500
00591-0862-01	LISINOPRIL HCTZ 20/25MG TAB 100
00591-0862-05	LISINOPRIL HCTZ 20/25MG TAB 500
00591-0240-01	LORAZEPAM 0.5MG TAB 100
00591-0240-10	LORAZEPAM 0.5MG TAB 1000
00591-0240-05	LORAZEPAM 0.5MG TAB 500
00591-0241-01	LORAZEPAM 1MG TAB 100
00591-0241-10	LORAZEPAM 1MG TAB 1000
00591-0241-05	LORAZEPAM 1MG TAB 500
00591-0242-01	LORAZEPAM 2MG TAB 100
00591-0242-10	LORAZEPAM 2MG TAB 1000
00591-0242-05	LORAZEPAM 2MG TAB 500
45963-0633-04	LOVASTATIN 10MG TAB 500
45963-0633-01	LOVASTATIN 10MG TAB 60
45963-0634-04	LOVASTATIN 20MG TAB 500
45963-0634-01	LOVASTATIN 20MG TAB 60
45963-0635-04	LOVASTATIN 40MG TAB 500
45963-0635-01	LOVASTATIN 40MG TAB 60
52544-0847-28	LOW-OGESTREL 0.3/0.03MG 6x28 TAB 168
00591-0370-01	LOXAPINE 10MG CAP 100
00591-0371-01	LOXAPINE 25MG CAP 100
00591-0372-01	LOXAPINE 50MG CAP 100
00591-0369-01	LOXAPINE 5MG CAP 100
52544-0495-01	LOXITANE 10MG CAP 100
52544-0494-01	LOXITANE 5MG CAP 100
52544-0949-28	LUTERA 0.1MG/0.02MG TAB 6X28 168
52544-0691-30	MATZIM LA 180MG TAB 30
52544-0691-19	MATZIM LA 180MG TAB 90
52544-0692-30	MATZIM LA 240MG TAB 30
52544-0692-19	MATZIM LA 240MG TAB 90

52544-0693-30	MATZIM LA 300MG TAB 30
52544-0693-19	MATZIM LA 300MG TAB 90
52544-0694-30	MATZIM LA 360MG TAB 30
52544-0694-19	MATZIM LA 360MG TAB 90
52544-0695-30	MATZIM LA 420MG TAB 30
52544-0695-19	MATZIM LA 420MG TAB 90
52544-0634-01	MAXIDONE 10/750MG TAB 100
00591-2720-60	METFORMIN HCL ER 1000MG TAB 60
00591-2719-60	METFORMIN HCL ER 500MG TAB 60
62037-0571-01	METFORMIN HCL XR 500MG TAB 100
62037-0571-10	METFORMIN HCL XR 500MG TAB 1000
62037-0577-01	METFORMIN HCL XR 750MG TAB 100
62037-0577-10	METFORMIN HCL XR 750MG TAB 1000
00591-5883-01	METHYLPHENIDATE HCL 10MG TAB 100
00591-5884-01	METHYLPHENIDATE HCL 20MG TAB 100
00591-5882-01	METHYLPHENIDATE HCL 5MG TAB 100
00591-2715-01	METHYLPHENIDATE HCL ER 18MG TAB 100
00591-2716-01	METHYLPHENIDATE HCL ER 27MG TAB 100
00591-2717-01	METHYLPHENIDATE HCL ER 36MG TAB 100
00591-2718-01	METHYLPHENIDATE HCL ER 54MG TAB 100
67767-0200-01	METHYLPHENIDATE HCL 20MG ER CAP 100
67767-0201-01	METHYLPHENIDATE HCL 30MG ER CAP 100
67767-0202-01	METHYLPHENIDATE HCL 40MG ER CAP 100
00591-2468-01	METOCLOPRAMIDE 10MG TAB 100
00591-2468-10	METOCLOPRAMIDE 10MG TAB 1000
00591-2468-05	METOCLOPRAMIDE 10MG TAB 500
00591-2467-01	METOCLOPRAMIDE 5MG TAB 100
00591-2467-05	METOCLOPRAMIDE 5MG TAB 500
00591-0463-01	METOPROLOL TARTRATE 100MG TAB 100
00591-0463-10	METOPROLOL TARTRATE 100MG TAB 1000
00591-0462-01	METOPROLOL TARTRATE 50MG TAB 100
00591-0462-10	METOPROLOL TARTRATE 50MG TAB 1000
62037-0832-01	METOPROLOL SUCCINATE ER 100MG TAB 100
62037-0832-10	METOPROLOL SUCCINATE ER 100MG TAB 1000
62037-0833-01	METOPROLOL SUCCINATE ER 200MG TAB 100
62037-0830-01	METOPROLOL SUCCINATE ER 25MG TAB 100
62037-0830-10	METOPROLOL SUCCINATE ER 25MG TAB 1000
62037-0831-01	METOPROLOL SUCCINATE ER 50MG TAB 100
62037-0831-10	METOPROLOL SUCCINATE ER 50MG TAB 1000
00591-2521-01	METRONIDAZOLE 250MG TAB 100
00591-2521-25	METRONIDAZOLE 250MG TAB 250
00591-2521-05	METRONIDAZOLE 250MG TAB 500
00591-2522-50	METRONIDAZOLE 500MG TAB 50
00591-2522-05	METRONIDAZOLE 500MG TAB 500
00472-0911-45	METRONIDAZOLE CREAM 0.75% 45GM
00472-0912-02	METRONIDAZOLE LOTION 0.75% 2OZ
00472-1738-03	MICON 200MG VAG SUPP 3 ACT

52544-0951-21	MICROGESTIN 1.5MG/30MCG TAB 6X21 126
52544-0950-21	MICROGESTIN 1MG/20MCG TAB 6X21 126
52544-0631-28	MICROGESTIN FE 1.5MG/30MCG TAB 6X28 168
52544-0630-28	MICROGESTIN FE 1MG/20MCG TAB 6X28 168
52544-0622-01	MICROZIDE 12.5MG CAP 100
00591-5695-50	MINOCYCLINE HCL 100MG CAP 50
00591-5694-01	MINOCYCLINE HCL 50MG CAP 100
00591-5694-60	MINOCYCLINE HCL 50MG CAP 60
00591-3153-01	MINOCYCLINE HCL 75MG CAP 100
00591-5643-01	MINOXIDIL 10MG TAB 100
00591-5643-05	MINOXIDIL 10MG TAB 500
00591-5642-01	MINOXIDIL 2.5MG TAB 100
00591-5642-05	MINOXIDIL 2.5MG TAB 500
00591-1117-10	MIRTAZAPINE 15MG TAB 1000
00591-1117-30	MIRTAZAPINE 15MG TAB 30
00591-1118-10	MIRTAZAPINE 30MG TAB 1000
00591-1118-30	MIRTAZAPINE 30MG TAB 30
00591-1119-30	MIRTAZAPINE 45MG TAB 30
00591-2230-15	MIRTAZAPINE 15MG ORAL DIS TAB 30 BLISTE
00591-2231-15	MIRTAZAPINE 30MG ORAL DIS TAB 30 BLISTE
00228-3059-11	MIXED AMPHETAMINE SALTS ER 10MG CP 100
00228-3063-11	MIXED AMPHETAMINE SALTS ER 15MG CP 100
00228-3060-11	MIXED AMPHETAMINE SALTS ER 20MG CP 100
00228-3064-11	MIXED AMPHETAMINE SALTS ER 25MG CP 100
00228-3061-11	MIXED AMPHETAMINE SALTS ER 30MG CP 100
00228-3062-11	MIXED AMPHETAMINE SALTS ER 5MG CAP 100
00591-3499-01	MODAFINIL 100MG TAB 100
00591-3499-30	MODAFINIL 100MG TAB 30
00591-3500-01	MODAFINIL 200MG TAB 100
00591-3500-30	MODAFINIL 200MG TAB 30
52544-0247-28	MONONESSA 0.25 + 0.035MG TAB 6X28
00228-3507-11	MORPHINE SULF ER 100MG CAP 100
00228-3502-11	MORPHINE SULF ER 20MG CAP 100
00228-3503-11	MORPHINE SULF ER 30MG CAP 100
00228-3504-11	MORPHINE SULF ER 50MG CAP 100
00228-3505-11	MORPHINE SULF ER 60MG CAP 100
00228-3506-11	MORPHINE SULF ER 80MG CAP 100
00591-3670-01	NABUMETONE 500MG TAB 100
00591-3670-05	NABUMETONE 500MG TAB 500
00591-3671-01	NABUMETONE 750MG TAB 100
00591-3671-05	NABUMETONE 750MG TAB 500
00591-3355-01	NATEGLINIDE 120MG TAB 100
00591-3354-01	NATEGLINIDE 60MG TAB 100
52544-0550-28	NECON 0.5MG +35MCG TAB 6x28 168
52544-0552-28	NECON 1/35 1MG+35MCG TAB 6x28 168
52544-0245-31	NECON 1/50 1+50MCG TAB 3x28
52544-0554-28	NECON 10/11 0.5+35MCG/1+35MCG TAB 6X28

52544-0936-28	NECON 7/7/7 0.5;0.75;1+0.035MG TB 6X28
00591-2190-45	NEOMYCIN 40MG/ML POLYMYXIN B 10X1ML AMP
00591-2190-50	NEOMYCIN 40MG/ML POLYMYXIN B 50X1ML AMP
52544-0977-01	NEPHRO-VITE RX TAB 100
52544-0287-54	NEXT CHOICE ONE DOSE 1.5MG TAB 1 EA
00228-2497-10	NIFEDIPINE 10MG CAP 100
00228-2530-10	NIFEDIPINE 20MG CAP 100
45963-0152-02	NIFEDIPINE ER 90MG TAB 100
00591-3137-60	NIZATIDINE 150MG CAP 60
00591-3138-30	NIZATIDINE 300MG CAP 30
52544-0629-28	NORA-BE NORETHINDRONE 0.35MG TAB 168
52544-0539-01	NORCO 10/325MG TAB 100
52544-0161-05	NORCO 10/325MG TAB 500
52544-0913-01	NORCO 5/325MG TAB 100
52544-0162-01	NORCO 7.5/325MG TAB 100
52544-0259-28	NORINYL 1+35 1/0.035MG TAB 6x28 WALLETTE
52544-0265-31	NORINYL 1+50 1/0.05MG TAB 3X28
52544-0235-28	NOR-QD 0.35MG TAB 6x28 168
00591-5786-01	NORTRIPTYLINE HCL 10MG CAP 100
00591-5786-05	NORTRIPTYLINE HCL 10MG CAP 500
00591-5787-01	NORTRIPTYLINE HCL 25MG CAP 100
00591-5787-10	NORTRIPTYLINE HCL 25MG CAP 1000
00591-5787-05	NORTRIPTYLINE HCL 25MG CAP 500
00591-5788-01	NORTRIPTYLINE HCL 50MG CAP 100
00591-5788-05	NORTRIPTYLINE HCL 50MG CAP 500
00591-5789-01	NORTRIPTYLINE HCL 75MG CAP 100
00591-0149-87	SOD FERRIC GLUC 62.5MG INJ 10X5 ML 10 VL
00472-0163-15	NYSTATIN 100K UNT CRM 15G ACT
00472-0163-30	NYSTATIN 100K UNT CRM 30G ACT
00472-0166-15	NYSTATIN 100K UNT ONT 15G ACT
00472-0166-30	NYSTATIN 100K UNT ONT 30G ACT
52544-0848-28	OGESTREL 0.5/0.05MG TAB 3X28 84
62037-0640-01	OMEPRAZOLE DR 40MG CAP 100
62037-0640-10	OMEPRAZOLE DR 40MG CAP 1000
62037-0640-30	OMEPRAZOLE DR 40MG CAP 30
45963-0538-30	ONDANSETRON 4MG TAB 30
45963-0539-30	ONDANSETRON 8MG TAB 30
00591-3222-47	ORPHENADRINE CITRATE INJ 30MG/ML 2ML A10
00591-3544-01	OXANDROLONE 2.5MG TAB 100
00228-2067-10	OXAZEPAM 10MG CAP 100
00228-2067-50	OXAZEPAM 10MG CAP 500
00228-2069-10	OXAZEPAM 15MG CAP 100
00228-2069-50	OXAZEPAM 15MG CAP 500
00228-2073-10	OXAZEPAM 30MG CAP 100
00228-2878-11	OXYCODONE 15MG TAB 100
00228-2879-11	OXYCODONE 30MG TAB 100
00591-0932-01	OXYCODONE/APAP 10/325MG TAB 100

00591-0825-01	OXYCODONE/APAP 10/650MG TAB 100
00591-0749-01	OXYCODONE/APAP 5/325MG TAB 100
00591-0749-05	OXYCODONE/APAP 5/325MG TAB 500
00591-0737-01	OXYCODONE/APAP 5/500MG CAP 100
00591-0737-05	OXYCODONE/APAP 5/500MG CAP 500
00591-0933-01	OXYCODONE/APAP 7.5/325MG TAB 100
00591-0824-01	OXYCODONE/APAP 7.5/500MG TAB 100
00591-3551-01	OXYCODONE/ASP 4.8355/325MG TAB 100
00228-4029-11	OXYCODONE/IBUPROFEN 5MG/400MG TAB 100
00228-3262-11	OXYMORPHONE ER 15MG TAB 100
00228-3261-11	OXYMORPHONE ER 7.5MG TAB 100
52544-0920-08	OXYTROL OXYBUT TS(US) 3.9MG/D P8
45963-0569-08	PANTOPRAZOLE DR 20MG TAB 90
45963-0570-08	PANTOPRAZOLE DR 40MG TAB 90
00591-0396-01	PENTAZOCINE HCL/APAP 25/650MG TAB 100
00591-0395-01	PENTAZOCINE/NALOX HCL 50/0.5MG TAB 100
00472-0242-60	PERMETHRIN 5% CRM 60G ACT
45963-0327-11	PHENDIMATREZINE TARTRATE 35MG TAB 100
45963-0327-96	PHENDIMETRAZINE TARTRATE 35MG TAB 1000
00472-5002-08	PHENYTOIN 125MG/5ML ORAL SUSP 8OZ
00228-2801-11	PILOCARPINE HCL 5MG TAB 100
00228-2837-11	PILOCARPINE HCL 7.5MG TAB 100
00591-3205-30	PIOGLITAZONE HCL 15MG TAB 30
00591-3205-05	PIOGLITAZONE HCL 15MG TAB 500
00591-3205-19	PIOGLITAZONE HCL 15MG TAB 90
00591-3206-30	PIOGLITAZONE HCL 30MG TAB 30
00591-3206-05	PIOGLITAZONE HCL 30MG TAB 500
00591-3206-19	PIOGLITAZONE HCL 30MG TAB 90
00591-3207-30	PIOGLITAZONE HCL 45MG TAB 30
00591-3207-05	PIOGLITAZONE HCL 45MG TAB 500
00591-3207-19	PIOGLITAZONE HCL 45MG TAB 90
00591-3204-13	PODOFILOX TOP 0.5% SOLN 3.5ML 3.5
62037-0710-01	POTASSIUM CHLORIDE ER 10MEQ TAB 100
62037-0999-01	POTASSIUM CHLORIDE ER 20MEQ TAB 100
62037-0999-10	POTASSIUM CHLORIDE ER 20MEQ TAB 1000
62037-0999-05	POTASSIUM CHLORIDE ER 20MEQ TAB 500
62037-0560-01	POTASSIUM CHLORIDE XR 10MEQ CAP 100
62037-0560-10	POTASSIUM CHLORIDE XR 10MEQ CAP 1000
62037-0560-05	POTASSIUM CHLORIDE XR 10MEQ CAP 500
62037-0560-90	POTASSIUM CHLORIDE XR 10MEQ CAP 90
62037-0559-01	POTASSIUM CHLORIDE XR 8MEQ CAP 100
62037-0559-05	POTASSIUM CHLORIDE XR 8MEQ CAP 500
16252-0527-50	PRAVASTATIN SODIUM 20MG TAB 500
00591-5442-01	PREDNISONE 10MG TAB 100
00591-5442-10	PREDNISONE 10MG TAB 1000
00591-5442-05	PREDNISONE 10MG TAB 500
00591-5443-01	PREDNISONE 20MG TAB 100

00591-5443-10	PREDNISONE 20MG TAB 1000
00591-5443-05	PREDNISONE 20MG TAB 500
00591-5052-01	PREDNISONE 5MG TAB 100
00591-5052-10	PREDNISONE 5MG TAB 1000
52544-0079-60	PREQUE 10 TAB 60
00591-5321-01	PRIMIDONE 250MG TAB 100
00591-5321-10	PRIMIDONE 250MG TAB 1000
00591-5347-01	PROBENECID 500MG TAB 100
00591-5347-10	PROBENECID 500MG TAB 1000
00591-5325-01	PROBENECID/COLCHIC 500/0.5MG TAB 100
00591-3128-79	PROGESTERONE IN OIL INJ 50MG 1X10ML
00591-3964-01	PROGESTERONE 100MG CAP 100
00591-3965-01	PROGESTERONE 200MG CAP 100
00472-1627-16	PROMETH/COD 6.25/10MG/5ML SYP 16OZ
00472-1627-04	PROMETH/COD 6.25/10MG/5ML SYP 4OZ
00472-1629-16	PROMETH/COD 6.25/5/10MG/5ML SYP 16OZ
00472-1628-16	PROMETH VS 6.25/5MG/5ML SYP 16OZ
00591-5307-01	PROMETHAZINE HCL 25MG TAB 100
00591-5307-10	PROMETHAZINE HCL 25MG TAB 1000
00591-5319-01	PROMETHAZINE HCL 50MG TAB 100
00591-2160-39	PROMETHAZINE HCL 12.5MG SUP 12 UD
00591-2161-39	PROMETHAZINE HCL 25MG SUP 12 UD
00591-0582-01	PROPAFENONE HCL 150MG TAB 100
00591-0583-01	PROPAFENONE HCL 225MG TAB 100
00591-5554-01	PROPRANOLOL HCL 10MG TAB 100
00591-5554-10	PROPRANOLOL HCL 10MG TAB 1000
00591-5555-01	PROPRANOLOL HCL 20MG TAB 100
00591-5555-10	PROPRANOLOL HCL 20MG TAB 1000
00591-5556-01	PROPRANOLOL HCL 40MG TAB 100
00591-5556-10	PROPRANOLOL HCL 40MG TAB 1000
00591-5557-01	PROPRANOLOL HCL 80MG TAB 100
00591-5557-05	PROPRANOLOL HCL 80MG TAB 500
00228-2780-11	PROPRANOLOL ER 120MG CAP 100
00228-2780-50	PROPRANOLOL ER 120MG CAP 500
00228-2781-11	PROPRANOLOL ER 160MG CAP 100
00228-2781-50	PROPRANOLOL ER 160MG CAP 500
00228-2778-11	PROPRANOLOL ER 60MG CAP 100
00228-2778-50	PROPRANOLOL ER 60MG CAP 500
00228-2779-11	PROPRANOLOL ER 80MG CAP 100
00228-2779-50	PROPRANOLOL ER 80MG CAP 500
00228-2348-10	PROPYLTHIOURACIL 50MGTAB 100
52544-0966-91	QUASENSE 0.15/0.03MG TAB 3X91 273
00591-5438-01	QUINIDINE SULFATE 200MG TAB 100
00591-5454-01	QUINIDINE SULFATE 300MG TAB 100
16252-0570-30	RAMIPRIL 1.25MG CAP 30
16252-0573-01	RAMIPRIL 10MG CAP 100
16252-0573-50	RAMIPRIL 10MG CAP 500

16252-0571-01	RAMIPRIL 2.5MG CAP 100
16252-0571-50	RAMIPRIL 2.5MG CAP 500
16252-0572-01	RAMIPRIL 5MG CAP 100
16252-0572-50	RAMIPRIL 5MG CAP 500
00472-0383-16	RANITIDINE 15MG/ML SYRUP 16 OZ
52544-0151-30	RAPAFLO 4MG CAP 30
52544-0152-30	RAPAFLO 8MG CAP 30
52544-0152-19	RAPAFLO 8MG CAP 90
52544-0954-28	RECLIPSEN 0.15+0.3MG 6X28 TAB 168
00591-3208-60	RIVASTIGMINE TARTRATE 1.5MG CAP 60
00591-3209-60	RIVASTIGMINE TARTRATE 3MG CAP 60
00591-3210-60	RIVASTIGMINE TARTRATE 4.5MG CAP 60
00591-3211-60	RIVASTIGMINE TARTRATE 6MG CAP 60
00591-3612-30	ROPINIROLE HCL ER 12MG TAB 30
00591-3611-30	ROPINIROLE HCL ER 2MG TAB 30
00591-3611-19	ROPINIROLE HCL ER 2MG TAB 90
00591-3613-30	ROPINIROLE HCL ER 4MG TAB 30
00591-3613-19	ROPINIROLE HCL ER 4MG TAB 90
00591-3700-30	ROPINIROLE HCL ER 6MG TAB 30
00591-3614-30	ROPINIROLE HCL ER 8MG TAB 30
00591-3614-19	ROPINIROLE HCL ER 8MG TAB 90
00228-3661-03	ROPINIROLE ER 12MG TAB 30
00228-3658-03	ROPINIROLE ER 2MG TAB 30
00228-3658-09	ROPINIROLE ER 2MG TAB 90
00228-3659-03	ROPINIROLE ER 4MG TAB 30
00228-3659-09	ROPINIROLE ER 4MG TAB 90
00228-3640-03	ROPINIROLE ER 6MG TAB 30
00228-3660-03	ROPINIROLE ER 8MG TAB 30
00228-3660-09	ROPINIROLE ER 8MG TAB 90
00591-3780-19	SILDENAFIL CITRATE 20MG TAB 90
00591-0810-83	SILVER SULFADIAZINE CREAM 1% TUB 25GM
00591-0810-85	SILVER SULFADIAZINE CREAM 1% TUBE 85GM
00591-0810-46	SILVER SULFADIAZINE CREAM 1%JAR 400GM
00591-0810-55	SILVER SULFADIAZINE CREAM 1%JAR 50GM
00228-2673-11	SPIRONOLACTONE 100MG TAB 100
00228-2673-50	SPIRONOLACTONE 100MG TAB 500
00228-2803-11	SPIRONOLACTONE 25MG TAB 100
00228-2803-50	SPIRONOLACTONE 25MG TAB 500
00228-2672-11	SPIRONOLACTONE 50MG TAB 100
00228-2672-50	SPIRONOLACTONE 50MG TAB 500
52544-0967-28	SRONYX 0.10+0.02MG TAB 6X28
00591-0780-01	SUCRALFATE 1GM TAB 100
00591-0780-05	SUCRALFATE 1GM TAB 500
00591-0796-01	SULFASALAZINE 500MG TAB 100
00591-0796-10	SULFASALAZINE 500MG TAB 1000
00591-0796-05	SULFASALAZINE 500MG TAB 500
00591-5661-01	SULINDAC 150MG TAB 100

00591-5661-05	SULINDAC 150MG TAB 500
00591-5660-01	SULINDAC 200MG TAB 100
00591-5660-05	SULINDAC 200MG TAB 500
16252-0592-99	SUMATRIPTAN 100MG TAB 9
16252-0590-99	SUMATRIPTAN 25MG TAB 9
16252-0591-99	SUMATRIPTAN 50MG TAB 9
00591-2472-18	TAMOXIFEN CITRATE 10MG TAB 180
00591-2472-60	TAMOXIFEN CITRATE 10MG TAB 60
00591-2473-30	TAMOXIFEN CITRATE 20MG TAB 30
00591-2473-19	TAMOXIFEN CITRATE 20MG TAB 90
00228-2996-11	TAMSULOSIN HCL 0.4MG 100 CAP
00228-2996-50	TAMSULOSIN HCL 0.4MG 500 CAP
62037-0696-30	TAZTIA XT 120MG CAP 30
62037-0696-90	TAZTIA XT 120MG CAP 90
62037-0697-30	TAZTIA XT 180MG CAP 30
62037-0697-90	TAZTIA XT 180MG CAP 90
62037-0698-30	TAZTIA XT 240MG CAP 30
62037-0698-90	TAZTIA XT 240MG CAP 90
62037-0699-30	TAZTIA XT 300MG CAP 30
62037-0699-90	TAZTIA XT 300MG CAP 90
62037-0700-30	TAZTIA XT 360MG CAP 30
62037-0700-90	TAZTIA XT 360MG CAP 90
00228-2076-10	TEMAZEPAM 15MG CAP 100
00228-2076-50	TEMAZEPAM 15MG CAP 500
00228-2077-10	TEMAZEPAM 30MG CAP 100
00228-2077-50	TEMAZEPAM 30MG CAP 500
00591-3196-89	TERCONAZOLE CREAM 0.4% 45 GM
00591-3197-52	TERCONAZOLE CREAM 0.8% 20 GM
00591-3223-79	TESTOSTERONE CYP INJ 200MG/ML 10ML V1 1
00591-3221-26	TESTOSTERONE ENA INJ 200MG/ML 5ML VIAL 1
00591-2234-01	TETRACYCLINE HCL 250MG CAP 100
00591-2234-10	TETRACYCLINE HCL 250MG CAP 1000
00591-2235-01	TETRACYCLINE HCL 500MG CAP 100
00591-2235-10	TETRACYCLINE HCL 500MG CAP 1000
52544-0143-31	TILIA FE 1/20;30;35MCG+75FE TAB 3X28
00591-2788-86	TIZANIDINE HCL 2MG CAP 150
00591-2789-86	TIZANIDINE HCL 4MG CAP 150
00591-2790-86	TIZANIDINE HCL 6MG CAP 150
16252-0568-60	TOPIRAMATE 15MG CAP 60
16252-0569-60	TOPIRAMATE 25MG CAP 60
16252-0541-30	TRANDOLAPRIL 1MG TAB 30
16252-0542-90	TRANDOLAPRIL 2MG TAB 90
16252-0543-90	TRANDOLAPRIL 4MG TAB 90
00591-3720-30	TRANEXAMIC ACID 650MG TAB 30
52544-0188-76	TRELSTAR 11.25MG MIXJECT VIAL 1
52544-0189-76	TRELSTAR 3.75MG MIXJECT VIAL 1
52544-0092-76	TRELSTAR 6 MONTH 22.5MG MIXJECT 1 VIAL

00472-0117-20	TRETINOIN 0.025% CREAM 20G ACT
00472-0117-45	TRETINOIN 0.025% CREAM 45G ACT
00591-0424-01	TRIAMTERENE W/HCTZ 37.5/25MG TAB 100
00591-0424-05	TRIAMTERENE W/HCTZ 37.5/25MG TAB 500
00591-0348-01	TRIAMTERENE W/HCTZ 75/50MG TAB 100
00591-0348-10	TRIAMTERENE W/HCTZ 75/50MG TAB 1000
00591-0348-05	TRIAMTERENE W/HCTZ 75/50MG TAB 500
00591-5335-01	TRIHEXYPHENIDYL HCL 2MG TAB 100
00591-5335-10	TRIHEXYPHENIDYL HCL 2MG TAB 1000
00591-5337-01	TRIHEXYPHENIDYL HCL 5MG TAB 100
00591-5337-10	TRIHEXYPHENIDYL HCL 5MG TAB 1000
00591-5571-01	TRIMETHOPRIM 100MG TAB 100
45963-0295-30	TRIMIPRAMINE MAL 100MG CAP 30
45963-0293-30	TRIMIPRAMINE MAL 25MG CAP 30
45963-0294-30	TRIMIPRAMINE MAL 50MG CAP 30
52544-0248-28	TRINESSA .180;.215;.250+.035MG TAB 6x28
52544-0274-28	TRI-NORINYL .5;1;.5/.035MG TAB 6X28
52544-0291-28	TRIVORA.05/.03+.075/.04+.125/.03MG T6X28
00591-3636-30	TROSPIUM CHL ER 60MG CAP 30
00591-3159-01	URSODIOL 300MG CAP 100
00591-2368-01	URSODIOL 250MG TAB 100
00591-2369-01	URSODIOL 500MG TAB 100
00591-3249-30	VALACYCLOVIR HCL 1000MG CAPTAB 30
00591-3248-30	VALACYCLOVIR HCL 500MG CAPTAB 30
00591-3248-19	VALACYCLOVIR HCL 500MG CAPTAB 90
45963-0559-30	VALACYCLOVIR 1GM TAB 30
45963-0559-08	VALACYCLOVIR 1GM TAB 90
45963-0558-30	VALACYCLOVIR 500 MG TAB 30
45963-0558-08	VALACYCLOVIR 500 MG TAB 90
00591-4012-01	VALPROIC ACID 250MG CAP 100
00591-0426-16	VALPROIC ACID 250MG/5ML ORAL SOL 16OZ
00591-2316-10	VALSARTAN/HCTZ 160/12.5MG TAB 1000
00591-2316-19	VALSARTAN/HCTZ 160/12.5MG TAB 90
00591-2317-10	VALSARTAN/HCTZ 160/25MG TAB 1000
00591-2317-19	VALSARTAN/HCTZ 160/25MG TAB 90
00591-2318-19	VALSARTAN/HCTZ 320/12.5MG TAB 90
00591-2319-19	VALSARTAN/HCTZ 320/25MG TAB 90
00591-2315-10	VALSARTAN/HCTZ 80/12.5MG TAB 1000
00591-2315-19	VALSARTAN/HCTZ 80/12.5MG TAB 90
00591-3560-15	VANCOMYCIN HCL 125MG CAP 2 X 10
00591-3561-15	VANCOMYCIN HCL 250MG CAP 2 X 10
00591-0404-01	VERAPAMIL HCL(PH) 40MG TAB 100
00591-0345-01	VERAPAMIL HCL(WH) 120MG TAB 100
00591-0345-10	VERAPAMIL HCL(WH) 120MG TAB 1000
00591-0345-05	VERAPAMIL HCL(WH) 120MG TAB 500
00591-0343-01	VERAPAMIL HCL(WH) 80MG TAB 100
00591-0343-10	VERAPAMIL HCL(WH) 80MG TAB 1000

00591-0343-05	VERAPAMIL HCL(WH) 80MG TAB 500
00591-2880-01	VERAPAMIL HCL SR PELLET 120MG CAP 100
00591-2882-01	VERAPAMIL HCL SR PELLET 180MG CAP 100
00591-2884-01	VERAPAMIL HCL SR PELLET 240MG CAP 100
00591-2886-01	VERAPAMIL HCL SR PELLET 360MG CAP 100
52544-0982-31	VESTURA 3/0.02MG TAB 3X28
52544-0981-31	ZARAH 3/0.03MG TAB 3X28
52544-0953-28	ZENCHENT 0.4/0.035MG 6X28 TAB 168
52544-0292-31	ZENCHENT FE .4MG/35MCG CHEWTAB 3X28
00228-3482-11	ZOLPIDEM TARTRATE ER 12.5MG TAB 100
00228-3482-50	ZOLPIDEM TARTRATE ER 12.5MG TAB 500
00228-3481-11	ZOLPIDEM TARTRATE ER 6.25MG TAB 100
00228-3481-50	ZOLPIDEM TARTRATE ER 6.25MG TAB 500
52544-0383-28	ZOVIA 1/35E 1/35MCG TAB 6X28
52544-0384-28	ZOVIA 1/50E 1/50MCG TAB 6X28

OTC Products - Corona & Gurnee 605

NDC	Description
00472-1105-34	BACITRACIN ZINC OINT 1/2 OZ ACT
00472-1105-56	BACITRACIN ZINC OINT 1 OZ ACT
00472-0220-63	CLOTRIMAZOLE 45G VAG CR 1 APP ACT
00472-0220-41	CLOTRIMAZOLE 45G VAG CR 7 APP ACT
00472-1200-06	FEVERALL SUPP 80MG 6/CTN
00472-1200-50	FEVERALL SUPP 80MG 50/CTN
00472-1201-06	FEVERALL SUPP 120MG 6/CTN
00472-1201-50	FEVERALL SUPP 120MG 50/CTN
00472-1202-06	FEVERALL SUPP 325MG 6/CTN
00472-1202-50	FEVERALL SUPP 325MG 50/CTN
00472-1203-50	FEVERALL SUPP 650MG 50/CTN
00472-0343-56	HYDROCORTISONE 1% OTC CR 1 OZ ACT
00472-0339-56	HYDROCORTISONE/ALOE 1% CR 1 OZ ACT
00472-0345-56	HYDROCORTISONE 1% OTC OINT 1 OZ ACT
00472-1261-94	IBUPROFEN SUS DF 4OZ ACT
00472-1263-94	IBUPROFEN SUS BBG 4OZ ACT
00472-1255-94	IBUPROFEN SUS BERRY 4OZ ACT
45963-0125-23	IBUPROFEN INFANT DROPS 1/2 OZ
45963-0125-24	IBUPROFEN INFANT DROPS 1 OZ
00472-0735-14	MICONAZOLE 2% CR 1/2 OZ ACT
00472-0735-56	MICONAZOLE 2% CR 1 OZ ACT
00472-0735-42	MICONAZOLE 2% CR 1-1/2OZ ACT
00472-0730-41	MICON 2% VAG CRM 45G 7APP ACT
00472-0730-63	MICON 2% VAG CRM 45G 1APP ACT
00472-1736-07	MICON 100MG VAG SUPP 7 ACT
00472-0066-75	MINOXIDIL 2% TOPICAL SOL TWIN
00472-0066-73	MINOXIDIL 2% TOPICAL SOL SINGLE
00472-0094-75	MINOXIDIL 5% TOPICAL SOL TWIN
00472-0094-73	MINOXIDIL 5% TOPICAL SOL SINGLE
00472-5242-67	PERMETHRIN 1% LOTION 2 OZ ACT
00472-5242-69	PERMETHRIN 1% LOTION 2X2 OZ ACT
00472-0179-34	TRIPLE ANTI OINT 1/2 OZ ACT
00472-0179-56	TRIPLE ANTI OINT 1 OZ ACT

NDC	Description	Schedule
55253-0074-30	FENTANYL CITRATE EQ ORAL TRANS 1200MCG30	CII
55253-0075-30	FENTANYL CITRATE EQ ORAL TRANS 1600MCG30	CII
55253-0070-30	FENTANYL CITRATE EQ ORAL TRANS 200MCG 30	CII
55253-0071-30	FENTANYL CITRATE EQ ORAL TRANS 400MCG 30	CII
55253-0072-30	FENTANYL CITRATE EQ ORAL TRANS 600MCG 30	CII
55253-0073-30	FENTANYL CITRATE EQ ORAL TRANS 800MCG 30	CII
00591-3214-72	FENTANYL PATCH 100MCG 5	CII
00591-3198-72	FENTANYL PATCH 25MCG 5	CII
00591-3212-72	FENTANYL PATCH 50MCG 5	CII
00591-3213-72	FENTANYL PATCH 75MCG 5	CII
46987-0324-11	KADIAN ER 100MG CAP 100	CII
46987-0410-11	KADIAN ER 10MG CAP 100	CII
46987-0329-11	KADIAN ER 130MG CAP 100	CII
46987-0330-11	KADIAN ER 150MG CAP 100	CII
46987-0377-11	KADIAN ER 200MG CAP 100	CII
46987-0322-11	KADIAN ER 20MG CAP 100	CII
46987-0325-11	KADIAN ER 30MG CAP 100	CII
46987-0327-11	KADIAN ER 40MG CAP 100	CII
46987-0323-11	KADIAN ER 50MG CAP 100	CII
46987-0326-11	KADIAN ER 60MG CAP 100	CII
46987-0328-11	KADIAN ER 70MG CAP 100	CII
46987-0412-11	KADIAN ER 80MG CAP 100	CII
00591-5883-01	METHYLPHENIDATE HCL 10MG TAB 100	CII
00591-5884-01	METHYLPHENIDATE HCL 20MG TAB 100	CII
00591-5882-01	METHYLPHENIDATE HCL 5MG TAB 100	CII
00591-2715-01	METHYLPHENIDATE HCL ER 18MG TAB 100	CII
00591-2716-01	METHYLPHENIDATE HCL ER 27MG TAB 100	CII
00591-2717-01	METHYLPHENIDATE HCL ER 36MG TAB 100	CII
00591-2718-01	METHYLPHENIDATE HCL ER 54MG TAB 100	CII
67767-0200-01	METHYLPHENIDATE HCL 20MG ER CAP 100	CII
67767-0201-01	METHYLPHENIDATE HCL 30MG ER CAP 100	CII
67767-0202-01	METHYLPHENIDATE HCL 40MG ER CAP 100	CII
00228-3059-11	MIXED AMPHETAMINE SALTS ER 10MG CP 100	CII
00228-3063-11	MIXED AMPHETAMINE SALTS ER 15MG CP 100	CII
00228-3060-11	MIXED AMPHETAMINE SALTS ER 20MG CP 100	CII
00228-3064-11	MIXED AMPHETAMINE SALTS ER 25MG CP 100	CII
00228-3061-11	MIXED AMPHETAMINE SALTS ER 30MG CP 100	CII
00228-3062-11	MIXED AMPHETAMINE SALTS ER 5MG CAP 100	CII
00228-3507-11	MORPHINE SULF ER 100MG CAP 100	CII
00228-3502-11	MORPHINE SULF ER 20MG CAP 100	CII
00228-3503-11	MORPHINE SULF ER 30MG CAP 100	CII
00228-3504-11	MORPHINE SULF ER 50MG CAP 100	CII
00228-3505-11	MORPHINE SULF ER 60MG CAP 100	CII
00228-3506-11	MORPHINE SULF ER 80MG CAP 100	CII
00228-2878-11	OXYCODONE 15MG TAB 100	CII
00228-2879-11	OXYCODONE 30MG TAB 100	CII

00591-0932-01	OXYCODONE/APAP 10/325MG TAB 100	CII
00591-0825-01	OXYCODONE/APAP 10/650MG TAB 100	CII
00591-0749-01	OXYCODONE/APAP 5/325MG TAB 100	CII
00591-0749-05	OXYCODONE/APAP 5/325MG TAB 500	CII
00591-0737-01	OXYCODONE/APAP 5/500MG CAP 100	CII
00591-0737-05	OXYCODONE/APAP 5/500MG CAP 500	CII
00591-0933-01	OXYCODONE/APAP 7.5/325MG TAB 100	CII
00591-0824-01	OXYCODONE/APAP 7.5/500MG TAB 100	CII
00591-3551-01	OXYCODONE/ASP 4.8355/325MG TAB 100	CII
00228-4029-11	OXYCODONE/IBUPROFEN 5MG/400MG TAB 100	CII
00228-3262-11	OXYMORPHONE ER 15MG TAB 100	CII
00228-3261-11	OXYMORPHONE ER 7.5MG TAB 100	CII
52544-0076-60	ANDRODERM 2MG/DY P 60	CIII
52544-0077-30	ANDRODERM 4MG/DY P 30	CIII
00591-3220-01	BUTAL/APAP/CAF/COD 50/325/40/30MG CAP100	CIII
00228-3154-03	BUPREN/NALOX 2/0.5MG TAB 30	CIII
00228-3155-03	BUPREN/NALOX 8/2MG TAB 30	CIII
00591-3546-01	BUTAL/ASA/CAF/COD 50/325/40/30MG CAP 100	CIII
00591-3546-05	BUTAL/ASA/CAF/COD 50/325/40/30MG CAP 500	CIII
00591-3219-01	BUTAL/ASA/CAFF 50/325/40MG CAP 100	CIII
00591-3593-60	DRONABINOL 10MG CAP 60	CIII
00591-3591-60	DRONABINOL 2.5MG CAP 60	CIII
00591-3592-60	DRONABINOL 5MG CAP 60	CIII
52544-0958-01	FIORICET/CODEINE 50/325/40/30MG CAP 100	CIII
52544-0955-01	FIORINAL 50/325/40MG CAP 100	CIII
52544-0956-01	FIORINAL/COD 50/325/40/30MG CAP 100	CIII
00591-0853-01	HYDROCODONE/APAP 10/325MG TAB 100	CIII
00591-2612-05	HYDROCODONE/APAP 10/325MG TAB 500	CIII
00591-2609-01	HYDROCODONE/APAP 10/500MG TAB 100	CIII
00591-2609-05	HYDROCODONE/APAP 10/500MG TAB 500	CIII
00591-2610-01	HYDROCODONE/APAP 10/650MG TAB 100	CIII
00591-2610-05	HYDROCODONE/APAP 10/650MG TAB 500	CIII
00591-0517-01	HYDROCODONE/APAP 10/660MG TAB 100	CIII
00591-2607-01	HYDROCODONE/APAP 10/750MG TAB 100	CIII
00591-0388-01	HYDROCODONE/APAP 2.5/500MG TAB 100	CIII
00591-3202-01	HYDROCODONE/APAP 5/325MG TAB 100	CIII
00591-0349-01	HYDROCODONE/APAP 5/500MG TAB 100	CIII
00591-0349-05	HYDROCODONE/APAP 5/500MG TAB 500	CIII
00591-2605-01	HYDROCODONE/APAP 7.5/325MG TAB 100	CIII
00591-0385-01	HYDROCODONE/APAP 7.5/500MG TAB 100	CIII
00591-0385-05	HYDROCODONE/APAP 7.5/500MG TAB 500	CIII
00591-2611-01	HYDROCODONE/APAP 7.5/650MG TAB 100	CIII
00591-2611-05	HYDROCODONE/APAP 7.5/650MG TAB 500	CIII
00591-0387-01	HYDROCODONE/APAP 7.5/750MG TAB 100	CIII
00591-0387-05	HYDROCODONE/APAP 7.5/750MG TAB 500	CIII
62037-0524-01	HYDROCODONE/IBUPROFEN 7.5/200MG TAB 100	CIII
62037-0524-05	HYDROCODONE/IBUPROFEN 7.5/200MG TAB 500	CIII

00472-1030-16	HYDROMET 5/1.5MG/5ML SYR 16OZ ACT	CIII
52544-0634-01	MAXIDONE 10/750MG TAB 100	CIII
52544-0161-01	NORCO 10/325MG TAB 100	CIII
52544-0161-05	NORCO 10/325MG TAB 500	CIII
52544-0913-01	NORCO 5/325MG TAB 100	CIII
52544-0162-01	NORCO 7.5/325MG TAB 100	CIII
00591-3544-01	OXANDROLONE 2.5MG TAB 100	CIII
45963-0327-11	PHENDIMATREZINE TARTRATE 35MG TAB 100	CIII
45963-0327-96	PHENDIMETRAZINE TARTRATE 35MG TAB 1000	CIII
00591-3223-79	TESTOSTERONE CYP INJ 200MG/ML 10ML V1 1	CIII
00591-3221-26	TESTOSTERONE ENA INJ 200MG/ML 5ML VIAL 1	CIII
00228-2027-10	ALPRAZOLAM 0.25MG TAB 100	CIV
00228-2027-96	ALPRAZOLAM 0.25MG TAB 1000	CIV
00228-2027-50	ALPRAZOLAM 0.25MG TAB 500	CIV
00228-2029-10	ALPRAZOLAM 0.5MG TAB 100	CIV
00228-2029-96	ALPRAZOLAM 0.5MG TAB 1000	CIV
00228-2029-50	ALPRAZOLAM 0.5MG TAB 500	CIV
00228-2031-10	ALPRAZOLAM 1MG TAB 100	CIV
00228-2031-96	ALPRAZOLAM 1MG TAB 1000	CIV
00228-2031-50	ALPRAZOLAM 1MG TAB 500	CIV
00228-2039-10	ALPRAZOLAM 2MG TAB 100	CIV
00228-2039-50	ALPRAZOLAM 2MG TAB 500	CIV
00228-3083-06	ALPRAZOLAM ER 0.5MG TAB 60	CIV
00228-3084-06	ALPRAZOLAM ER 1MG TAB 60	CIV
00228-3087-06	ALPRAZOLAM ER 2MG TAB 60	CIV
00228-3086-06	ALPRAZOLAM ER 3MG TAB 60	CIV
00228-4019-11	ALPRAZOLAM 0.25MG ODT 100	CIV
00228-4022-11	ALPRAZOLAM 0.5MG ODT 100	CIV
00228-4024-11	ALPRAZOLAM 1MG ODT 100	CIV
00228-4025-11	ALPRAZOLAM 2MG ODT 100	CIV
00591-5513-01	CARISOPRODOL 350MG TAB 100	CIV
00591-5513-10	CARISOPRODOL 350MG TAB 1000	CIV
00591-5513-05	CARISOPRODOL 350MG TAB 500	CIV
00228-3003-11	CLONAZEPAM 0.5MG TAB 100	CIV
00228-3003-50	CLONAZEPAM 0.5MG TAB 500	CIV
00228-3004-11	CLONAZEPAM 1.0MG TAB 100	CIV
00228-3004-50	CLONAZEPAM 1.0MG TAB 500	CIV
00228-3005-11	CLONAZEPAM 2.0MG TAB 100	CIV
00228-3005-50	CLONAZEPAM 2.0MG TAB 500	CIV
00591-5620-01	DIAZEPAM 10MG TAB 100	CIV
00591-5620-10	DIAZEPAM 10MG TAB 1000	CIV
00591-5620-05	DIAZEPAM 10MG TAB 500	CIV
00591-5621-01	DIAZEPAM 2MG TAB 100	CIV
00591-5621-10	DIAZEPAM 2MG TAB 1000	CIV
00591-5621-05	DIAZEPAM 2MG TAB 500	CIV
00591-5619-01	DIAZEPAM 5MG TAB 100	CIV
00591-5619-10	DIAZEPAM 5MG TAB 1000	CIV

00591-5619-05	DIAZEPAM 5MG TAB 500	CIV
00591-0783-01	DIETHYLPROPION HCL 25MG TAB 100	CIV
00591-0782-01	DIETHYLPROPION HCL ER (CR) 75MG TAB 100	CIV
00591-0744-01	ESTAZOLAM 1MG TAB 100	CIV
00591-0745-01	ESTAZOLAM 2MG TAB 100	CIV
00591-0240-01	LORAZEPAM 0.5MG TAB 100	CIV
00591-0240-10	LORAZEPAM 0.5MG TAB 1000	CIV
00591-0240-05	LORAZEPAM 0.5MG TAB 500	CIV
00591-0241-01	LORAZEPAM 1MG TAB 100	CIV
00591-0241-10	LORAZEPAM 1MG TAB 1000	CIV
00591-0241-05	LORAZEPAM 1MG TAB 500	CIV
00591-0242-01	LORAZEPAM 2MG TAB 100	CIV
00591-0242-10	LORAZEPAM 2MG TAB 1000	CIV
00591-0242-05	LORAZEPAM 2MG TAB 500	CIV
00591-3499-01	MODAFINIL 100MG TAB 100	CIV
00591-3499-30	MODAFINIL 100MG TAB 30	CIV
00591-3500-01	MODAFINIL 200MG TAB 100	CIV
00591-3500-30	MODAFINIL 200MG TAB 30	CIV
00228-2067-10	OXAZEPAM 10MG CAP 100	CIV
00228-2067-50	OXAZEPAM 10MG CAP 500	CIV
00228-2069-10	OXAZEPAM 15MG CAP 100	CIV
00228-2069-50	OXAZEPAM 15MG CAP 500	CIV
00228-2073-10	OXAZEPAM 30MG CAP 100	CIV
00591-0396-01	PENTAZOCINE HCL/APAP 25/650MG TAB 100	CIV
00591-0395-01	PENTAZOCINE/NALOX HCL 50/0.5MG TAB 100	CIV
00228-2076-10	TEMAZEPAM 15MG CAP 100	CIV
00228-2076-50	TEMAZEPAM 15MG CAP 500	CIV
00228-2077-10	TEMAZEPAM 30MG CAP 100	CIV
00228-2077-50	TEMAZEPAM 30MG CAP 500	CIV
00228-3482-11	ZOLPIDEM TARTRATE ER 12.5MG TAB 100	CIV
00228-3482-50	ZOLPIDEM TARTRATE ER 12.5MG TAB 500	CIV
00228-3481-11	ZOLPIDEM TARTRATE ER 6.25MG TAB 100	CIV
00228-3481-50	ZOLPIDEM TARTRATE ER 6.25MG TAB 500	CIV
00472-1627-16	PROMETH/COD 6.25/10MG/5ML SYP 16OZ	CV
00472-1627-04	PROMETH/COD 6.25/10MG/5ML SYP 4OZ	CV
00472-1629-16	PROMETH/COD 6.25/5/10MG/5ML SYP 16OZ	CV

RX Products – Gurnee 705

NDC	Description
16252-0599-02	ALENDRONATE SODIUM 35MG TAB 12UD
16252-0599-44	ALENDRONATE SODIUM 35MG TAB 4UD
16252-0601-02	ALENDRONATE SODIUM 70MG TAB 12UD
16252-0601-44	ALENDRONATE SODIUM 70MG TAB 4UD
52544-0204-31	GENERESS FE .8MG/25MCG TAB 3x28
00591-0461-01	GLIPIZIDE 10MG TAB 100
00591-0461-10	GLIPIZIDE 10MG TAB 1000
00591-0461-05	GLIPIZIDE 10MG TAB 500
00591-0460-01	GLIPIZIDE 5MG TAB 100
00591-0460-10	GLIPIZIDE 5MG TAB 1000
00591-0460-05	GLIPIZIDE 5MG TAB 500
00591-0845-01	GLIPIZIDE ER 10MG TAB 100
00591-0845-10	GLIPIZIDE ER 10MG TAB 1000
00591-0845-15	GLIPIZIDE ER 10MG TAB BLISTER 30
00591-0900-30	GLIPIZIDE ER 2.5MG TAB 30
00591-0844-01	GLIPIZIDE ER 5MG TAB 100
00591-0844-10	GLIPIZIDE ER 5MG TAB 1000
00591-0844-15	GLIPIZIDE ER 5MG TAB BLISTER 30
00591-3973-01	GLIPIZIDE METFORMIN HCL 5/500MG TAB 100
00591-3971-01	GLIPIZIDE METFORMIN HCL2.5/250MG TAB 100
00591-3972-01	GLIPIZIDE METFORMIN HCL2.5/500MG TAB 100
00228-2751-11	GLYBURIDE/METFORMIN 1.25/250MG TAB 100
00228-2751-50	GLYBURIDE/METFORMIN 1.25/250MG TAB 500
00228-2752-11	GLYBURIDE/METFORMIN 2.5/500MG TAB 100
00228-2752-50	GLYBURIDE/METFORMIN 2.5/500MG TAB 500
00228-2753-11	GLYBURIDE/METFORMIN 5/500MG TAB 100
00228-2753-50	GLYBURIDE/METFORMIN 5/500MG TAB 500
00472-1270-16	IBUPROFEN 100MG/5ML RX ORAL SUSP 16 OZ
00472-1270-94	IBUPROFEN 100MG/5ML RX ORAL SUSP 4 OZ
00591-3433-30	IPRATROPIUM B ALB 0.5/3MG INH SLN 30X3ML
00591-3433-60	IPRATROPIUM B ALB 0.5/3MG INH SLN 60X3ML
00591-3798-83	IPRATROPIUM BROMIDE 0.02% 25X2.5ML 62.5
00591-3798-30	IPRATROPIUM BROMIDE 0.02% 30X2.5ML 75
00591-3798-60	IPRATROPIUM BROMIDE 0.02% 60X2.5ML 150
16252-0547-33	IPRATROPIUM/ALBUTEROL INH.5MG/3MG 30X3ML
16252-0547-66	IPRATROPIUM/ALBUTEROL INH.5MG/3MG 60X3ML
00591-2918-23	LEVALBUTEROL HCL 0.31MG INH SOL PCH 24x3
00591-2919-23	LEVALBUTEROL HCL 0.63MG INH SOL PCH 24x3
00591-2920-23	LEVALBUTEROL HCL 1.25MG INH SOL PCH 24x3
52544-0847-28	LOW-OGESTREL 0.3/0.03MG 6x28 TAB 168
52544-0951-21	MICROGESTIN 1.5MG/30MCG TAB 6X21 126
52544-0950-21	MICROGESTIN 1MG/20MCG TAB 6X21 126
52544-0631-28	MICROGESTIN FE 1.5MG/30MCG TAB 6X28 168

RX Products – Gurnee 705

NDC	Description
52544-0630-28	MICROGESTIN FE 1MG/20MCG TAB 6X28 168
52544-0247-28	MONONESSA 0.25 + 0.035MG TAB 6X28
52544-0936-28	NECON 7/7/7 0.5;0.75;1+0.035MG TB 6X28
52544-0287-54	NEXT CHOICE ONE DOSE 1.5MG TAB 1 EA
62037-0710-01	POTASSIUM CHLORIDE ER 10MEQ TAB 100
62037-0999-01	POTASSIUM CHLORIDE ER 20MEQ TAB 100
62037-0999-10	POTASSIUM CHLORIDE ER 20MEQ TAB 1000
62037-0999-05	POTASSIUM CHLORIDE ER 20MEQ TAB 500
62037-0560-01	POTASSIUM CHLORIDE XR 10MEQ CAP 100
62037-0560-10	POTASSIUM CHLORIDE XR 10MEQ CAP 1000
62037-0560-05	POTASSIUM CHLORIDE XR 10MEQ CAP 500
62037-0560-90	POTASSIUM CHLORIDE XR 10MEQ CAP 90
62037-0559-01	POTASSIUM CHLORIDE XR 8MEQ CAP 100
62037-0559-05	POTASSIUM CHLORIDE XR 8MEQ CAP 500
52544-0248-28	TRINESSA .180;.215;.250+.035MG TAB 6x28

OTC Products – Gurnee 705

NDC	Description
28201052506	ALLERGY CR W/ZINC 1 OZ
84579052506	ALLERGY CR W/ZINC 1 OZ
11110052506	ALLERGY CR W/ZINC 1 OZ
15127052506	ALLERGY CR W/ZINC 1 OZ
11917052506	ALLERGY CR W/ZINC 1 OZ
40986061802	APAP CHERRY CHILDS 2 OZ
40986061804	APAP CHERRY CHILDS 4 OZ
40986061902	APAP DF CHRY INFANT 2 OZ
40986061904	APAP DF CHRY INFANT 4 OZ
50428110506	BACI ZINC OINT 1 OZ
53116110506	BACI ZINC OINT 1 OZ
28201110506	BACI ZINC OINT 1 OZ
11110110506	BACI ZINC OINT 1 OZ
11822110506	BACI ZINC OINT 1 OZ
23317110502	BACI ZINC OINT 1 OZ
40986022001	CLOTRIMAZOLE 1 APP 45 GM
00000032811	CLOTRIMAZOLE 1 APP 45 GM
49348079376	CLOTRIMAZOLE 1 APP 45 GM
49022084306	CLOTRIMAZOLE 1 APP 45 GM
00439507003	CLOTRIMAZOLE 1% AF 1 OZ
63868035006	CLOTRIMAZOLE 1% AF 1 OZ
40986035006	CLOTRIMAZOLE 1% AF 1 OZ
11822035006	CLOTRIMAZOLE 1% AF 1 OZ
11822035005	CLOTRIMAZOLE 1% AF 1/2 OZ

OTC Products – Gurnee 705

NDC	Description
11822035105	CLOTRIMAZOLE 1% JI 1/2 OZ
50428000306	DBL ANTI OINT 1 OZ
11917000306	DBL ANTI OINT 1 OZ
53116000305	DBL ANTI OINT 1/2 OZ
11822000305	DBL ANTI OINT 1/2 OZ
50428082206	DBL W/PRAMOXINE CR 1 OZ
11822082206	DBL W/PRAMOXINE CR 1 OZ
50428082205	DBL W/PRAMOXINE CR 1/2 OZ
84579082205	DBL W/PRAMOXINE CR 1/2 OZ
11110082205	DBL W/PRAMOXINE CR 1/2 OZ
11917082201	DBL W/PRAMOXINE CR 1/2 OZ
11917082205	DBL W/PRAMOXINE CR 1/2 OZ
00472120150	FEVERALL SUPPS 120MG 50'S
00472120106	FEVERALL SUPPS 120MG 6'S
00472120250	FEVERALL SUPPS 325MG 50'S
00472120206	FEVERALL SUPPS 325MG 6'S
00472120350	FEVERALL SUPPS 650MG 50'S
00472120050	FEVERALL SUPPS 80MG 50'S
00472120006	FEVERALL SUPPS 80MG 6'S
02306008312	HYDRO .5% CR 2 OZ
00007905466	HYDRO 1% OTC CR 1 OZ
11110034306	HYDRO 1% OTC CR 1 OZ
40986034306	HYDRO 1% OTC CR 1 OZ
15127034306	HYDRO 1% OTC CR 1 OZ
00000663809	HYDRO 1% OTC CR 1 OZ
11110034302	HYDRO 1% OTC CR 2 OZ
11917034302	HYDRO 1% OTC CR 2 OZ
50428034506	HYDRO 1% OTC OINT 1 OZ
40986034506	HYDRO 1% OTC OINT 1 OZ
15127034506	HYDRO 1% OTC OINT 1 OZ
11917034501	HYDRO 1% OTC OINT 1 OZ
11917018301	HYDRO 1% OTC OINT 1 OZ
63868033901	HYDRO ALOE 1% CR 1 OZ
63868033906	HYDRO ALOE 1% CR 1 OZ
50428033901	HYDRO ALOE 1% CR 1 OZ
28201033906	HYDRO ALOE 1% CR 1 OZ
00904762331	HYDRO ALOE 1% CR 1 OZ
15127033906	HYDRO ALOE 1% CR 1 OZ
11917033901	HYDRO ALOE 1% CR 1 OZ
50428033908	HYDRO ALOE 1% CR TWN 2OZ
50428033904	HYDRO ALOE CR 1% 2 OZ
11917033902	HYDRO ALOE CR 1% 2 OZ
50428033909	HYDRO ALOE CR 1% 2 X 1 OZ
84579034106	HYDRO PLUS 12 CR 1 OZ
11110034106	HYDRO PLUS 12 CR 1 OZ

OTC Products – Gurnee 705

NDC	Description
15127034106	HYDRO PLUS 12 CR 1 OZ
70038125003	IBPRO INFANT DRP DF 1 OZ
63868125003	IBPRO INFANT DRP DF 1 OZ
50428125204	IBPRO INFANT DRP DF 1 OZ
84579125204	IBPRO INFANT DRP DF 1 OZ
11357125003	IBPRO INFANT DRP DF 1 OZ
14832125204	IBPRO INFANT DRP DF 1 OZ
40986125003	IBPRO INFANT DRP DF 1 OZ
11822125204	IBPRO INFANT DRP DF 1 OZ
15127125003	IBPRO INFANT DRP DF 1 OZ
11917125204	IBPRO INFANT DRP DF 1 OZ
23317125204	IBPRO INFANT DRP DF 1 OZ
50428125205	IBPRO INFNT DRP DF 1/2 OZ
50428125203	IBPRO INFNT DRP DF 1/2 OZ
28201125203	IBPRO INFNT DRP DF 1/2 OZ
14832125203	IBPRO INFNT DRP DF 1/2 OZ
11822125203	IBPRO INFNT DRP DF 1/2 OZ
11917125203	IBPRO INFNT DRP DF 1/2 OZ
23317125203	IBPRO INFNT DRP DF 1/2 OZ
70038125504	IBPRO OTC BERRY 4OZ
63868125504	IBPRO OTC BERRY 4OZ
28201125504	IBPRO OTC BERRY 4OZ
84579125504	IBPRO OTC BERRY 4OZ
00904530920	IBPRO OTC BERRY 4OZ
11357125504	IBPRO OTC BERRY 4OZ
70253125504	IBPRO OTC BERRY 4OZ
40986125504	IBPRO OTC BERRY 4OZ
15127125504	IBPRO OTC BERRY 4OZ
11917125504	IBPRO OTC BERRY 4OZ
63868125508	IBPRO OTC BERRY 8OZ
00904530909	IBPRO OTC BERRY 8OZ
40986125508	IBPRO OTC BERRY 8OZ
70038126204	IBPRO OTC GRAPE 4OZ
63868126204	IBPRO OTC GRAPE 4OZ
84579126204	IBPRO OTC GRAPE 4OZ
00904557720	IBPRO OTC GRAPE 4OZ
11357126204	IBPRO OTC GRAPE 4OZ
40986126204	IBPRO OTC GRAPE 4OZ
15127126204	IBPRO OTC GRAPE 4OZ
11917126204	IBPRO OTC GRAPE 4OZ
63868126304	IBUPRO BUBBLE GUM 4 OZ
28201126304	IBUPRO BUBBLE GUM 4 OZ
11357126304	IBUPRO BUBBLE GUM 4 OZ
70253126304	IBUPRO BUBBLE GUM 4 OZ
40986126304	IBUPRO BUBBLE GUM 4 OZ

OTC Products – Gurnee 705

NDC	Description
11917126304	IBUPRO BUBBLE GUM 4 OZ
23317126304	IBUPRO BUBBLE GUM 4 OZ
70038126104	IBUPROFEN DF 4 OZ CTN
11357126104	IBUPROFEN DF 4 OZ CTN
14832126104	IBUPROFEN DF 4 OZ CTN
40986126104	IBUPROFEN DF 4 OZ CTN
11822126104	IBUPROFEN DF 4 OZ CTN
11917126104	IBUPROFEN DF 4 OZ CTN
23317126104	IBUPROFEN DF 4 OZ CTN
40986073506	MICON CR 2% 1 OZ
10939719205	MICONAZOLE SUPP'S 7'S
63868073003	MICONAZOLE VAG CR 1'S
50428073001	MICONAZOLE VAG CR 1'S
28201073003	MICONAZOLE VAG CR 1'S
84579073001	MICONAZOLE VAG CR 1'S
00904773445	MICONAZOLE VAG CR 1'S
40986073001	MICONAZOLE VAG CR 1'S
00007400217	MICONAZOLE VAG CR 7'S
50428073007	MICONAZOLE VAG CR 7'S
00904773457	MICONAZOLE VAG CR 7'S
11822073001	MICONAZOLE VAG CR 7'S
11917730502	MICONAZOLE VAG CR 7'S
23317073007	MICONAZOLE VAG CR 7'S
50428006605	MINOXIDIL 2% WOMENS SNGLE
50428006608	MINOXIDIL 2% WOMENS TRPLE
11822006606	MINOXIDIL 2% WOMENS TRPLE
23317006606	MINOXIDIL 2% WOMENS TRPLE
40986006604	MINOXIDIL 2% WOMENS TWIN
14299040201	MINOXIDIL 5% SINGLES
50428009403	MINOXIDIL 5% SINGLES
50428009407	MINOXIDIL 5% TRIPLES
11822009407	MINOXIDIL 5% TRIPLES
23317009407	MINOXIDIL 5% TRIPLES
50428009404	MINOXIDIL 5% TWINS
40986009405	MINOXIDIL 5% TWINS
50428731003	M-ZOLE 3 - 1APP
37205731003	M-ZOLE 3 - 1APP
50428731004	M-ZOLE 3 - 3 APP
84579731004	M-ZOLE 3 - 3 APP
00904541501	M-ZOLE 3 - 3 APP
37205731004	M-ZOLE 3 - 3 APP
40986731004	M-ZOLE 3 - 3 APP
11822731004	M-ZOLE 3 - 3 APP
41190731004	M-ZOLE 3 - 3 APP
23317731004	M-ZOLE 3 - 3 APP

OTC Products – Gurnee 705

NDC	Description
50428524209	PERMETHRIN 1% LTN - TWINS
41220524209	PERMETHRIN 1% LTN - TWINS
11357524209	PERMETHRIN 1% LTN - TWINS
41250524209	PERMETHRIN 1% LTN - TWINS
40986524209	PERMETHRIN 1% LTN - TWINS
49348524209	PERMETHRIN 1% LTN - TWINS
84579524207	PERMETHRIN 1% LTN SINGLES
62011524207	PERMETHRIN 1% LTN SINGLES
49348524207	PERMETHRIN 1% LTN SINGLES
11917018106	TRIPLE ANTI MS OINT 1 OZ
00003518735	TRIPLE ANTI OINT 1 OZ
63868017906	TRIPLE ANTI OINT 1 OZ
50428017906	TRIPLE ANTI OINT 1 OZ
53116017906	TRIPLE ANTI OINT 1 OZ
28201017906	TRIPLE ANTI OINT 1 OZ
84579017906	TRIPLE ANTI OINT 1 OZ
00904073431	TRIPLE ANTI OINT 1 OZ
11110017906	TRIPLE ANTI OINT 1 OZ
11822017906	TRIPLE ANTI OINT 1 OZ
15127017906	TRIPLE ANTI OINT 1 OZ
11917017906	TRIPLE ANTI OINT 1 OZ
23317017906	TRIPLE ANTI OINT 1 OZ
50428017905	TRIPLE ANTI OINT 1/2 OZ
00904073436	TRIPLE ANTI OINT 1/2 OZ
11822017905	TRIPLE ANTI OINT 1/2 OZ
15127017905	TRIPLE ANTI OINT 1/2 OZ
11917017905	TRIPLE ANTI OINT 1/2 OZ
50428017908	TRIPLE ANTI OINT 2 X 1 OZ
50428149206	TRIPLE ANTI OINT EF 1 OZ
50428149202	TRIPLE ANTI OINT EF 2 OZ
50428149205	TRIPLE ANTI OINT EF1/2 OZ
50428149208	TRIPLE ANTI OINT EF2X2 OZ
00009905894	TRIPLE W/PRAMOXINE 1 OZ
50428082306	TRIPLE W/PRAMOXINE 1 OZ
53116082306	TRIPLE W/PRAMOXINE 1 OZ
11357082306	TRIPLE W/PRAMOXINE 1 OZ
11110082306	TRIPLE W/PRAMOXINE 1 OZ
11822082306	TRIPLE W/PRAMOXINE 1 OZ
11917082306	TRIPLE W/PRAMOXINE 1 OZ
23317082306	TRIPLE W/PRAMOXINE 1 OZ
50428082305	TRIPLE W/PRAMOXINE 1/2 OZ
84579082305	TRIPLE W/PRAMOXINE 1/2 OZ
11917082305	TRIPLE W/PRAMOXINE 1/2 OZ
11822082308	TRIPLE W/PRAMOXINE TWIN

LIST OF REGISTERED AGENTS FOR ACTAVIS PHARMA, INC.

(C T CORPORATION SYSTEM)

C T Corporation System 2 North Jackson Street Suite 605 Montgomery, AL 36104 Phone: 334-649-4100	**C T Corporation System** 9360 Glacier Highway Suite 202 Juneau, AK 99801 Phone: 907-586-3340
C T Corporation System 2390 East Camelback Road Phoenix, AZ 85016 Phone: 602-381-9104	**Bill Battles** (Navajo Nation) 203 Shonto Boulevard Window Rock, AZ 86515 Phone: 928-871-2525
The Corporation Company 124 West Capitol Avenue Suite 1900 Little Rock, AR 72201-3736 Phone: 501-244-9034	**C T Corporation System** 818 West Seventh Street 2nd Floor Los Angeles, CA 90017 Phone: 213-627-8252
The Corporation Company 1675 Broadway Suite 1200 Denver, CO 80202 Phone: 303-629-2500	**C T Corporation System** One Corporate Center Floor 11 Hartford, CT 06103-3220 Phone: 860-724-9044
The Corporation Trust Company Corporation Trust Center 1209 Orange Street Wilmington, DE 19801 Phone: 800-667-3394	**C T Corporation System** 1200 South Pine Island Road Plantation, FL 33324 Phone: 954-473-5503
C T Corporation System (Atlanta) 1201 Peachtree Street, NE Atlanta, GA 30361 Phone: 404-888-6488	**The Corporation Process Company** (Duluth) 2180 Satellite Blvd. Suite 400 Duluth, GA 30097 Phone: 770-281-8857
The Corporation Company, Inc. 1136 Union Mall Suite 301 Honolulu, HI 96813 Phone: (808) 524-4488	**CT Corporation System** 921 S Orchard Street Suite G Boise, ID 83705 Phone: 208-342-7251
C T Corporation System (Chicago) 208 South LaSalle Street Suite 814 Chicago,IL 60604 Phone: 312-263-1414	**C T Corporation System** 150 West Market Street Suite 800 Indianapolis, IN 46204 Phone: 317-352-3500
C T Corporation System 500 East Court Avenue Suite 200 Des Moines, IA 50309 Phone: 515-245-4469	**The Corporation Company, Inc.** 112 S.W. Seventh Street Suite 3C Topeka, KS 66603 Phone: 785-233-5517
C T Corporation System 306 West Main Street Suite 512 Frankfort, KY 40601 Phone: 502-875-6424	**C T Corporation System** 5615 Corporate Boulevard Suite 400B Baton Rouge, LA 70808 Phone: 225-922-4490

LIST OF REGISTERED AGENTS FOR ACTAVIS PHARMA, INC.

(C T CORPORATION SYSTEM)

Page 2

CT Corporation System 1536 Main Street Readfield, ME 04355 Phone: (800) 675-6350 Main contact is Ken Keene	**The Corporation Trust Incorporated** 351 West Camden Street Baltimore, MD 21201 Phone: 410-539-2837
C T Corporation System 155 Federal Street Suite 700 Boston, MA 02110 Phone: 617-757-6400	**The Corporation Company** 30600 Telegraph Road Suite 2345 Bingham Farms, MI 48025-4530 Phone: 248-646-9033
C T Corporation System Inc. 100 South 5th Street Suite 1075 Minneapolis, MN 55402 Phone: 612-333-4315	**C T Corporation System** 645 Lakeland East Drive Suite 101 Flowood, MS 39232 Phone: 601-936-7400
C T Corporation System 120 South Central Avenue Clayton, MO 63105 Phone: 314-863-5545	**C T Corporation System** 208 North Broadway Suite 313 Billings, MT 59101 Phone: 406-248-7646
C T Corporation System 6003 Old Cheney Road Suite 300 Lincoln, NE 68516 Phone: 402-323-3828 Main contact is Kurtis Kotera	**The Corporation Trust Company of Nevada** 311 South Division Street Carson City, NV 89703 Phone: 775-888-4070
C T Corporation System 9 Capitol Street Concord, NH 03301 Phone: 603-224-2341	**The Corporation Trust Company** 820 Bear Tavern Road West Trenton, NJ 08628 Phone: 609-538-1818
C T Corporation System 123 East Marcy Santa Fe, NM 87501 Phone: 505-983-9122	**C T Corporation System** 111 Eighth Avenue 13th Floor New York, NY 10011 Phone: 212-894-8800
C T Corporation System 150 Fayetteville Street Box 1011 Raleigh, NC 27601 Phone: 919-821-7139	**C T Corporation System** 314 East Thayer Avenue Bismarck, ND 58501 Phone: 701-223-2890
C T Corporation System 1300 East Ninth Street Cleveland, OH 44114 Phone: 216-802-2121	**The Corporation Company** 1833 South Morgan Road Oklahoma City, OK 73128 Phone: 405-324-8180
C T Corporation System 388 State Street Suite 420 Salem, OR 97301 Phone: 503-566-6883	**C T Corporation System** 116 Pine Street Suite 320 Harrisburg, PA 17101 Phone: 717-234-6004

LIST OF REGISTERED AGENTS FOR ACTAVIS PHARMA, INC.

(C T CORPORATION SYSTEM)

CT Corporation System 450 Veterans Memorial Parkway Suite 7A East Providence, RI 02914 Phone: 401-274-9100	**C T Corporation System** 2 Office Park Court Suite 103 Columbia, SC 29223 Phone: 803-699-6130
C T Corporation System 319 South Coteau Street Pierre, SD 57501 Phone: 605-224-5826	**C T Corporation System** 800 South Gay Street Suite 2021 Knoxville, TN 37929 Phone: 865-342-3522
C T Corporation System 350 North St. Paul Street Suite 2900 Dallas, TX 75201-4234 Phone: 214-979-1172	**C T Corporation System** 1108 East South Union Ave Midvale, UT 84047 Phone: 801-984-8160
C T Corporation System 400 Cornerstone Drive Suite 240 Williston, VT 05495 Phone: 802-878-1500	**C T Corporation System** 4701 Cox Road Suite 301 Glen Allen, VA 23060-6802 Phone: 804-217-7255
C T Corporation System 505 Union Ave. SE Suite 120 Olympia, WA 98501 Phone: 360-357-6794	**C T Corporation System** 1015 15th Street, NW Suite 1000 Washington, DC 20005 Phone: 202-572-3100
C T Corporation System 5400 D Big Tyler Road Charleston, WV 25313 Phone: 304-776-1152	**C T Corporation System** 8040 Excelsior Drive Suite 200 Madison, WI 53717 Phone: 608-833-4821
CT Corporation System 1712 Pioneer Avenue #120 Cheyenne, WY 82001 Phone: 307-632-2333	

Florida Department of Business & Professional Regulation

Florida Department of Business and Professional Regulation
Drugs, Devices, and Cosmetics Program
1940 North Monroe Street, Tallahassee FL 32399-0783
Phone 850.717.1800

CHANGE OF ADDRESS OR NAME CHANGE

An establishment permit or a product registration is valid only for the name and address to which it is issued.

PERMIT NAME: The name in which the permit is issued must be the name in which the company is doing business, i.e., the name that appears on purchase, sales, and shipping documents. **The permit name will be changed, at no cost, upon notification to the department provided the new name complies with Rule 61N-1.015(2)(b), Florida Administrative Code.** However, if the name change is a result of a change in ownership, a new application and permit is required.

PERMIT ADDRESS: A new physical location must meet minimal requirements before a permit authorizing business at the new address can be issued. If the establishment is located in Florida, you must complete and sign the Questionnaire and Affidavit on the reverse side of this form.

FEES: There is no charge for a name change or for a change in mailing address of an establishment permit. There is no charge for a change related to a product registration.

$25 if the permit is issued to a Complimentary Drug Distributor located outside of Florida, Veterinary Prescription Drug Wholesaler located outside of Florida, Non-Resident Prescription Drug Manufacturer or Out-of-State Prescription Drug Wholesaler, Third Party Logistics Provider located outside of Florida, or a Health Care Clinic Establishment.

$100 if the permit is issued to a Prescription Drug Manufacturer, Prescription Drug Repackager, Over-the-Counter Drug Manufacturer, Compressed Medical Gas Manufacturer, Device Manufacturer, Cosmetic Manufacturer, Prescription Drug Wholesaler (including Broker Only), Compressed Medical Gas Wholesaler, Retail Pharmacy Wholesaler, Complimentary Drug Distributor located in Florida, Freight Forwarder, Veterinary Legend Drug Retailer, Limited Veterinary Prescription Drug Wholesaler, Veterinary Prescription Drug Wholesaler located in Florida, Medical Oxygen Retailer, Third Party Logistics Provider located in Florida, or any of the Restricted Prescription Drug Distributors.

$25 for each permit, in addition to the $100 fee above, if multiple permits under the same permitted name and address (in state) are relocated concurrently to one new location (in state).

Please print or type legibly.

Permit/Registration Number(s)			
Old Permit Name			
New Permit Name (limit to 41 characters)			
Old Physical Address			
New Physical Address (include suite number)			
City	**State**	**Zip Code**	**County**
New Mailing Address (include suite number)			
City	**State**	**Zip**	
New Telephone Number	**Facsimile Number**		
New Opening Hours	**Effective Date of Change**		

_____
Signature of Authorized Representative

_____
Title

Make checks payable to: **Florida Department of Business and Professional Regulation**

Mail to: **Florida Department of Business and Professional Regulation, Drugs, Devices, and Cosmetics Program, 1940 North Monroe Street, Tallahassee FL 32399-0783.**
If you have questions, please call (850) 717-1800.

A **Retail Pharmacy Wholesaler** must attach a copy of the community pharmacy permit issued to the new address.

A **Complimentary Drug Distributor** located outside Florida, **Non-Resident Prescription Drug Manufacturer, Veterinary Prescription Drug Wholesaler** located outside of Florida, or an **Out-of-State Prescription Drug Wholesaler** must attach a copy of the resident state's permit that authorizes the distribution of prescription drugs from that new address.

SUBMIT TIMELY TO AVOID ADMINISTRATIVE SANCTIONS FOR OPERATING WITHOUT A VALID PERMIT
Establishments located in Florida must complete the page 3.

CHANGE OF ADDRESS QUESTIONNAIRE AND AFFIDAVIT

You must answer all questions if the establishment is located in Florida.

1. Is the new address a residence?	**2. Is the new address located in a residential area?**
_____ Yes _____No	_____ Yes _____No
3. Are there any other permits or licenses issued by any agency in Florida that authorize the purchase or possession of prescription drugs at this address?	
_____ Yes _____No If yes, provide the permit name(s) and type of permit(s): _____	
4. Will this new address ever take possession of prescription drugs, including the delivery of medical oxygen to patients?	
_____ Yes _____No If yes, answer the following questions, otherwise go directly to question #5.	
4a. Does the new address have an alarm system?	**4b. What type of alarm is it?**
_____ Yes _____No	_____ Monitored ____ Audible Alarm _ Other (Explain: _____)
4c. Does the new address have air conditioning where prescription drugs will be held?	**4d. Does the new address have temperature and humidity recording devices?**
_____ Yes _____No	_____ Yes _____No
4e. Is the area where prescription drugs will be held lighted?	**4f. Is there adequate space to store, handle, examine, pick, fill orders, and process returns?**
_____ Yes _____No	_____ Yes _____No
4g. Is there a quarantine area at the new address?	**4h. Are entry areas where prescription drugs are held limited to authorized personnel?**
_____ Yes _____No	_____ Yes _____No
5. Is the new location clean and orderly?	**6. Is the new location free from infestation by insects, rodents, birds, pests or other animals?**
_____ Yes _____No	_____ Yes _____No
7. Are your policies and procedures current for your new location?	
_____ Yes _____No	
8. Do your invoices, shipping records or other documentation reflect your current address?	
_____ Yes _____No If not, how do you plan to reflect the new address on your records? _____	
9. Will the records that are required to be maintained under Chapter 499, F.S., be stored and maintained at this new address?	
_____ Yes _____No If not, where will they be stored and maintained? _____	

10. Will you be filling oxygen containers at this new address?
_____ Yes _____No
If yes, has this new address passed an inspection by the local fire marshal? _____ Yes _____ No
11. Is the move to the new location related to the sale of some or all of the business?
_____ Yes _____No If yes, attach a detailed explanation.
12. Who should we contact if we have questions about your responses to this questionnaire?
Name: _____ Telephone #: _____
13. Do you agree to submit a photocopy of your municipal occupational license for the new address upon your receipt? (If local government will not issue an occupational license to your establishment, submit letters from the city and county government stating one is not needed.
_____ Yes _____No

AFFIDAVIT *I do solemnly swear or affirm that the information provided in this affidavit is true and correct. I understand that if my responses are misleading or inaccurate, the permit issued to this new address may be suspended or revoked.*

_____ _____

Signature of Owner or Corporate Officer Date

_____

Title

7:50:03 PM 6/18/2013

Data Contained In Search Results Is Current As Of 06/18/2013 07:47 PM.

Search Results

Please see our glossary of terms for an explanation of the license status shown in these search results.

For additional information, including any complaints or discipline, click on the name.

License Type	Name	Name Type	License Number/ Rank	Status/Expires
Non-resident Prescription Drug Manufacturer	**WATSON PHARMA PRIVATE LIMITED**	Primary	261206 NRPDM	Current, 03/31/2015
	License Location Address*: N-15 PLOT NO. N-15 MIDC MAHARASHTRA 412506 **Main Address*:** 400 INTERPACE PARKWAY PARSIPPANY, NJ 07054			
Non-resident Prescription Drug Manufacturer	**WATSON PHARMA PRIVATE LIMITED**	Primary	26956 NRPDM	Current 01/31/2015
	License Location Address*: PLOT NO AS TO AL, PHASE 1A SALVISA, - 99999 **Main Address*:** 360 MT KEMBLE AVE MORRISTOWN, NJ 07962			
Non-resident Prescription Drug Manufacturer	**WATSON PHARMA PRIVATE LIMITED**	Primary	261079 NRPDM	Current, 01/31/2014
	License Location Address*: 301 CORPORATE ENCLAVE MUMBAI MAHARSHTA 400099 **Main Address*:** 400 INTERPACE PARKWAY PARSIPPANY, NJ 07054			
Non-resident Prescription Drug Manufacturer	**WATSON PHARMA, INC.**	DBA	26276 NRPDM	Current 11/30/2014
	License Location Address*: 605 TRI-STATE PARKWAY GURNEE, IL 60031 **Main Address*:** 605 TRI-STATE PARKWAY GURNEE, IL 60031			
Non-resident Prescription Drug Manufacturer	**WATSON PHARMA, INC.**	DBA	26283 NRPDM	Current 06/30/2014
	License Location Address*: 2455 WARDLOW ROAD CORONA, CA 928802891 **Main Address*:** 2455 WARDLOW ROAD CORONA, CA 928802891			
Complimentary Drug Distributor	**WATSON PHARMA, INC.**	DBA	40270 Comp Drug Distr	Current 06/30/2014
	License Location Address*: 605 TRI-STATE PARKWAY GURNEE, IL 60031 **Main Address*:** 605 TRI-STATE PARKWAY GURNEE, IL 60031			
Non-resident Prescription Drug Manufacturer	**WATSON PHARMA, INC.**	DBA	26275 NRPDM	Voluntary Relinquishment 05/31/2010
	License Location Address*: 39 MT. EBO ROAD SOUTH BREWSTER, NY 105094004 **Main Address*:** 39 MT. EBO ROAD SOUTH BREWSTER, NY 105094004			
Out-of-State Prescription Drug Wholesale Distributor	**WATSON PHARMA, INC.**	DBA	231073 Out of FL-Whole	Closed 11/30/2004
	License Location Address*: 605 TRI-STATE PARKWAY GURNEE, IL 60031			

Main Address*: 605 TRI-STATE PARKWAY GURNEE, IL 60031

Out-of-State Prescription Drug Wholesale Distributor	**WATSON PHARMA, INC.**	DBA	231254 Out of FL-Whole	Closed 05/31/2004

License Location Address*: 39 MT. EBO ROAD SOUTH BREWSTER, NY 105094004
Main Address*: 39 MT. EBO ROAD SOUTH BREWSTER, NY 105094004

Out-of-State Prescription Drug Wholesale Distributor	**WATSON PHARMA, INC.**	DBA	23187 Out of FL-Whole	Closed 03/31/2004

License Location Address*: 311 BONNIE CIRCLE CORONA, CA 91720
Main Address*: 360 MT. KEMBLE AVENUE MORRISTOWN, NJ 079606655

Page 1 of 2 GO << < > >> Back New Search

*** denotes**
Main Address - This address is the Primary Address on file.
Mailing Address - This is the address where the mail associated with a particular license will be sent (if different from the Main or License Location addresses).
License Location Address - This is the address where the place of business is physically located.

1940 North Monroe Street, Tallahassee FL 32399 :: Email: **Customer Contact Center** :: Customer Contact Center: 850.487.1395

Mary-Lou Schoonover

From: Mary-Lou Schoonover
Sent: Wednesday, June 19, 2013 6:27 PM
To: Deborah M Penza
Cc: Lynn DaCunha; Tom P Napoli
Subject: Florida Reg --Update

It took a little digging but...I found it...I guess we HOLD....

A **Complimentary Drug Distributor** located outside Florida, **Non-Resident Prescription Drug Manufacturer, Veterinary Prescription Drug Wholesaler** located outside of Florida, or an **Out-of-State Prescription Drug Wholesaler** must attach a copy of the resident state's permit that authorizes the distribution of prescription drugs from that new address.

From: Mary-Lou Schoonover
Sent: Wednesday, June 19, 2013 6:14 PM
To: Deborah M Penza
Cc: Lynn DaCunha; Tom P Napoli
Subject: Florida Reg

I am going to prepare to send the FL documents out on Friday since it is only a Letter of Notification and the Name Change form. Since we have been unable to locate anywhere in writing where the Dept. is "requiring" additional documents to accompany the name change form, are you comfortable with us moving forward submitting the documentation as is?

Of course I am expecting for them to push back and ask for additional documentation. However, once they log in the letter and the change form, can they "legally" say that we are not in compliance especially, if we counter with the fact that there is nothing in writing requiring any additional documents.

The "requirement" for the additional documents has only been communicated verbally. Can the Dept. legally enforce a "requirement" that is not documented?

Please let me know your thoughts on this and how you think we should proceed.

Thanks!
M-L

From: Deborah M Penza
Sent: Wednesday, June 19, 2013 5:30 PM
To: Mary-Lou Schoonover
Subject: RE: Florida Reg

I agree. Thanks for double-checking this.

From: Mary-Lou Schoonover
Sent: Wednesday, June 19, 2013 4:47 PM
To: Deborah M Penza
Subject: Florida Reg

Hey Deb!

Here's the Florida Reg that is reference on the Change of Address/Name Change Form (specifically the highlighted piece). I've attached the full version. I don't see anything here that should cause us any concerns.

61N-1.015 Licensing, Application, Permitting.

This section addresses the application and permitting requirements of persons regulated under Part I of Chapter 499, F.S.

(1) Any person that is required under Sections 499.001-.081, F.S., to have a permit shall apply to the department for the appropriate permit on forms indicated in this rule. Inquiries regarding requests for an application or licensing may be directed to The Department of Business and Professional Regulation, Drugs, Devices, and Cosmetics Program, at 1940 N. Monroe Street, Tallahassee, Florida 32399 or telephone number (850) 717-1800. Applications may be downloaded from the bureau's web site at www.myfloridalicense.com.

(2) A permit is valid only for the name and address to which it is issued. The name in which a permit is issued will be changed, at no cost, upon notification to the department.

(a) The name in which the permit is issued must be the name in which the company is doing business, i.e., the name that appears on purchase and sales invoices.

(b) A permit that authorizes the purchase of prescription drugs will not be issued in a name identical to the name used by any other establishment or licensed permit holder at that address authorized to purchase prescription drugs pursuant to Chapter 465, F.S., or the statutes regulating a practitioner authorized to purchase prescription drugs except:

1. A Restricted Rx Drug Distributor – Charitable Organization permit will be issued in the name of the charitable organization or health care entity, and

2. A Medical Oxygen Retailer permit may be issued in the name of a nursing home's Class I Institutional Pharmacy permit.

(c) A person must be available for inspection at the permitted address during the business hours identified on the application form, holidays excluded. Permanent changes to these business hours must be communicated to the department in writing. At a minimum, these business hours must meet the following standards:

1. For an establishment applying for a permit or permitted as a prescription drug wholesaler or prescription drug wholesaler – broker only, the establishment must designate a minimum of 20 hours weekly between the hours of 8:00 a.m. and 5:00 p.m. EST, Monday through Friday, and at least one day of the week provide for four consecutive hours.

2. For an establishment applying for a permit or permitted only as a medical oxygen retailer and which does not transfill medical oxygen containers at the permitted establishment, the establishment must designate a minimum of four (4) hours weekly between the hours of 8:00 a.m. and 5:00 p.m. EST, Monday through Friday, and at least one day of the week provide for two consecutive hours. Furthermore if less than 10 hours weekly are designated, a medical oxygen retailer must be available by telephone between the hours of 8:00 a.m. to 5:00 p.m., Monday through Friday, to schedule an appointment within 24 hours of the department's telephone call for an inspection during non-designated business hours.

3. Other applicants and permitted establishments must designate a minimum of 10 hours weekly between the hours of 8:00 a.m. and 5:00 p.m. EST, Monday through Friday, and at least one day of the week provide for two consecutive hours. These standards set forth minimum business hours and agents of the Department of Business and Professional Regulation and the Department of Law Enforcement may inspect, monitor, and investigate during other hours as authorized by law.

Thanks!
M-L

Mary-Lou Schoonover,
DEA Compliance Analyst
Actavis, Inc.
400 Interpace Parkway, Building A
Parsippany, NJ 07054-1120
Phone: 862-261-7486
Fax: (862) 261-7927
mary-lou.schoonover@actavis.com
www.actavis.com

Actavis

CHALLENGE · CONNECT · COMMIT

Our Winning Way

SPH1

FedEx Express Package US Airbill

FedEx Tracking Number 8033 5827 7538

Form ID No. 0215

1 From Please print and press hard.

Date 7/12/13

Sender's FedEx Account Number 1441-8681-8

Sender's Name Mary-Lou Schoonover

Phone (862) 261-7486

Company ACTAVIS

Address 400 INTERPACE PKWY

Dept./Floor/Suite/Room

City PARSIPPANY State NJ ZIP 07054-1120

2 Your Internal Billing Reference
First 24 characters will appear on invoice.

3 To

Recipient's Name Rebecca Burnett Phone 850, 717-1800

Company FL Dept of Business & Prof Reg.

Address Div of Drugs, Devices & Cosmetics

We cannot deliver to P.O. boxes or P.O. ZIP codes. Dept./Floor/Suite/Room

HOLD Weekday
FedEx location address REQUIRED. NOT available for FedEx First Overnight.

HOLD Saturday
FedEx location address REQUIRED. Available ONLY for FedEx Priority Overnight and FedEx 2Day to select locations.

Address 1940 North Monroe St

Use this line for the HOLD location address or for continuation of your shipping address.

City Tallahassee State FL ZIP 32399-0783

0108422535

Pack it back like a pro. Go to fedex.com/packaging

4 Express Package Service *To most locations.

NOTE: Service order has changed. Please select carefully.

Packages up to 150 lbs.
For packages over 150 lbs., use the new FedEx Express Freight US Airbill.

Next Business Day

- [ ] FedEx First Overnight
Earliest next business morning delivery to select locations. Friday shipments will be delivered on Monday unless SATURDAY Delivery is selected.
- [x] FedEx Priority Overnight
Next business morning.* Friday shipments will be delivered on Monday unless SATURDAY Delivery is selected.
- [ ] FedEx Standard Overnight
Next business afternoon.* Saturday Delivery NOT available.

2 or 3 Business Days

- [ ] FedEx 2Day A.M.
Second business morning.* Saturday Delivery NOT available.
- [ ] FedEx 2Day
Second business afternoon.* Thursday shipments will be delivered on Monday unless SATURDAY Delivery is selected.
- [ ] FedEx Express Saver
Third business day.* Saturday Delivery NOT available.

5 Packaging *Declared value limit $500.

- [x] FedEx Envelope*
- [ ] FedEx Pak*
- [ ] FedEx Box
- [ ] FedEx Tube
- [ ] Other

6 Special Handling and Delivery Signature Options

- [ ] SATURDAY Delivery
NOT available for FedEx Standard Overnight, FedEx 2Day A.M., or FedEx Express Saver.
- [x] No Signature Required
Package may be left without obtaining a signature for delivery.
- [ ] Direct Signature
Someone at recipient's address may sign for delivery. Fee applies.
- [ ] Indirect Signature
If no one is available at recipient's address, someone at a neighboring address may sign for delivery. For residential deliveries only. Fee applies.

Does this shipment contain dangerous goods?
One box must be checked

- [ ] No
- [ ] Yes As per attached Shipper's Declaration.
- [ ] Yes Shipper's Declaration not required.
- [ ] Dry Ice Dry Ice, 9, UN 1845 ____ x ____ kg

Dangerous goods (including dry ice) cannot be shipped in FedEx packaging or placed in a FedEx Express Drop Box.

- [ ] Cargo Aircraft Only

7 Payment Bill to:

Enter FedEx Acct. No. or Credit Card No. below.

- [x] Sender Acct. No. in Section 1 will be billed.
- [ ] Recipient
- [ ] Third Party
- [ ] Credit Card
- [ ] Cash/Check

FedEx Acct. No. Credit Card No. Exp. Date

Total Packages ____ Total Weight ____ lbs. Total Declared Value† $ ____ .00

†Our liability is limited to US$100 unless you declare a higher value. See back for details. By using this Airbill you agree to the service conditions on the back of this Airbill and in the current FedEx Service Guide, including terms that limit our liability.

611

Rev. Date 2/12 • Part #163134 • ©1994–2012 FedEx • PRINTED IN U.S.A. SRS

PULL AND RETAIN THIS COPY BEFORE AFFIXING TO THE PACKAGE. NO POUCH NEEDED.